PDF_Name,Match,T-Test Permutation,Distance
5351-px-171-011-app1611-protocol,302 subjects,null,-1
5351-px-171-011-app1611-protocol,84 subjects,null,-1
5351-px-171-011-app1611-protocol,84   subjects,null,-1
5351-px-171-011-app1611-protocol,80 subjects,null,-1
5351-px-171-011-app1611-protocol,250 subjects,null,-1
5351-px-171-011-app1611-protocol,250 similar   subjects,null,-1
5351-px-171-011-app1611-protocol,250 similar subjects,null,-1
5351-px-171-011-app1611-protocol,2 SAFETY ANALYSIS SET  All subjects,null,-1
5351-px-171-011-app1611-protocol,2   Female subjects,null,-1
5351-px-171-011-app1611-protocol,302 patients,null,-1
5351-px-171-011-app1611-protocol,17 patients,null,-1
5351-px-171-011-app1611-protocol,305 patients,null,-1
5351-px-171-011-app1611-protocol,78 patients,null,-1
5351-px-171-011-app1611-protocol,266 patients,null,-1
5351-px-171-011-app1611-protocol,266 similar patients,null,-1
5351-px-171-011-app1611-protocol,0    For patients,null,-1
5351-px-171-011-app1611-protocol,7 POSTTREATMENT VISIT   For patients,null,-1
5351-px-171-011-app1611-protocol,0   For patients,null,-1
5351-px-171-011-app1611-protocol,2 SAFETY ANALYSIS SET   All patients,null,-1
5351-px-171-011-app1611-protocol,19 revised   For patients,null,-1
5351-px-171-011-app1611-protocol,0   For patients,null,-1
5351-px-171-011-app1611-protocol,7 POSTTREATMENT VISIT  For patients,null,-1
5351-px-171-011-app1611-protocol,0  For patients,null,-1
5351-px-171-011-app1611-protocol,2 SAFETY ANALYSIS SET  All patients,null,-1
5351-px-171-011-app1611-protocol,6 POST-TREATMENT VISIT  For patients,null,-1
5351-px-171-011-app1611-protocol,84 patients,null,-1
5351-px-171-011-app1611-protocol,2   For IgA patients,null,-1
5351-px-171-011-app1611-protocol,total of 302,null,-1
5351-px-171-011-app1611-protocol,total of 420,null,-1
5351-px-171-011-app1611-protocol,total of 253,null,-1
5351-px-171-011-app1611-protocol,total of   302,null,-1
5351-px-171-011-app1611-protocol,total   of 302,null,-1
5351-px-171-011-app1611-protocol,total of 84,null,-1
5351-px-171-011-app1611-protocol,266 patients enrolled,null,-1
5351-px-171-011-app1611-protocol,302 patients enrolled,null,-1
5351-px-171-011-app1611-protocol,84   subjects enrolled,null,-1
5351-px-171-011-app1611-protocol,84 subjects enrolled,null,-1
m5321-tr-0452-171-s-csr-with-app,total of 108,null,-1
m5322-121315-s-csr-with-app,n = 3,null,-1
m5322-px-171-008-app1611-protocol,15 evaluable patients,null,-1
m5322-px-171-008-app1611-protocol,29 patients,null,-1
m5322-px-171-008-app1611-protocol,36 patients,null,-1
m5322-px-171-008-app1611-protocol,003 enrolled MM patients,null,-1
m5322-px-171-008-app1611-protocol,13 patients,null,-1
m5322-px-171-008-app1611-protocol,5 patients,null,-1
m5322-px-171-008-app1611-protocol,250 patients,null,-1
m5322-px-171-008-app1611-protocol,70 patients,null,-1
m5322-px-171-008-app1611-protocol,14 patients,null,-1
m5322-px-171-008-app1611-protocol,62 patients,null,-1
m5322-px-171-008-app1611-protocol,17 patients,null,-1
m5322-px-171-008-app1611-protocol,10 patients,null,-1
m5322-px-171-008-app1611-protocol,16 patients,null,-1
m5322-px-171-008-app1611-protocol,23 patients,null,-1
m5322-px-171-008-app1611-protocol,11 patients,null,-1
m5322-px-171-008-app1611-protocol,1 OVERVIEW   All patients,null,-1
m5322-px-171-008-app1611-protocol,003 enrolled,null,-1
m5322-px-171-008-app1619-sap,15 evaluable patients,null,-1
m5322-px-171-008-s-csr-body,15 evaluable patients,null,-1
m5322-px-171-008-s-csr-body,9 patients,null,-1
m5322-px-171-008-s-csr-body,6 patients,null,-1
m5322-px-171-008-s-csr-body,4 patients,null,-1
m5322-px-171-008-s-csr-body,17 patients,null,-1
m5322-px-171-008-s-csr-body,700 patients,null,-1
m5322-px-171-008-s-csr-body,1 Carfilzomib  All patients,null,-1
m5322-px-171-008-s-csr-body,1 Contraceptives  Female patients,null,-1
m5322-px-171-008-s-csr-body,18 patients,null,-1
m5322-px-171-008-s-csr-body,2 patients,null,-1
m5322-px-171-008-s-csr-body,12 patients,null,-1
m5322-px-171-008-s-csr-body,14 patients,null,-1
m5322-px-171-008-s-csr-body,5 patients,null,-1
m5322-px-171-008-s-csr-body,3 patients,null,-1
m5322-px-171-008-s-csr-body,11 patients,null,-1
m5322-px-171-008-s-csr-body,1  Five patients,null,-1
m5322-px-171-008-s-csr-body,18 is a summary of patients,null,-1
m5322-px-171-008-s-csr-body,19 is a summary of patients,null,-1
m5322-px-171-008-s-csr-body,18 enrolled patients,null,-1
m5322-px-171-008-s-csr-body,N = 17,null,-1
m5322-px-171-008-s-csr-body,N = 12,null,-1
m5322-px-171-008-s-csr-body,N = 11,null,-1
m5322-px-171-008-s-csr-body,N=17,null,-1
m5322-px-171-008-s-csr-body,N=18,null,-1
m5322-px-171-008-s-csr-body,N=      17,null,-1
m5322-px-171-008-s-csr-body,total of 6,null,-1
m5322-px-171-008-s-csr-body,18 were enrolled,null,-1
m5322-px-171-008-s-csr-body,18 patients enrolled,null,-1
m5322-px-171-008-s-csr-body,18 enrolled,null,-1
m5322-tr-0077-171-s-csr-with-app,4 patients,null,-1
m5322-tr-0077-171-s-csr-with-app, data obtained from M3,null,-1
m5322-tr-0201-171-s-csr-with-app,4 patients,null,-1
m5323-opt-2012-070-s-csr-with-app,n = 1, t test ,10613
m5323-tr-1183-171-s-csr-with-app,n=3,null,-1
m5332-tr-0204-171-s-csr-with-app,62 subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,3 subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,3 additional subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,6 subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,3 more subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,12 total subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,12 subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,3 displays the disposition of subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,2 subjects,null,-1
m5332-tr-0204-171-s-csr-with-app,22 and the number of patients,null,-1
m5332-tr-0204-171-s-csr-with-app,30 patients,null,-1
m5332-tr-0204-171-s-csr-with-app,2 patients,null,-1
m5332-tr-0204-171-s-csr-with-app,3 patients,null,-1
m5332-tr-0204-171-s-csr-with-app,total of 340,null,-1
m5332-tr-0204-171-s-csr-with-app,30 patients enrolled,null,-1
m5332-tr-0398-171-s-csr-with-app,47 and the number of subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,43      In subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,3 eligible subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,3 additional subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,3 subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,6 subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,3 Three more subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,24 subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,3 displays the disposition of subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,47 subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,2        Excludes subjects,null,-1
m5332-tr-0398-171-s-csr-with-app,4 patients,null,-1
m5332-tr-0398-171-s-csr-with-app,n=3,null,-1
m5332-tr-0398-171-s-csr-with-app,n=8,null,-1
m5332-tr-0398-171-s-csr-with-app,n=5,null,-1
m5332-tr-0398-171-s-csr-with-app,n= 2,null,-1
m5332-tr-0398-171-s-csr-with-app,n=2,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 2,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 3,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 1,null,-1
m5332-tr-0398-171-s-csr-with-app,n= 1,null,-1
m5332-tr-0398-171-s-csr-with-app,n= 3,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 4,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 5,null,-1
m5332-tr-0398-171-s-csr-with-app,n=1,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 9,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 8,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 7,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 14,null,-1
m5332-tr-0398-171-s-csr-with-app,n = 10,null,-1
m5332-tr-0398-171-s-csr-with-app,total   of 1344,null,-1
m5332-tr-0398-171-s-csr-with-app,total of 660,null,-1
m5332-tr-0398-171-s-csr-with-app,total of 164,null,-1
m5332-tr-0398-171-s-csr-with-app,total of 991,null,-1
m5332-tr-0398-171-s-csr-with-app,total of 24,null,-1
m5332-tr-0398-171-s-csr-with-app,47 subjects enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,1b subjects and at least five subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,2 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,235 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,3 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,6   subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,6 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,12   additional subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,16 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,30 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,12 additional subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,14 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,36 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,65 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,120 subjects,null,-1
m5332-tr-0475-171-s-csr-with-app,3 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,14 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,16 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,5 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,30 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,2 patients,null,-1
m5332-tr-0475-171-s-csr-with-app,187  Since a low number of patients,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 30,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 3,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 5,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 13,null,-1
m5332-tr-0475-171-s-csr-with-app,n=23,null,-1
m5332-tr-0475-171-s-csr-with-app,n=4,null,-1
m5332-tr-0475-171-s-csr-with-app,n=10,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 1,null,-1
m5332-tr-0475-171-s-csr-with-app,n = 4,null,-1
m5332-tr-0475-171-s-csr-with-app,n=2,null,-1
m5332-tr-0475-171-s-csr-with-app,N= 30,null,-1
m5332-tr-0475-171-s-csr-with-app,N= 3,null,-1
m5332-tr-0475-171-s-csr-with-app,N= 6,null,-1
m5332-tr-0475-171-s-csr-with-app,N=13,null,-1
m5332-tr-0475-171-s-csr-with-app,N=1,null,-1
m5332-tr-0475-171-s-csr-with-app,N=5,null,-1
m5332-tr-0475-171-s-csr-with-app,N=3,null,-1
m5332-tr-0475-171-s-csr-with-app,N=30,null,-1
m5332-tr-0475-171-s-csr-with-app,N=6,null,-1
m5332-tr-0475-171-s-csr-with-app,total of 14,null,-1
m5332-tr-0475-171-s-csr-with-app,total of 30,null,-1
m5332-tr-0475-171-s-csr-with-app,total of 3,null,-1
m5332-tr-0475-171-s-csr-with-app,14 patients enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,14 patients were enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,14 subjects will be enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,235 subjects will be enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,36 subjects may be   enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,65 subjects were enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app,120 subjects may be enrolled,null,-1
m5332-tr-0475-171-s-csr-with-app, data from Day 1,null,-1
m5332-tr-0475-171-s-csr-with-app, data from 1,null,-1
m5332-tr-0479-171-s-csr-with-app,5 subjects,null,-1
m5332-tr-0479-171-s-csr-with-app,14  All patients,null,-1
m5332-tr-0479-171-s-csr-with-app,15  All patients,null,-1
m5332-tr-0479-171-s-csr-with-app,"2,380 newly diagnosed MM patients",null,-1
m5332-tr-0479-171-s-csr-with-app,1 INCLUSION CRITERIA  All patients,null,-1
m5332-tr-0479-171-s-csr-with-app,1353 patients,null,-1
m5332-tr-0479-171-s-csr-with-app,1027 patients,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 8,null,-1
m5332-tr-0479-171-s-csr-with-app,N=12,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 7,null,-1
m5332-tr-0479-171-s-csr-with-app,N=11,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 6,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 1,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 3,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 4,null,-1
m5332-tr-0479-171-s-csr-with-app,N= 2,null,-1
m5332-tr-0479-171-s-csr-with-app,N=8,null,-1
m5332-tr-0479-171-s-csr-with-app,N=9,null,-1
m5332-tr-0479-171-s-csr-with-app,N=5,null,-1
m5332-tr-0479-171-s-csr-with-app,N=6,null,-1
m5332-tr-0479-171-s-csr-with-app,N=3,null,-1
m5332-tr-0479-171-s-csr-with-app,N=4,null,-1
m5332-tr-0479-171-s-csr-with-app,N=7,null,-1
m5332-tr-0479-171-s-csr-with-app,N=1,null,-1
m5332-tr-0479-171-s-csr-with-app,N=0,null,-1
m5332-tr-0479-171-s-csr-with-app,N=2,null,-1
m5332-tr-0961-171-s-csr-with-app,33 enrolled MM subjects,null,-1
m5332-tr-0961-171-s-csr-with-app,2 lists the number of subjects,null,-1
m5332-tr-0961-171-s-csr-with-app,33 MM patients,null,-1
m5332-tr-0961-171-s-csr-with-app,n=26,null,-1
m5332-tr-0961-171-s-csr-with-app,n=7,null,-1
m5332-tr-0961-171-s-csr-with-app,n=6,null,-1
m5332-tr-0961-171-s-csr-with-app,n=5,null,-1
m5332-tr-0961-171-s-csr-with-app,n=4,null,-1
m5332-tr-0961-171-s-csr-with-app,n=32,null,-1
m5332-tr-0961-171-s-csr-with-app,n=1,null,-1
m5332-tr-0961-171-s-csr-with-app,n=14,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 21,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 6,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 18,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 5,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 5,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 4,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 2,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 3,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 30,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 28,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 27,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 1,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 3,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 12,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 1,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 10,null,-1
m5332-tr-0961-171-s-csr-with-app,n=21,null,-1
m5332-tr-0961-171-s-csr-with-app,n=30,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 51,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 46,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 45,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 8,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 9,null,-1
m5332-tr-0961-171-s-csr-with-app,N = 16,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 7,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 6,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 12,null,-1
m5332-tr-0961-171-s-csr-with-app,n=2,null,-1
m5332-tr-0961-171-s-csr-with-app,n=3,null,-1
m5332-tr-0961-171-s-csr-with-app,n=10,null,-1
m5332-tr-0961-171-s-csr-with-app,n=12,null,-1
m5332-tr-0961-171-s-csr-with-app,n=9,null,-1
m5332-tr-0961-171-s-csr-with-app,n=8,null,-1
m5332-tr-0961-171-s-csr-with-app,n=16,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 223,null,-1
m5332-tr-0961-171-s-csr-with-app,n = 2390,null,-1
m5332-tr-0961-171-s-csr-with-app,total of 53,null,-1
m5332-tr-0961-171-s-csr-with-app,33 enrolled,null,-1
m5332-tr-0961-171-s-csr-with-app, data from the 2,null,-1
m5332-tr-0961-171-s-csr-with-app, data from the 36,null,-1
m5333-tr-1160-171-s-csr-with-app,50 multiple myeloma subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,8 PK-evaluable subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,16 subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,001      Four subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,7 subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,001      normal subjects,null,-1
m5333-tr-1160-171-s-csr-with-app,N=13,null,-1
m5333-tr-1160-171-s-csr-with-app,N=7,null,-1
m5333-tr-1160-171-s-csr-with-app,N=10,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 13,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 7,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 10,null,-1
m5333-tr-1160-171-s-csr-with-app,n = 11,null,-1
m5333-tr-1160-171-s-csr-with-app,n = 5,null,-1
m5333-tr-1160-171-s-csr-with-app,n = 10,null,-1
m5333-tr-1160-171-s-csr-with-app,n = 6,null,-1
m5333-tr-1160-171-s-csr-with-app,n = 4,null,-1
m5333-tr-1160-171-s-csr-with-app,N=8,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 8,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 6,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 11,null,-1
m5333-tr-1160-171-s-csr-with-app,N = 5,null,-1
m5333-tr-1160-171-s-csr-with-app,001      Subjects were enrolled,null,-1
m5333-tr-1160-171-s-csr-with-app, data of PR-389,null,-1
m5333-tr-1160-171-s-csr-with-app, data of PR-413,null,-1
m5333-tr-1160-171-s-csr-with-app, data of PR-519,null,-1
m5333-tr-1161-171-s-csr-with-app,10 PK-evaluable subjects,null,-1
m5333-tr-1161-171-s-csr-with-app,40 subjects,null,-1
m5333-tr-1161-171-s-csr-with-app,4 subjects,null,-1
m5333-tr-1161-171-s-csr-with-app,28 subjects,null,-1
m5333-tr-1161-171-s-csr-with-app,2 subjects,null,-1
m5333-tr-1161-171-s-csr-with-app,N=10,null,-1
m5333-tr-1161-171-s-csr-with-app,N=14,null,-1
m5333-tr-1161-171-s-csr-with-app,N=5,null,-1
m5333-tr-1161-171-s-csr-with-app,N=9,null,-1
m5333-tr-1161-171-s-csr-with-app,N=8,null,-1
m5333-tr-1161-171-s-csr-with-app,N=1,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 10,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 14,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 5,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 8,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 1,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 8,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 12,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 13,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 4,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 6,null,-1
m5333-tr-1161-171-s-csr-with-app,n = 11,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 12,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 6,null,-1
m5333-tr-1161-171-s-csr-with-app,N = 4,null,-1
m5333-tr-1161-171-s-csr-with-app,N=13,null,-1
m5333-tr-1161-171-s-csr-with-app,N=4,null,-1
m5333-tr-1161-171-s-csr-with-app,N=6,null,-1
m5333-tr-1161-171-s-csr-with-app, data of PR-389,null,-1
m5333-tr-1161-171-s-csr-with-app, data of PR-413,null,-1
m5333-tr-1161-171-s-csr-with-app, data of PR-519,null,-1
m5334-tr-0453-171-s-csr-with-app,15 evaluable patients,null,-1
m5334-tr-0453-171-s-csr-with-app,18 evaluable   patients,null,-1
m5334-tr-0453-171-s-csr-with-app,18 patients,null,-1
m5334-tr-0453-171-s-csr-with-app,12 patients,null,-1
m5334-tr-0453-171-s-csr-with-app,11 CONCLUSIONS  Seventeen patients,null,-1
m5334-tr-0453-171-s-csr-with-app,N = 17,null,-1
m5334-tr-0453-171-s-csr-with-app,N = 12,null,-1
m5334-tr-0453-171-s-csr-with-app,N = 11,null,-1
m5334-tr-0453-171-s-csr-with-app,n=17,null,-1
m5334-tr-0453-171-s-csr-with-app,18 enrolled,null,-1
m5334-tr-0494-171-s-csr-with-app,15 evaluable   patients,null,-1
m5334-tr-0494-171-s-csr-with-app,N = 15,null,-1
m5334-tr-0494-171-s-csr-with-app,N = 13,null,-1
m5334-tr-0494-171-s-csr-with-app,N = 9,null,-1
m5334-tr-0494-171-s-csr-with-app,N = 11,null,-1
m5334-tr-0494-171-s-csr-with-app,total of 221,null,-1
m5335-tr-0482-171-s-csr-addendum,n = 154,null,-1
m5335-tr-0482-171-s-csr-with-app,236 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,28 solid tumor patients,null,-1
m5335-tr-0482-171-s-csr-with-app,37 multiple myeloma patients,null,-1
m5335-tr-0482-171-s-csr-with-app,45 unique patients,null,-1
m5335-tr-0482-171-s-csr-with-app,20 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,96 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,40 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,35 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,37 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,28 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,110 MM patients,null,-1
m5335-tr-0482-171-s-csr-with-app,44 MM patients,null,-1
m5335-tr-0482-171-s-csr-with-app,43 MM patients,null,-1
m5335-tr-0482-171-s-csr-with-app,40 MM patients,null,-1
m5335-tr-0482-171-s-csr-with-app,30 ST patients,null,-1
m5335-tr-0482-171-s-csr-with-app,005 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,250 patients,null,-1
m5335-tr-0482-171-s-csr-with-app,n = 6,null,-1
m5335-tr-0482-171-s-csr-with-app,total of 1488,null,-1
m5335-tr-0482-171-s-csr-with-app, data from 5,null,-1
m5335-tr-0482-171-s-csr-with-app, data from   5,null,-1
m5335-tr-1015-171-s-csr-with-app,443 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,266 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,102 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,35 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,51 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,28 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,43 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,39 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,29 ST subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,73 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,792 randomized   subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,106 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,272 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,98 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,19 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,31 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,13 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,7 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,9 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,107 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,14 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,4 subjects,null,-1
m5335-tr-1015-171-s-csr-with-app,N=443,null,-1
m5335-tr-1015-171-s-csr-with-app,N=3226,null,-1
m5335-tr-1015-171-s-csr-with-app,n=102,null,-1
m5335-tr-1015-171-s-csr-with-app,n=51,null,-1
m5335-tr-1015-171-s-csr-with-app,n=43,null,-1
m5335-tr-1015-171-s-csr-with-app,n=39,null,-1
m5335-tr-1015-171-s-csr-with-app,n=106,null,-1
m5335-tr-1015-171-s-csr-with-app,n=443,null,-1
m5335-tr-1015-171-s-csr-with-app,n=19,null,-1
m5335-tr-1015-171-s-csr-with-app,n=31,null,-1
m5335-tr-1015-171-s-csr-with-app,n=13,null,-1
m5335-tr-1015-171-s-csr-with-app,n=7,null,-1
m5335-tr-1015-171-s-csr-with-app,n=9,null,-1
m5335-tr-1015-171-s-csr-with-app,total of 229,null,-1
m5335-tr-1015-171-s-csr-with-app, data from 6,null,-1
m5335-tr-1092-171-s-csr-with-app,102 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,359 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,443 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,106 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,236 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,792 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,266 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,285   A subset of subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,35 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,51 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,28 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,43 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,39 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,29 solid tumor subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,009 study and a subset of subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,006   where subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,1140 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,748 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,392 subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,359 multiple myeloma subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,009 where subjects,null,-1
m5335-tr-1092-171-s-csr-with-app,N = 359,null,-1
m5335-tr-1092-171-s-csr-with-app,N = 443,null,-1
m5335-tr-1092-171-s-csr-with-app,N =1140,null,-1
m5335-tr-1092-171-s-csr-with-app,N=50,null,-1
m5335-tr-1092-171-s-csr-with-app,N=286,null,-1
m5335-tr-1092-171-s-csr-with-app,N=23,null,-1
m5335-tr-1092-171-s-csr-with-app,n=102,null,-1
m5335-tr-1092-171-s-csr-with-app,n=51,null,-1
m5335-tr-1092-171-s-csr-with-app,n=43,null,-1
m5335-tr-1092-171-s-csr-with-app,n=39,null,-1
m5335-tr-1092-171-s-csr-with-app,n=106,null,-1
m5335-tr-1092-171-s-csr-with-app,total of 102,null,-1
m5335-tr-1092-171-s-csr-with-app,total of 106,null,-1
m5335-tr-1092-171-s-csr-with-app,   dataset of 359,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 6,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 106,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 51,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 43,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 39,null,-1
m5335-tr-1092-171-s-csr-with-app, data from 29,null,-1
m5335-tr-1092-171-s-csr-with-app, data from PX-171,null,-1
m5342-tr-0118-171-s-csr-with-app,N=2, t-test ,27836
m5342-tr-0118-171-s-csr-with-app,N=4, t-test ,28168
m5342-tr-0427-171-s-csr-with-app,5 multiple myeloma subjects, t-test ,28069
m5342-tr-0427-171-s-csr-with-app,2 subjects, t-test ,28257
m5342-tr-0427-171-s-csr-with-app,4 subjects, t-test ,36941
m5342-tr-0427-171-s-csr-with-app,3 patients, t-test ,7060
m5342-tr-0427-171-s-csr-with-app,2 patients, t-test ,7130
m5342-tr-0427-171-s-csr-with-app,n=2, t-test ,30443
m5342-tr-0427-171-s-csr-with-app,n=7, t-test ,30606
m5342-tr-0427-171-s-csr-with-app,n=3, t-test ,30931
m5342-tr-0476-171-s-csr-with-app,2 patients, t-test ,17450
m5342-tr-0476-171-s-csr-with-app,7 patients, t-test ,38709
m5342-tr-0476-171-s-csr-with-app,3 patients, t-test ,42249
m5342-tr-0476-171-s-csr-with-app,5 study sites enrolled, t-test ,30331
m5342-tr-0477-171-s-csr-with-app,16 patients, t-test ,10011
m5342-tr-0477-171-s-csr-with-app,15 patients, t-test ,9977
m5342-tr-0477-171-s-csr-with-app,6 patients, t-test ,10010
m5342-tr-0477-171-s-csr-with-app,2 patients, t-test ,5344
m5342-tr-0477-171-s-csr-with-app,1 patients, t-test ,36
m5342-tr-0477-171-s-csr-with-app,9 patients, t-test ,47193
m5342-tr-0477-171-s-csr-with-app,4 patients, t-test ,47480
m5342-tr-0478-171-s-csr-with-app,33 patients, t-test ,19636
m5342-tr-0478-171-s-csr-with-app,32 patients, t-test ,19614
m5342-tr-0478-171-s-csr-with-app,2 patients, t-test ,19613
m5342-tr-0478-171-s-csr-with-app,3 patients, t-test ,19635
m5342-tr-0478-171-s-csr-with-app,9 patients, t-test ,21210
m5342-tr-0478-171-s-csr-with-app,4 patients, t-test ,29317
m5342-tr-0478-171-s-csr-with-app,n  = 9, t-test ,3679
m5342-tr-0478-171-s-csr-with-app,n  = 11, t-test ,4129
m5342-tr-0478-171-s-csr-with-app,n = 10, t-test ,4388
m5342-tr-0478-171-s-csr-with-app,N = 4, t-test ,17985
m5342-tr-0478-171-s-csr-with-app,N = 3, t-test ,18068
m5342-tr-0478-171-s-csr-with-app,N = 5, t-test ,18167
m5342-tr-0478-171-s-csr-with-app,N = 1, t-test ,18378
m5342-tr-0478-171-s-csr-with-app,5 study sites enrolled, t-test ,22688
m5351-2011-003-app1611-protocol,130 subjects,null,-1
m5351-2011-003-app1611-protocol,159 subjects,null,-1
m5351-2011-003-app1611-protocol,640   subjects,null,-1
m5351-2011-003-app1611-protocol,888 patients,null,-1
m5351-2011-003-app1611-protocol,100 patients,null,-1
m5351-2011-003-app1611-protocol,300 patients,null,-1
m5351-2011-003-app1611-protocol,150 patients,null,-1
m5351-2011-003-app1611-protocol,15 patients,null,-1
m5351-2011-003-app1611-protocol,56 patients,null,-1
m5351-2011-003-app1611-protocol,24 multiple myeloma patients,null,-1
m5351-2011-003-app1611-protocol,004 included patients,null,-1
m5351-2011-003-app1611-protocol,3 prior therapies where the patients,null,-1
m5351-2011-003-app1611-protocol,8 cycles and patients,null,-1
m5351-2011-003-app1611-protocol,202 patients,null,-1
m5351-2011-003-app1611-protocol,193 response evaluable patients,null,-1
m5351-2011-003-app1611-protocol,13 of   these patients,null,-1
m5351-2011-003-app1611-protocol,642 patients,null,-1
m5351-2011-003-app1611-protocol,8 cycles and   patients,null,-1
m5351-2011-003-app1611-protocol,222 patients,null,-1
m5351-2011-003-app1611-protocol,130 patients,null,-1
m5351-2011-003-app1611-protocol,2012   For patients,null,-1
m5351-2011-003-app1611-protocol,17 patients,null,-1
m5351-2011-003-app1611-protocol,179 patients,null,-1
m5351-2011-003-app1611-protocol,21 patients,null,-1
m5351-2011-003-app1611-protocol,8 patients,null,-1
m5351-2011-003-app1611-protocol,1500 patients,null,-1
m5351-2011-003-app1611-protocol,2 patients,null,-1
m5351-2011-003-app1611-protocol,2012  where patients,null,-1
m5351-2011-003-app1611-protocol,14 patients,null,-1
m5351-2011-003-app1611-protocol,6 patients,null,-1
m5351-2011-003-app1611-protocol,22 patients,null,-1
m5351-2011-003-app1611-protocol,3 patients,null,-1
m5351-2011-003-app1611-protocol,7 patients,null,-1
m5351-2011-003-app1611-protocol,22 multiple myeloma patients,null,-1
m5351-2011-003-app1611-protocol,3  •     In patients,null,-1
m5351-2011-003-app1611-protocol,100   patients,null,-1
m5351-2011-003-app1611-protocol,56   patients,null,-1
m5351-2011-003-app1611-protocol,888   patients,null,-1
m5351-2011-003-app1611-protocol,150   patients,null,-1
m5351-2011-003-app1611-protocol,14   patients,null,-1
m5351-2011-003-app1611-protocol,22 multiple myeloma   patients,null,-1
m5351-2011-003-app1611-protocol,3  After patients,null,-1
m5351-2011-003-app1611-protocol,2  For patients,null,-1
m5351-2011-003-app1611-protocol,3  A subset of patients,null,-1
m5351-2011-003-app1611-protocol,12  •     In a subset of patients,null,-1
m5351-2011-003-app1611-protocol,10  •     In a subset of patients,null,-1
m5351-2011-003-app1611-protocol,100150 patients,null,-1
m5351-2011-003-app1611-protocol,300   patients,null,-1
m5351-2011-003-app1611-protocol,13 of these patients,null,-1
m5351-2011-003-app1611-protocol,149    CONFIDENTIAL   these patients,null,-1
m5351-2011-003-app1611-protocol,22   footnotes   k  All patients,null,-1
m5351-2011-003-app1611-protocol,24   footnotes   j  For patients,null,-1
m5351-2011-003-app1611-protocol,193 response   evaluable patients,null,-1
m5351-2011-003-app1611-protocol,1 prior therapy    For patients,null,-1
m5351-2011-003-app1611-protocol,N=35,null,-1
m5351-2011-003-app1611-protocol,N=129,null,-1
m5351-2011-003-app1611-protocol,n=148,null,-1
m5351-2011-003-app1611-protocol,n=74,null,-1
m5351-2011-003-app1611-protocol,n = 6,null,-1
m5351-2011-003-app1611-protocol,N = 35,null,-1
m5351-2011-003-app1611-protocol,N = 129,null,-1
m5351-2011-003-app1611-protocol,n = 148,null,-1
m5351-2011-003-app1611-protocol,n = 74,null,-1
m5351-2011-003-app1611-protocol,total of 24,null,-1
m5351-2011-003-app1611-protocol,total of 888,null,-1
m5351-2011-003-app1611-protocol,202 patients enrolled,null,-1
m5351-2011-003-app1611-protocol,130 patients enrolled,null,-1
m5351-2011-003-app1611-protocol,888 patients enrolled,null,-1
m5351-2011-003-app1611-protocol,8 patients were enrolled,null,-1
m5351-2011-003-app1611-protocol,202 patients   enrolled,null,-1
m5351-2011-003-app1611-protocol, data cutoff of 15,null,-1
m5351-2011-003-app1619-sap,70 women, t-test ,2815157
m5351-2011-003-app1619-sap,537 participants, t-test ,229823
m5351-2011-003-app1619-sap,60 the percentage of randomized subjects, t-test ,328581
m5351-2011-003-app1619-sap,266 subjects, t-test ,2787752
m5351-2011-003-app1619-sap,526 subjects, t-test ,2787786
m5351-2011-003-app1619-sap,5 subjects, t-test ,2788690
m5351-2011-003-app1619-sap,3 subjects, t-test ,2788756
m5351-2011-003-app1619-sap,8 subjects, t-test ,2788894
m5351-2011-003-app1619-sap,888 subjects, t-test ,2792331
m5351-2011-003-app1619-sap,100 subjects, t-test ,2795240
m5351-2011-003-app1619-sap,300 subjects, t-test ,2795272
m5351-2011-003-app1619-sap,150 subjects, t-test ,2795292
m5351-2011-003-app1619-sap,151 subjects, t-test ,2807832
m5351-2011-003-app1619-sap,75 subjects, t-test ,2807846
m5351-2011-003-app1619-sap,76 subjects, t-test ,2807876
m5351-2011-003-app1619-sap,48 subjects, t-test ,2808166
m5351-2011-003-app1619-sap,40 subjects, t-test ,2808195
m5351-2011-003-app1619-sap,114  Fourteen subjects, t-test ,2808776
m5351-2011-003-app1619-sap,13 subjects, t-test ,2808825
m5351-2011-003-app1619-sap,28 subjects, t-test ,2810066
m5351-2011-003-app1619-sap,19 subjects, t-test ,2810397
m5351-2011-003-app1619-sap,11 subjects, t-test ,2810446
m5351-2011-003-app1619-sap,17 subjects, t-test ,2810565
m5351-2011-003-app1619-sap,9 subjects, t-test ,2810398
m5351-2011-003-app1619-sap,6 subjects, t-test ,2787754
m5351-2011-003-app1619-sap,2 subjects, t-test ,2810750
m5351-2011-003-app1619-sap,114  subjects, t-test ,2811661
m5351-2011-003-app1619-sap,0 subjects, t-test ,2795242
m5351-2011-003-app1619-sap,61 subjects, t-test ,2833881
m5351-2011-003-app1619-sap,63 subjects, t-test ,2833919
m5351-2011-003-app1619-sap,148 subjects, t-test ,2837636
m5351-2011-003-app1619-sap,74 subjects, t-test ,2837651
m5351-2011-003-app1619-sap,114  A higher incidence of subjects, t-test ,2851486
m5351-2011-003-app1619-sap,115 subjects, t-test ,2852113
m5351-2011-003-app1619-sap,41 subjects, t-test ,2852457
m5351-2011-003-app1619-sap,12 subjects, t-test ,2852522
m5351-2011-003-app1619-sap,31 subjects, t-test ,2860394
m5351-2011-003-app1619-sap,18 subjects, t-test ,2860565
m5351-2011-003-app1619-sap,125 subjects, t-test ,2863280
m5351-2011-003-app1619-sap,62 subjects, t-test ,2863324
m5351-2011-003-app1619-sap,23 subjects, t-test ,2863421
m5351-2011-003-app1619-sap,7 Cd subjects, t-test ,2863550
m5351-2011-003-app1619-sap,10 Vd subjects, t-test ,2863568
m5351-2011-003-app1619-sap,109 subjects, t-test ,2864976
m5351-2011-003-app1619-sap,16 subjects, t-test ,2865036
m5351-2011-003-app1619-sap,2 Vd subjects, t-test ,2865086
m5351-2011-003-app1619-sap,14 subjects, t-test ,2865226
m5351-2011-003-app1619-sap,88 subjects, t-test ,2792332
m5351-2011-003-app1619-sap,9 Cd   subjects, t-test ,2865877
m5351-2011-003-app1619-sap,12 Vd subjects, t-test ,2865897
m5351-2011-003-app1619-sap,53 subjects, t-test ,2868857
m5351-2011-003-app1619-sap,12 Cd subjects, t-test ,2869125
m5351-2011-003-app1619-sap,15 Vd subjects, t-test ,2869144
m5351-2011-003-app1619-sap,9 Cd subjects, t-test ,2869205
m5351-2011-003-app1619-sap,13 Vd subjects, t-test ,2869223
m5351-2011-003-app1619-sap,46 subjects, t-test ,2869521
m5351-2011-003-app1619-sap,7 subjects, t-test ,2810566
m5351-2011-003-app1619-sap,22 subjects, t-test ,2869765
m5351-2011-003-app1619-sap,3 Cd subjects, t-test ,2870539
m5351-2011-003-app1619-sap,7 Vd subjects, t-test ,2870557
m5351-2011-003-app1619-sap,4 subjects, t-test ,2837652
m5351-2011-003-app1619-sap,5 Cd   subjects, t-test ,2872971
m5351-2011-003-app1619-sap,3 additional subjects, t-test ,2897173
m5351-2011-003-app1619-sap,3 outlier subjects, t-test ,2899252
m5351-2011-003-app1619-sap,4 outlier subjects, t-test ,2901629
m5351-2011-003-app1619-sap,15 subjects, t-test ,2852114
m5351-2011-003-app1619-sap,32 subjects, t-test ,2907245
m5351-2011-003-app1619-sap,10 subjects, t-test ,2907310
m5351-2011-003-app1619-sap,780 subjects, t-test ,2950762
m5351-2011-003-app1619-sap,197 subjects, t-test ,3040491
m5351-2011-003-app1619-sap,170 subjects, t-test ,3784459
m5351-2011-003-app1619-sap,544  subjects, t-test ,4287546
m5351-2011-003-app1619-sap,4  CONFIDENTIAL  subjects, t-test ,5241583
m5351-2011-003-app1619-sap,22 Group B subjects, t-test ,5241621
m5351-2011-003-app1619-sap,15 Group A subjects, t-test ,5241665
m5351-2011-003-app1619-sap,25 Group B subjects, t-test ,5241698
m5351-2011-003-app1619-sap,178 subjects, t-test ,5243839
m5351-2011-003-app1619-sap,899 subjects, t-test ,5251186
m5351-2011-003-app1619-sap,20 subjects, t-test ,5251953
m5351-2011-003-app1619-sap,895 subjects, t-test ,5255483
m5351-2011-003-app1619-sap,929  subjects, t-test ,6733841
m5351-2011-003-app1619-sap,2012   Eligible patients, t-test ,52997
m5351-2011-003-app1619-sap,888 patients, t-test ,51191
m5351-2011-003-app1619-sap,444 patients, t-test ,51177
m5351-2011-003-app1619-sap,100 patients, t-test ,43637
m5351-2011-003-app1619-sap,200 patients, t-test ,43620
m5351-2011-003-app1619-sap,4   Eligible patients, t-test ,43506
m5351-2011-003-app1619-sap,300 patients, t-test ,40744
m5351-2011-003-app1619-sap,150 patients, t-test ,40770
m5351-2011-003-app1619-sap,5 RANDOMIZATION  Eligible patients, t-test ,40941
m5351-2011-003-app1619-sap,50 patients, t-test ,40771
m5351-2011-003-app1619-sap,9  patients, t-test ,147097
m5351-2011-003-app1619-sap,256 patients, t-test ,171363
m5351-2011-003-app1619-sap,32  patients, t-test ,207818
m5351-2011-003-app1619-sap,537 lung cancer patients, t-test ,213139
m5351-2011-003-app1619-sap,111 patients, t-test ,224707
m5351-2011-003-app1619-sap,10 patients, t-test ,231902
m5351-2011-003-app1619-sap,76 patients, t-test ,232691
m5351-2011-003-app1619-sap,888  patients, t-test ,265763
m5351-2011-003-app1619-sap,1 at post-baseline if patients, t-test ,292074
m5351-2011-003-app1619-sap,526 patients, t-test ,2930807
m5351-2011-003-app1619-sap,302 patients, t-test ,2953660
m5351-2011-003-app1619-sap,302  patients, t-test ,2954942
m5351-2011-003-app1619-sap,96 101 197   Treated patients, t-test ,3045187
m5351-2011-003-app1619-sap,7         Total number of patients, t-test ,3045337
m5351-2011-003-app1619-sap,197 patients, t-test ,3053497
m5351-2011-003-app1619-sap,5 total patients, t-test ,3058369
m5351-2011-003-app1619-sap,197 randomized patients, t-test ,3072284
m5351-2011-003-app1619-sap,168 patients, t-test ,3072309
m5351-2011-003-app1619-sap,151 149 300   Treated patients, t-test ,3194618
m5351-2011-003-app1619-sap,32         Total number of patients, t-test ,3194833
m5351-2011-003-app1619-sap,300   patients, t-test ,3218817
m5351-2011-003-app1619-sap,50 100 150 200 250 300  Number of patients, t-test ,3221307
m5351-2011-003-app1619-sap,6 total patients, t-test ,3226410
m5351-2011-003-app1619-sap,5   Number of patients, t-test ,3248819
m5351-2011-003-app1619-sap,300 randomized patients, t-test ,3258093
m5351-2011-003-app1619-sap,154 patients, t-test ,3258144
m5351-2011-003-app1619-sap,12 patients, t-test ,3258835
m5351-2011-003-app1619-sap,268 patients, t-test ,3270917
m5351-2011-003-app1619-sap,268   patients, t-test ,3273166
m5351-2011-003-app1619-sap,271 273   Treated patients, t-test ,3660235
m5351-2011-003-app1619-sap,36        Total number of patients, t-test ,3660457
m5351-2011-003-app1619-sap,151 149   Treated patients, t-test ,3660976
m5351-2011-003-app1619-sap,20        Total number of patients, t-test ,3661138
m5351-2011-003-app1619-sap,544   patients, t-test ,3685846
m5351-2011-003-app1619-sap,544 patients, t-test ,3688545
m5351-2011-003-app1619-sap,11 total patients, t-test ,3691640
m5351-2011-003-app1619-sap,34 patients, t-test ,3724782
m5351-2011-003-app1619-sap,544 randomized patients, t-test ,3729711
m5351-2011-003-app1619-sap,482 patients, t-test ,3744167
m5351-2011-003-app1619-sap,87 of patients, t-test ,3913698
m5351-2011-003-app1619-sap,445 450   Treated patients, t-test ,4698118
m5351-2011-003-app1619-sap,67 100        Total number of patients, t-test ,4698341
m5351-2011-003-app1619-sap,895   patients, t-test ,4724365
m5351-2011-003-app1619-sap,895 patients, t-test ,4726985
m5351-2011-003-app1619-sap,8 total   patients, t-test ,4730384
m5351-2011-003-app1619-sap,83 patients, t-test ,4767532
m5351-2011-003-app1619-sap,895 randomized patients, t-test ,4777212
m5351-2011-003-app1619-sap,872 patients, t-test ,4789029
m5351-2011-003-app1619-sap,178 of patients, t-test ,4873129
m5351-2011-003-app1619-sap,464 465   Treated patients, t-test ,5259293
m5351-2011-003-app1619-sap,128 192        Total number of patients, t-test ,5259514
m5351-2011-003-app1619-sap,929   patients, t-test ,5279762
m5351-2011-003-app1619-sap,100 200 300 400 500 600 700 800 900  Number of patients, t-test ,5282115
m5351-2011-003-app1619-sap,929 patients, t-test ,5282908
m5351-2011-003-app1619-sap,919 patients, t-test ,5290532
m5351-2011-003-app1619-sap,131 patients, t-test ,5322687
m5351-2011-003-app1619-sap,38 patients, t-test ,5428471
m5351-2011-003-app1619-sap,202 patients, t-test ,5487991
m5351-2011-003-app1619-sap,137 196        Total number of patients, t-test ,5988514
m5351-2011-003-app1619-sap,166 patients, t-test ,6053679
m5351-2011-003-app1619-sap,44 patients, t-test ,51176
m5351-2011-003-app1619-sap,n = 200, t-test ,238327
m5351-2011-003-app1619-sap,n = 25, t-test ,238393
m5351-2011-003-app1619-sap,N = 266, t-test ,324797
m5351-2011-003-app1619-sap,N = 465, t-test ,330294
m5351-2011-003-app1619-sap,N= 464, t-test ,330307
m5351-2011-003-app1619-sap,N = 464, t-test ,337913
m5351-2011-003-app1619-sap,N=465, t-test ,405234
m5351-2011-003-app1619-sap,N=464, t-test ,405259
m5351-2011-003-app1619-sap,n=799, t-test ,1057898
m5351-2011-003-app1619-sap,n=803, t-test ,1058910
m5351-2011-003-app1619-sap,n=763, t-test ,1062143
m5351-2011-003-app1619-sap,n=719, t-test ,1063156
m5351-2011-003-app1619-sap,n=663, t-test ,1066390
m5351-2011-003-app1619-sap,n=586, t-test ,1067403
m5351-2011-003-app1619-sap,n=520, t-test ,1070637
m5351-2011-003-app1619-sap,n=468, t-test ,1071650
m5351-2011-003-app1619-sap,n=412, t-test ,1074884
m5351-2011-003-app1619-sap,n=376, t-test ,1075897
m5351-2011-003-app1619-sap,n=304, t-test ,1079131
m5351-2011-003-app1619-sap,n=236, t-test ,1080144
m5351-2011-003-app1619-sap,n=210, t-test ,1083378
m5351-2011-003-app1619-sap,n=162, t-test ,1084390
m5351-2011-003-app1619-sap,n=132, t-test ,1087624
m5351-2011-003-app1619-sap,n=101, t-test ,1088637
m5351-2011-003-app1619-sap,n=77, t-test ,1091870
m5351-2011-003-app1619-sap,n=63, t-test ,1092881
m5351-2011-003-app1619-sap,n=52, t-test ,1070637
m5351-2011-003-app1619-sap,N=121, t-test ,1099202
m5351-2011-003-app1619-sap,N=135, t-test ,1099222
m5351-2011-003-app1619-sap,n=225, t-test ,1099374
m5351-2011-003-app1619-sap,n=231, t-test ,1100386
m5351-2011-003-app1619-sap,n=221, t-test ,1103640
m5351-2011-003-app1619-sap,n=205, t-test ,1104653
m5351-2011-003-app1619-sap,n=197, t-test ,1107909
m5351-2011-003-app1619-sap,n=177, t-test ,1108922
m5351-2011-003-app1619-sap,n=174, t-test ,1112177
m5351-2011-003-app1619-sap,n=163, t-test ,1113190
m5351-2011-003-app1619-sap,n=143, t-test ,1116446
m5351-2011-003-app1619-sap,n=129, t-test ,1117459
m5351-2011-003-app1619-sap,n=111, t-test ,1120715
m5351-2011-003-app1619-sap,n=90, t-test ,1121728
m5351-2011-003-app1619-sap,n=79, t-test ,1057898
m5351-2011-003-app1619-sap,n=56, t-test ,1125992
m5351-2011-003-app1619-sap,n=46, t-test ,1071650
m5351-2011-003-app1619-sap,n=34, t-test ,1130257
m5351-2011-003-app1619-sap,n=25, t-test ,1133510
m5351-2011-003-app1619-sap,n=17, t-test ,1108922
m5351-2011-003-app1619-sap,n=13, t-test ,1087624
m5351-2011-003-app1619-sap,N=169, t-test ,1140864
m5351-2011-003-app1619-sap,N=182, t-test ,1140884
m5351-2011-003-app1619-sap,n=288, t-test ,1141036
m5351-2011-003-app1619-sap,n=280, t-test ,1145302
m5351-2011-003-app1619-sap,n=262, t-test ,1146315
m5351-2011-003-app1619-sap,n=238, t-test ,1149571
m5351-2011-003-app1619-sap,n=214, t-test ,1150584
m5351-2011-003-app1619-sap,n=189, t-test ,1153840
m5351-2011-003-app1619-sap,n=173, t-test ,1154853
m5351-2011-003-app1619-sap,n=158, t-test ,1158108
m5351-2011-003-app1619-sap,n=141, t-test ,1159120
m5351-2011-003-app1619-sap,n=119, t-test ,1162376
m5351-2011-003-app1619-sap,n=91, t-test ,1163389
m5351-2011-003-app1619-sap,n=88, t-test ,1166642
m5351-2011-003-app1619-sap,n=71, t-test ,1063156
m5351-2011-003-app1619-sap,n=59, t-test ,1170906
m5351-2011-003-app1619-sap,n=47, t-test ,1171917
m5351-2011-003-app1619-sap,n=32, t-test ,1176182
m5351-2011-003-app1619-sap,n=26, t-test ,1146315
m5351-2011-003-app1619-sap,N=49, t-test ,1182522
m5351-2011-003-app1619-sap,N=35, t-test ,1182542
m5351-2011-003-app1619-sap,n=68, t-test ,1186956
m5351-2011-003-app1619-sap,n=67, t-test ,1187967
m5351-2011-003-app1619-sap,n=51, t-test ,1192229
m5351-2011-003-app1619-sap,n=41, t-test ,1074884
m5351-2011-003-app1619-sap,n=35, t-test ,1196493
m5351-2011-003-app1619-sap,n=33, t-test ,1199745
m5351-2011-003-app1619-sap,n=21, t-test ,1083378
m5351-2011-003-app1619-sap,n=16, t-test ,1084390
m5351-2011-003-app1619-sap,n=14, t-test ,1116446
m5351-2011-003-app1619-sap,n=10, t-test ,1088637
m5351-2011-003-app1619-sap,n=6, t-test ,1066390
m5351-2011-003-app1619-sap,N=15, t-test ,1224146
m5351-2011-003-app1619-sap,N=10, t-test ,1224166
m5351-2011-003-app1619-sap,n=22, t-test ,1099374
m5351-2011-003-app1619-sap,n=24, t-test ,1228580
m5351-2011-003-app1619-sap,n=23, t-test ,1080144
m5351-2011-003-app1619-sap,n=20, t-test ,1104653
m5351-2011-003-app1619-sap,n=18, t-test ,1153840
m5351-2011-003-app1619-sap,n=15, t-test ,1158108
m5351-2011-003-app1619-sap,n=9, t-test ,1121728
m5351-2011-003-app1619-sap,n=7, t-test ,1057898
m5351-2011-003-app1619-sap,n=4, t-test ,1071650
m5351-2011-003-app1619-sap,n=2, t-test ,1080144
m5351-2011-003-app1619-sap,n=1, t-test ,1084390
m5351-2011-003-app1619-sap,N=111, t-test ,1265757
m5351-2011-003-app1619-sap,N=102, t-test ,1265777
m5351-2011-003-app1619-sap,n=185, t-test ,1265929
m5351-2011-003-app1619-sap,n=191, t-test ,1266941
m5351-2011-003-app1619-sap,n=170, t-test ,1270194
m5351-2011-003-app1619-sap,n=147, t-test ,1274461
m5351-2011-003-app1619-sap,n=124, t-test ,1275474
m5351-2011-003-app1619-sap,n=98, t-test ,1278728
m5351-2011-003-app1619-sap,n=82, t-test ,1279739
m5351-2011-003-app1619-sap,n=64, t-test ,1282991
m5351-2011-003-app1619-sap,n=61, t-test ,1284002
m5351-2011-003-app1619-sap,n=40, t-test ,1287253
m5351-2011-003-app1619-sap,n=27, t-test ,1288264
m5351-2011-003-app1619-sap,n=19, t-test ,1107909
m5351-2011-003-app1619-sap,n=8, t-test ,1058910
m5351-2011-003-app1619-sap,N=44, t-test ,1307377
m5351-2011-003-app1619-sap,N=37, t-test ,1307397
m5351-2011-003-app1619-sap,n=72, t-test ,1307549
m5351-2011-003-app1619-sap,n=75, t-test ,1308559
m5351-2011-003-app1619-sap,n=62, t-test ,1311807
m5351-2011-003-app1619-sap,n=53, t-test ,1316065
m5351-2011-003-app1619-sap,n=39, t-test ,1320325
m5351-2011-003-app1619-sap,n=28, t-test ,1141036
m5351-2011-003-app1619-sap,n=11, t-test ,1120715
m5351-2011-003-app1619-sap,n=5, t-test ,1067403
m5351-2011-003-app1619-sap,N=4, t-test ,405234
m5351-2011-003-app1619-sap,N=1, t-test ,1099202
m5351-2011-003-app1619-sap,N=16, t-test ,1140864
m5351-2011-003-app1619-sap,N=11, t-test ,1265757
m5351-2011-003-app1619-sap,N=8, t-test ,1426332
m5351-2011-003-app1619-sap,N=14, t-test ,1426352
m5351-2011-003-app1619-sap,n=12, t-test ,1117459
m5351-2011-003-app1619-sap,n=3, t-test ,1075897
m5351-2011-003-app1619-sap,N=20, t-test ,1509435
m5351-2011-003-app1619-sap,N=18, t-test ,1140884
m5351-2011-003-app1619-sap,n=36, t-test ,1509607
m5351-2011-003-app1619-sap,n=29, t-test ,1518118
m5351-2011-003-app1619-sap,N=34, t-test ,1550986
m5351-2011-003-app1619-sap,N=38, t-test ,1551006
m5351-2011-003-app1619-sap,n=65, t-test ,1555421
m5351-2011-003-app1619-sap,n=58, t-test ,1067403
m5351-2011-003-app1619-sap,n=54, t-test ,1560696
m5351-2011-003-app1619-sap,n=57, t-test ,1563950
m5351-2011-003-app1619-sap,n=38, t-test ,1569226
m5351-2011-003-app1619-sap,N=26, t-test ,1592634
m5351-2011-003-app1619-sap,n=31, t-test ,1601298
m5351-2011-003-app1619-sap,N=25, t-test ,1634172
m5351-2011-003-app1619-sap,n=43, t-test ,1634344
m5351-2011-003-app1619-sap,n=55, t-test ,1680136
m5351-2011-003-app1619-sap,n=42, t-test ,1685400
m5351-2011-003-app1619-sap,n=30, t-test ,1079131
m5351-2011-003-app1619-sap,N=21, t-test ,1717268
m5351-2011-003-app1619-sap,N=17, t-test ,1758874
m5351-2011-003-app1619-sap,N=12, t-test ,1099202
m5351-2011-003-app1619-sap,N=43, t-test ,1882387
m5351-2011-003-app1619-sap,n=70, t-test ,1883549
m5351-2011-003-app1619-sap,n=60, t-test ,1891047
m5351-2011-003-app1619-sap,n=48, t-test ,1895303
m5351-2011-003-app1619-sap,n=37, t-test ,1075897
m5351-2011-003-app1619-sap,N=23, t-test ,1923930
m5351-2011-003-app1619-sap,N=13, t-test ,1099222
m5351-2011-003-app1619-sap,N=27, t-test ,2130625
m5351-2011-003-app1619-sap,N=9, t-test ,2172270
m5351-2011-003-app1619-sap,N=0, t-test ,2213833
m5351-2011-003-app1619-sap,N=3, t-test ,1182542
m5351-2011-003-app1619-sap,N=2, t-test ,1509435
m5351-2011-003-app1619-sap,N=22, t-test ,2329322
m5351-2011-003-app1619-sap,N=29, t-test ,2370886
m5351-2011-003-app1619-sap,N=456, t-test ,2416546
m5351-2011-003-app1619-sap,N=463, t-test ,2416571
m5351-2011-003-app1619-sap,N = 76, t-test ,2812074
m5351-2011-003-app1619-sap,N = 75, t-test ,2812095
m5351-2011-003-app1619-sap,N = 151, t-test ,2812119
m5351-2011-003-app1619-sap,N =75, t-test ,2821853
m5351-2011-003-app1619-sap,N =151, t-test ,2821874
m5351-2011-003-app1619-sap,N = 74, t-test ,2838553
m5351-2011-003-app1619-sap,n = 76, t-test ,2884838
m5351-2011-003-app1619-sap,n = 55, t-test ,2884890
m5351-2011-003-app1619-sap,n = 33, t-test ,2884958
m5351-2011-003-app1619-sap,n = 18, t-test ,2885026
m5351-2011-003-app1619-sap,n = 8, t-test ,2885094
m5351-2011-003-app1619-sap,n = 0, t-test ,2885161
m5351-2011-003-app1619-sap,n = 52, t-test ,2895458
m5351-2011-003-app1619-sap,n = 42, t-test ,2895509
m5351-2011-003-app1619-sap,n = 13, t-test ,2895642
m5351-2011-003-app1619-sap,n = 6, t-test ,2895709
m5351-2011-003-app1619-sap,N=96, t-test ,3056834
m5351-2011-003-app1619-sap,N=101, t-test ,3056859
m5351-2011-003-app1619-sap,N=197, t-test ,3056883
m5351-2011-003-app1619-sap,N=84, t-test ,3073382
m5351-2011-003-app1619-sap,N=168, t-test ,3073430
m5351-2011-003-app1619-sap,N=151, t-test ,3224702
m5351-2011-003-app1619-sap,N=149, t-test ,3224728
m5351-2011-003-app1619-sap,N=300, t-test ,3224752
m5351-2011-003-app1619-sap,N=140, t-test ,3247964
m5351-2011-003-app1619-sap,N=128, t-test ,3247990
m5351-2011-003-app1619-sap,N=268, t-test ,3248014
m5351-2011-003-app1619-sap,N=19, t-test ,3056883
m5351-2011-003-app1619-sap,N=51, t-test ,3286613
m5351-2011-003-app1619-sap,N=36, t-test ,3286647
m5351-2011-003-app1619-sap,N=271, t-test ,3690109
m5351-2011-003-app1619-sap,N=273, t-test ,3690135
m5351-2011-003-app1619-sap,N=544, t-test ,3690159
m5351-2011-003-app1619-sap,N=247, t-test ,3714807
m5351-2011-003-app1619-sap,N=235, t-test ,3714833
m5351-2011-003-app1619-sap,N=482, t-test ,3721667
m5351-2011-003-app1619-sap,N=53, t-test ,3766665
m5351-2011-003-app1619-sap,N=39, t-test ,3766682
m5351-2011-003-app1619-sap,N=78, t-test ,3766699
m5351-2011-003-app1619-sap,N=87, t-test ,3766716
m5351-2011-003-app1619-sap,N=77, t-test ,3766733
m5351-2011-003-app1619-sap,N=72, t-test ,3766750
m5351-2011-003-app1619-sap,N=115, t-test ,4290255
m5351-2011-003-app1619-sap,N=120, t-test ,4290273
m5351-2011-003-app1619-sap,N=160, t-test ,4290291
m5351-2011-003-app1619-sap,N=129, t-test ,4290345
m5351-2011-003-app1619-sap,N=445, t-test ,4729009
m5351-2011-003-app1619-sap,N=450, t-test ,4729035
m5351-2011-003-app1619-sap,N=895, t-test ,4729059
m5351-2011-003-app1619-sap,N=437, t-test ,4755954
m5351-2011-003-app1619-sap,N=435, t-test ,4755980
m5351-2011-003-app1619-sap,N=872, t-test ,4764353
m5351-2011-003-app1619-sap,N=90, t-test ,4873571
m5351-2011-003-app1619-sap,N=88, t-test ,4873598
m5351-2011-003-app1619-sap,N=178, t-test ,4873623
m5351-2011-003-app1619-sap,N=929, t-test ,5285818
m5351-2011-003-app1619-sap,N=919, t-test ,5319547
m5351-2011-003-app1619-sap,N=28, t-test ,5366692
m5351-2011-003-app1619-sap,N=122, t-test ,5366709
m5351-2011-003-app1619-sap,N=127, t-test ,5366727
m5351-2011-003-app1619-sap,N=173, t-test ,5366745
m5351-2011-003-app1619-sap,N=139, t-test ,5366781
m5351-2011-003-app1619-sap,N=131, t-test ,5366799
m5351-2011-003-app1619-sap,N=444, t-test ,5393184
m5351-2011-003-app1619-sap,N=441, t-test ,5393210
m5351-2011-003-app1619-sap,N=885, t-test ,5393234
m5351-2011-003-app1619-sap,N=103, t-test ,5488664
m5351-2011-003-app1619-sap,N=99, t-test ,5488692
m5351-2011-003-app1619-sap,N=202, t-test ,5488717
m5351-2011-003-app1619-sap,N=174, t-test ,6098967
m5351-2011-003-app1619-sap,N=167, t-test ,6098985
m5351-2011-003-app1619-sap,N=133, t-test ,6099021
m5351-2011-003-app1619-sap,total of 888, t-test ,41952
m5351-2011-003-app1619-sap,total of 17, t-test ,184768
m5351-2011-003-app1619-sap,total of 8, t-test ,41952
m5351-2011-003-app1619-sap,total of 151, t-test ,2807823
m5351-2011-003-app1619-sap,total of 28, t-test ,2810057
m5351-2011-003-app1619-sap,total of 81, t-test ,2815129
m5351-2011-003-app1619-sap,total of 46, t-test ,2860327
m5351-2011-003-app1619-sap,total of 300, t-test ,2860429
m5351-2011-003-app1619-sap,total of 2, t-test ,2810057
m5351-2011-003-app1619-sap,total of 526, t-test ,2950350
m5351-2011-003-app1619-sap,total of302, t-test ,2953652
m5351-2011-003-app1619-sap,total of253, t-test ,2954558
m5351-2011-003-app1619-sap,total of 87, t-test ,3913689
m5351-2011-003-app1619-sap,total of 895, t-test ,4726976
m5351-2011-003-app1619-sap,total of 178, t-test ,4873120
m5351-2011-003-app1619-sap,total of 899, t-test ,5251177
m5351-2011-003-app1619-sap,total of 40, t-test ,5251309
m5351-2011-003-app1619-sap,total of 929, t-test ,5282899
m5351-2011-003-app1619-sap,888 patients enrolled, t-test ,41943
m5351-2011-003-app1619-sap,150 subjects were enrolled, t-test ,2925157
m5351-2011-003-app1619-sap,526 patients enrolled, t-test ,2930807
m5351-2011-003-app1619-sap,302  patients will be enrolled, t-test ,2954942
m5351-2011-003-app1619-sap,197 subjects enrolled, t-test ,3040491
m5351-2011-003-app1619-sap,300 subjects enrolled, t-test ,3191558
m5351-2011-003-app1619-sap,544  subjects enrolled, t-test ,4287546
m5351-2011-003-app1619-sap,895 patients have been enrolled, t-test ,4726985
m5351-2011-003-app1619-sap,40 subjects are enrolled, t-test ,5251318
m5351-2011-003-app1619-sap,895 subjects enrolled, t-test ,5255483
m5351-2011-003-app1619-sap,929  subjects enrolled, t-test ,6733841
m5351-2011-003-app1619-sap, data from 526, t-test ,2787775
m5351-2011-003-app1619-sap,   data from the 197, t-test ,3053480
m5351-2011-003-app1619-sap, data from the 300, t-test ,3218802
m5351-2011-003-app1619-sap, data from the 544, t-test ,3685831
m5351-2011-003-app1619-sap, data from the 895, t-test ,4724350
m5351-2011-003-app1619-sap, data from the 929, t-test ,5279747
m5351-2011-003-s-csr-body,"229,000 persons",null,-1
m5351-2011-003-s-csr-body,266 subjects,null,-1
m5351-2011-003-s-csr-body,61 subjects,null,-1
m5351-2011-003-s-csr-body,526 subjects,null,-1
m5351-2011-003-s-csr-body,22 subjects,null,-1
m5351-2011-003-s-csr-body,130 subjects,null,-1
m5351-2011-003-s-csr-body,888 eligible subjects,null,-1
m5351-2011-003-s-csr-body,2 study of subjects,null,-1
m5351-2011-003-s-csr-body,888 subjects,null,-1
m5351-2011-003-s-csr-body,100 subjects,null,-1
m5351-2011-003-s-csr-body,300 subjects,null,-1
m5351-2011-003-s-csr-body,150 subjects,null,-1
m5351-2011-003-s-csr-body,1096 subjects,null,-1
m5351-2011-003-s-csr-body,929 subjects,null,-1
m5351-2011-003-s-csr-body,919 subjects,null,-1
m5351-2011-003-s-csr-body,200 subjects,null,-1
m5351-2011-003-s-csr-body,105 subjects,null,-1
m5351-2011-003-s-csr-body,516 subjects,null,-1
m5351-2011-003-s-csr-body,218 subjects,null,-1
m5351-2011-003-s-csr-body,298 subjects,null,-1
m5351-2011-003-s-csr-body,4 subjects,null,-1
m5351-2011-003-s-csr-body,2 subjects,null,-1
m5351-2011-003-s-csr-body,5 subjects,null,-1
m5351-2011-003-s-csr-body,7 subjects,null,-1
m5351-2011-003-s-csr-body,19 subjects,null,-1
m5351-2011-003-s-csr-body,12 subjects,null,-1
m5351-2011-003-s-csr-body,9 subjects,null,-1
m5351-2011-003-s-csr-body,6 subjects,null,-1
m5351-2011-003-s-csr-body,125 subjects,null,-1
m5351-2011-003-s-csr-body,11 subjects,null,-1
m5351-2011-003-s-csr-body,18 subjects,null,-1
m5351-2011-003-s-csr-body,312 subjects,null,-1
m5351-2011-003-s-csr-body,505 subjects,null,-1
m5351-2011-003-s-csr-body,3 subjects,null,-1
m5351-2011-003-s-csr-body,424 subjects,null,-1
m5351-2011-003-s-csr-body,464 subjects,null,-1
m5351-2011-003-s-csr-body,258 subjects,null,-1
m5351-2011-003-s-csr-body,157 subjects,null,-1
m5351-2011-003-s-csr-body,23 subjects,null,-1
m5351-2011-003-s-csr-body,29 subjects,null,-1
m5351-2011-003-s-csr-body,8 subjects,null,-1
m5351-2011-003-s-csr-body,30 subjects,null,-1
m5351-2011-003-s-csr-body,28 subjects,null,-1
m5351-2011-003-s-csr-body,84 subjects,null,-1
m5351-2011-003-s-csr-body,208 sites screening subjects,null,-1
m5351-2011-003-s-csr-body,496 subjects,null,-1
m5351-2011-003-s-csr-body,929 relapsed multiple myeloma subjects,null,-1
m5351-2011-003-s-csr-body,0   Number of weeks subjects,null,-1
m5351-2011-003-s-csr-body,003   subjects,null,-1
m5351-2011-003-s-csr-body,95 subjects,null,-1
m5351-2011-003-s-csr-body,92 subjects,null,-1
m5351-2011-003-s-csr-body,75 subjects,null,-1
m5351-2011-003-s-csr-body,53 subjects,null,-1
m5351-2011-003-s-csr-body,68 subjects,null,-1
m5351-2011-003-s-csr-body,151 subjects,null,-1
m5351-2011-003-s-csr-body,3 additional subjects,null,-1
m5351-2011-003-s-csr-body,20 subjects,null,-1
m5351-2011-003-s-csr-body,003   The proportion of subjects,null,-1
m5351-2011-003-s-csr-body,003   The same proportion of subjects,null,-1
m5351-2011-003-s-csr-body,2   Vd Cd       Number of subjects,null,-1
m5351-2011-003-s-csr-body,10     Number of subjects,null,-1
m5351-2011-003-s-csr-body,0      Number of subjects,null,-1
m5351-2011-003-s-csr-body,1      Number of subjects,null,-1
m5351-2011-003-s-csr-body,1=number of subjects,null,-1
m5351-2011-003-s-csr-body,75   Number of subjects,null,-1
m5351-2011-003-s-csr-body,"10,710 deaths in patients",null,-1
m5351-2011-003-s-csr-body,3 prior therapies where the patients,null,-1
m5351-2011-003-s-csr-body,222 patients,null,-1
m5351-2011-003-s-csr-body,90 patients,null,-1
m5351-2011-003-s-csr-body,5 patients,null,-1
m5351-2011-003-s-csr-body,6 patients,null,-1
m5351-2011-003-s-csr-body,1   Prior Velcade patients,null,-1
m5351-2011-003-s-csr-body,526 patients,null,-1
m5351-2011-003-s-csr-body,n = 148,null,-1
m5351-2011-003-s-csr-body,n = 74,null,-1
m5351-2011-003-s-csr-body,n = 24,null,-1
m5351-2011-003-s-csr-body,n = 8,null,-1
m5351-2011-003-s-csr-body,N = 465,null,-1
m5351-2011-003-s-csr-body,N = 464,null,-1
m5351-2011-003-s-csr-body,N = 929,null,-1
m5351-2011-003-s-csr-body,n = 465,null,-1
m5351-2011-003-s-csr-body,n = 464,null,-1
m5351-2011-003-s-csr-body,n=9,null,-1
m5351-2011-003-s-csr-body,N = 456,null,-1
m5351-2011-003-s-csr-body,N = 463,null,-1
m5351-2011-003-s-csr-body,N=456,null,-1
m5351-2011-003-s-csr-body,N=463,null,-1
m5351-2011-003-s-csr-body,N = 46,null,-1
m5351-2011-003-s-csr-body,N = 4,null,-1
m5351-2011-003-s-csr-body,N=465,null,-1
m5351-2011-003-s-csr-body,N=464,null,-1
m5351-2011-003-s-csr-body,N=9,null,-1
m5351-2011-003-s-csr-body,N=929,null,-1
m5351-2011-003-s-csr-body,N=92,null,-1
m5351-2011-003-s-csr-body,N=46,null,-1
m5351-2011-003-s-csr-body,N=450,null,-1
m5351-2011-003-s-csr-body,N=452,null,-1
m5351-2011-003-s-csr-body,N=334,null,-1
m5351-2011-003-s-csr-body,N=357,null,-1
m5351-2011-003-s-csr-body,N=449,null,-1
m5351-2011-003-s-csr-body,N=451,null,-1
m5351-2011-003-s-csr-body,N=4,null,-1
m5351-2011-003-s-csr-body,N=462,null,-1
m5351-2011-003-s-csr-body,N=360,null,-1
m5351-2011-003-s-csr-body,N=75,null,-1
m5351-2011-003-s-csr-body,N=435,null,-1
m5351-2011-003-s-csr-body,N=355,null,-1
m5351-2011-003-s-csr-body,N=76,null,-1
m5351-2011-003-s-csr-body,N=64,null,-1
m5351-2011-003-s-csr-body,N=29,null,-1
m5351-2011-003-s-csr-body,N=35,null,-1
m5351-2011-003-s-csr-body,N=74,null,-1
m5351-2011-003-s-csr-body,total of 61,null,-1
m5351-2011-003-s-csr-body,total of   526,null,-1
m5351-2011-003-s-csr-body,total of 888,null,-1
m5351-2011-003-s-csr-body,total of 496,null,-1
m5351-2011-003-s-csr-body,total of 1096,null,-1
m5351-2011-003-s-csr-body,total of 929,null,-1
m5351-2011-003-s-csr-body,total of 919,null,-1
m5351-2011-003-s-csr-body,total of 147,null,-1
m5351-2011-003-s-csr-body,total of 4,null,-1
m5351-2011-003-s-csr-body,total of 9,null,-1
m5351-2011-003-s-csr-body,total of 417,null,-1
m5351-2011-003-s-csr-body,total of 464,null,-1
m5351-2011-003-s-csr-body,total of   98,null,-1
m5351-2011-003-s-csr-body,total of 75,null,-1
m5351-2011-003-s-csr-body,total of 19,null,-1
m5351-2011-003-s-csr-body,total of 32,null,-1
m5351-2011-003-s-csr-body,total of 200,null,-1
m5351-2011-003-s-csr-body,total of 95,null,-1
m5351-2011-003-s-csr-body,total of 22,null,-1
m5351-2011-003-s-csr-body,009 enrolled,null,-1
m5351-2011-003-s-csr-body,130 subjects enrolled,null,-1
m5351-2011-003-s-csr-body,888 subjects enrolled,null,-1
m5351-2011-003-s-csr-body,003 enrolled,null,-1
m5351-2011-003-s-csr-body,526 patients enrolled,null,-1
m5351-2011-003-s-csr-body, data from 6,null,-1
m5351-2011-003-s-csr-body, data from PX-171,null,-1
m5351-px-171-009-app1611-protocol,131  Confidential  participants,null,-1
m5351-px-171-009-app1611-protocol,780 subjects,null,-1
m5351-px-171-009-app1611-protocol,36 evaluable subjects,null,-1
m5351-px-171-009-app1611-protocol,32 subjects,null,-1
m5351-px-171-009-app1611-protocol,250 subjects,null,-1
m5351-px-171-009-app1611-protocol,390 subjects,null,-1
m5351-px-171-009-app1611-protocol,2 For subjects,null,-1
m5351-px-171-009-app1611-protocol,3 For subjects,null,-1
m5351-px-171-009-app1611-protocol,4 HYDRATION  All subjects,null,-1
m5351-px-171-009-app1611-protocol,700 subjects,null,-1
m5351-px-171-009-app1611-protocol,113  Confidential  retention of subjects,null,-1
m5351-px-171-009-app1611-protocol,60 subjects,null,-1
m5351-px-171-009-app1611-protocol,580 subjects,null,-1
m5351-px-171-009-app1611-protocol,39 subjects,null,-1
m5351-px-171-009-app1611-protocol,2 SAFETY ANALYSIS SET  All subjects,null,-1
m5351-px-171-009-app1611-protocol,350 subjects,null,-1
m5351-px-171-009-app1611-protocol,780  subjects,null,-1
m5351-px-171-009-app1611-protocol,131  Confidential  For subjects,null,-1
m5351-px-171-009-app1611-protocol,2   For subjects,null,-1
m5351-px-171-009-app1611-protocol,4 HYDRATION   All subjects,null,-1
m5351-px-171-009-app1611-protocol,103   discontinue subjects,null,-1
m5351-px-171-009-app1611-protocol,2 SAFETY ANALYSIS SET   All subjects,null,-1
m5351-px-171-009-app1611-protocol,2  For subjects,null,-1
m5351-px-171-009-app1611-protocol,3  For subjects,null,-1
m5351-px-171-009-app1611-protocol,103  Confidential  discontinue subjects,null,-1
m5351-px-171-009-app1611-protocol,92  Confidential  Male subjects,null,-1
m5351-px-171-009-app1611-protocol,total of 526,null,-1
m5351-px-171-009-app1611-protocol,total of 4,null,-1
m5351-px-171-009-app1611-protocol,total of 700,null,-1
m5351-px-171-009-app1611-protocol,total of 175,null,-1
m5351-px-171-009-app1611-protocol,total of 510,null,-1
m5351-px-171-009-app1611-protocol,total   of 700,null,-1
m5351-px-171-009-app1611-protocol,total of   700,null,-1
m5351-px-171-009-app1611-protocol,total of 502,null,-1
m5351-px-171-009-app1611-protocol,780 subjects will be   enrolled,null,-1
m5351-px-171-009-app1611-protocol,32 subjects have been enrolled,null,-1
m5351-px-171-009-app1611-protocol,780 subjects will be enrolled,null,-1
m5351-px-171-009-app1611-protocol,700 subjects enrolled,null,-1
m5351-px-171-009-app1611-protocol,700 subjects will be enrolled,null,-1
m5351-px-171-009-app1611-protocol,780  subjects will be enrolled,null,-1
m5351-px-171-009-app1611-protocol, data from 26,null,-1
m5351-px-171-009-app1619-sap,537 participants,null,-1
m5351-px-171-009-app1619-sap,780 subjects,null,-1
m5351-px-171-009-app1619-sap,390 subjects,null,-1
m5351-px-171-009-app1619-sap,4 RANDOMIZATION   Eligible subjects,null,-1
m5351-px-171-009-app1619-sap,700 subjects,null,-1
m5351-px-171-009-app1619-sap,60 subjects,null,-1
m5351-px-171-009-app1619-sap,9 subjects,null,-1
m5351-px-171-009-app1619-sap,780   subjects,null,-1
m5351-px-171-009-app1619-sap,2013   such subjects,null,-1
m5351-px-171-009-app1619-sap,350 subjects,null,-1
m5351-px-171-009-app1619-sap,3 SAFETY POPULATION   All subjects,null,-1
m5351-px-171-009-app1619-sap,580 subjects,null,-1
m5351-px-171-009-app1619-sap,888 subjects,null,-1
m5351-px-171-009-app1619-sap,50 patients,null,-1
m5351-px-171-009-app1619-sap,537 lung cancer patients,null,-1
m5351-px-171-009-app1619-sap,111 patients,null,-1
m5351-px-171-009-app1619-sap,10 patients,null,-1
m5351-px-171-009-app1619-sap,76 patients,null,-1
m5351-px-171-009-app1619-sap,780 patients,null,-1
m5351-px-171-009-app1619-sap,792 patients,null,-1
m5351-px-171-009-app1619-sap,84 patients,null,-1
m5351-px-171-009-app1619-sap,302 patients,null,-1
m5351-px-171-009-app1619-sap,888 patients,null,-1
m5351-px-171-009-app1619-sap,882 patients,null,-1
m5351-px-171-009-app1619-sap,700 relapsed myeloma patients,null,-1
m5351-px-171-009-app1619-sap,60 randomized patients,null,-1
m5351-px-171-009-app1619-sap,33 patients,null,-1
m5351-px-171-009-app1619-sap,700 patients,null,-1
m5351-px-171-009-app1619-sap,5 new patients,null,-1
m5351-px-171-009-app1619-sap,n=20,null,-1
m5351-px-171-009-app1619-sap,n = 200,null,-1
m5351-px-171-009-app1619-sap,n = 25,null,-1
m5351-px-171-009-app1619-sap,total of 700,null,-1
m5351-px-171-009-app1619-sap,total of   510,null,-1
m5351-px-171-009-app1619-sap,total of   502,null,-1
m5351-px-171-009-app1619-sap,total of 175,null,-1
m5351-px-171-009-app1619-sap,total of 526,null,-1
m5351-px-171-009-app1619-sap,700 subjects enrolled,null,-1
m5351-px-171-009-app1619-sap,700 subjects are   enrolled,null,-1
m5351-px-171-009-app1619-sap,700 subjects will be enrolled,null,-1
m5351-px-171-009-app1619-sap,792 patients enrolled,null,-1
m5351-px-171-009-p-csr-body,"229,000 persons",null,-1
m5351-px-171-009-p-csr-body,155 sites screening subjects,null,-1
m5351-px-171-009-p-csr-body,780 subjects,null,-1
m5351-px-171-009-p-csr-body,956 subjects,null,-1
m5351-px-171-009-p-csr-body,792 subjects,null,-1
m5351-px-171-009-p-csr-body,781 subjects,null,-1
m5351-px-171-009-p-csr-body,9 subjects,null,-1
m5351-px-171-009-p-csr-body,10 subjects,null,-1
m5351-px-171-009-p-csr-body,7 subjects,null,-1
m5351-px-171-009-p-csr-body,266 subjects,null,-1
m5351-px-171-009-p-csr-body,61 subjects,null,-1
m5351-px-171-009-p-csr-body,526 subjects,null,-1
m5351-px-171-009-p-csr-body,84 subjects,null,-1
m5351-px-171-009-p-csr-body,83 response-evaluable subjects,null,-1
m5351-px-171-009-p-csr-body,396 subjects,null,-1
m5351-px-171-009-p-csr-body,700 subjects,null,-1
m5351-px-171-009-p-csr-body,60 subjects,null,-1
m5351-px-171-009-p-csr-body,522 subjects,null,-1
m5351-px-171-009-p-csr-body,118 subjects,null,-1
m5351-px-171-009-p-csr-body,86 subjects,null,-1
m5351-px-171-009-p-csr-body,274 subjects,null,-1
m5351-px-171-009-p-csr-body,303 subjects,null,-1
m5351-px-171-009-p-csr-body,24 subjects,null,-1
m5351-px-171-009-p-csr-body,16 subjects,null,-1
m5351-px-171-009-p-csr-body,19 subjects,null,-1
m5351-px-171-009-p-csr-body,6 subjects,null,-1
m5351-px-171-009-p-csr-body,5 subjects,null,-1
m5351-px-171-009-p-csr-body,247 subjects,null,-1
m5351-px-171-009-p-csr-body,122 subjects,null,-1
m5351-px-171-009-p-csr-body,125 subjects,null,-1
m5351-px-171-009-p-csr-body,4 subjects,null,-1
m5351-px-171-009-p-csr-body,117 subjects,null,-1
m5351-px-171-009-p-csr-body,37 subjects,null,-1
m5351-px-171-009-p-csr-body,34 subjects,null,-1
m5351-px-171-009-p-csr-body,17 subjects,null,-1
m5351-px-171-009-p-csr-body,25 subjects,null,-1
m5351-px-171-009-p-csr-body,22 subjects,null,-1
m5351-px-171-009-p-csr-body,20 subjects,null,-1
m5351-px-171-009-p-csr-body,4 of these subjects,null,-1
m5351-px-171-009-p-csr-body,3 subjects,null,-1
m5351-px-171-009-p-csr-body,2 subjects,null,-1
m5351-px-171-009-p-csr-body,4   subjects,null,-1
m5351-px-171-009-p-csr-body,9  ajority of s   of subjects,null,-1
m5351-px-171-009-p-csr-body,54 subjects,null,-1
m5351-px-171-009-p-csr-body,80 subjects,null,-1
m5351-px-171-009-p-csr-body,21 subjects,null,-1
m5351-px-171-009-p-csr-body,7 additional subjects,null,-1
m5351-px-171-009-p-csr-body,42 subjects,null,-1
m5351-px-171-009-p-csr-body,129 subjects,null,-1
m5351-px-171-009-p-csr-body,142 subjects,null,-1
m5351-px-171-009-p-csr-body,160 subjects,null,-1
m5351-px-171-009-p-csr-body,30 subjects,null,-1
m5351-px-171-009-p-csr-body,33 subjects,null,-1
m5351-px-171-009-p-csr-body,20   Thirty subjects,null,-1
m5351-px-171-009-p-csr-body,27 subjects,null,-1
m5351-px-171-009-p-csr-body,71 subjects,null,-1
m5351-px-171-009-p-csr-body,26 subjects,null,-1
m5351-px-171-009-p-csr-body,14 subjects,null,-1
m5351-px-171-009-p-csr-body,53 subjects,null,-1
m5351-px-171-009-p-csr-body,12 subjects,null,-1
m5351-px-171-009-p-csr-body,1   More subjects,null,-1
m5351-px-171-009-p-csr-body,0 subjects,null,-1
m5351-px-171-009-p-csr-body,8 subjects,null,-1
m5351-px-171-009-p-csr-body,13 subjects,null,-1
m5351-px-171-009-p-csr-body,18 subjects,null,-1
m5351-px-171-009-p-csr-body,11 subjects,null,-1
m5351-px-171-009-p-csr-body,7   The proportion of subjects,null,-1
m5351-px-171-009-p-csr-body,7   Most of subjects,null,-1
m5351-px-171-009-p-csr-body,7   Fewer subjects,null,-1
m5351-px-171-009-p-csr-body,14 Rd subjects,null,-1
m5351-px-171-009-p-csr-body,55 subjects,null,-1
m5351-px-171-009-p-csr-body,36 subjects,null,-1
m5351-px-171-009-p-csr-body,3 study enrolled subjects,null,-1
m5351-px-171-009-p-csr-body,"10,710 deaths in patients",null,-1
m5351-px-171-009-p-csr-body,526 patients,null,-1
m5351-px-171-009-p-csr-body,N = 351,null,-1
m5351-px-171-009-p-csr-body,N = 353,null,-1
m5351-px-171-009-p-csr-body,n = 83,null,-1
m5351-px-171-009-p-csr-body,n = 51,null,-1
m5351-px-171-009-p-csr-body,n = 25,null,-1
m5351-px-171-009-p-csr-body,N = 445,null,-1
m5351-px-171-009-p-csr-body,n = 396,null,-1
m5351-px-171-009-p-csr-body,N = 792,null,-1
m5351-px-171-009-p-csr-body,n =  396,null,-1
m5351-px-171-009-p-csr-body,n = 39,null,-1
m5351-px-171-009-p-csr-body,N =      521,null,-1
m5351-px-171-009-p-csr-body,n =  85,null,-1
m5351-px-171-009-p-csr-body,N=396,null,-1
m5351-px-171-009-p-csr-body,N=792,null,-1
m5351-px-171-009-p-csr-body,N=  54,null,-1
m5351-px-171-009-p-csr-body,n = 392,null,-1
m5351-px-171-009-p-csr-body,n = 389,null,-1
m5351-px-171-009-p-csr-body,N = 781,null,-1
m5351-px-171-009-p-csr-body,N = 396,null,-1
m5351-px-171-009-p-csr-body,N = 392,null,-1
m5351-px-171-009-p-csr-body,N = 389,null,-1
m5351-px-171-009-p-csr-body,n = 1,null,-1
m5351-px-171-009-p-csr-body,n = 6,null,-1
m5351-px-171-009-p-csr-body,N= 389,null,-1
m5351-px-171-009-p-csr-body,n = 9,null,-1
m5351-px-171-009-p-csr-body,N = 38,null,-1
m5351-px-171-009-p-csr-body,N = 3,null,-1
m5351-px-171-009-p-csr-body,n = 17,null,-1
m5351-px-171-009-p-csr-body,n = 7,null,-1
m5351-px-171-009-p-csr-body,n = 14,null,-1
m5351-px-171-009-p-csr-body,n = 8,null,-1
m5351-px-171-009-p-csr-body,N=7,null,-1
m5351-px-171-009-p-csr-body,N=79,null,-1
m5351-px-171-009-p-csr-body,N=3,null,-1
m5351-px-171-009-p-csr-body,N=392,null,-1
m5351-px-171-009-p-csr-body,N=389,null,-1
m5351-px-171-009-p-csr-body,N=38,null,-1
m5351-px-171-009-p-csr-body,N=388,null,-1
m5351-px-171-009-p-csr-body,N=382,null,-1
m5351-px-171-009-p-csr-body,N=376,null,-1
m5351-px-171-009-p-csr-body,N=387,null,-1
m5351-px-171-009-p-csr-body,N=385,null,-1
m5351-px-171-009-p-csr-body,total of 780,null,-1
m5351-px-171-009-p-csr-body,total of 956,null,-1
m5351-px-171-009-p-csr-body,total of 792,null,-1
m5351-px-171-009-p-csr-body,total of 7,null,-1
m5351-px-171-009-p-csr-body,total of 61,null,-1
m5351-px-171-009-p-csr-body,total of 526,null,-1
m5351-px-171-009-p-csr-body,total of 84,null,-1
m5351-px-171-009-p-csr-body,total of 510,null,-1
m5351-px-171-009-p-csr-body,total of 72,null,-1
m5351-px-171-009-p-csr-body,total of 4,null,-1
m5351-px-171-009-p-csr-body,total of 151,null,-1
m5351-px-171-009-p-csr-body,total of 37,null,-1
m5351-px-171-009-p-csr-body,total of 17,null,-1
m5351-px-171-009-p-csr-body,total of 21,null,-1
m5351-px-171-009-p-csr-body,total of 9,null,-1
m5351-px-171-009-p-csr-body,total of 52,null,-1
m5351-px-171-009-p-csr-body,total of 54,null,-1
m5351-px-171-009-p-csr-body,total of 36,null,-1
m5351-px-171-009-p-csr-body,total of 49,null,-1
m5351-px-171-009-p-csr-body,total of 51,null,-1
m5351-px-171-009-p-csr-body,total of 42,null,-1
m5351-px-171-009-p-csr-body,total of 38,null,-1
m5351-px-171-009-p-csr-body,total of   792,null,-1
m5351-px-171-009-p-csr-body,total of 118,null,-1
m5351-px-171-009-p-csr-body,total of 86,null,-1
m5351-px-171-009-p-csr-body,total of 69,null,-1
m5351-px-171-009-p-csr-body,total of 13,null,-1
m5351-px-171-009-p-csr-body,total of 53,null,-1
m5351-px-171-009-p-csr-body,total of 12,null,-1
m5351-px-171-009-p-csr-body,total of 18,null,-1
m5351-px-171-009-p-csr-body,total of 23,null,-1
m5351-px-171-009-p-csr-body,total of 56,null,-1
m5351-px-171-009-p-csr-body,total of 70,null,-1
m5351-px-171-009-p-csr-body,total of 142,null,-1
m5351-px-171-009-p-csr-body,total of 30,null,-1
m5351-px-171-009-p-csr-body,total of 3,null,-1
m5351-px-171-009-p-csr-body,total of   2,null,-1
m5351-px-171-009-p-csr-body,total of   10,null,-1
m5351-px-171-009-p-csr-body,total of 2,null,-1
m5351-px-171-009-p-csr-body,total   of 6,null,-1
m5351-px-171-009-p-csr-body,total of 781,null,-1
m5351-px-171-009-p-csr-body,84 subjects were enrolled,null,-1
m5351-px-171-009-p-csr-body,009 enrolled,null,-1
m5351-px-171-009-p-csr-body,5 subjects enrolled,null,-1
m5351-px-171-009-p-csr-body,3 study enrolled,null,-1
m5351-px-171-009-p-csr-body,526 patients enrolled,null,-1
m5351-px-171-011-app1619-sap,4 RANDOMIZATION   Eligible subjects,null,-1
m5351-px-171-011-app1619-sap,302 subjects,null,-1
m5351-px-171-011-app1619-sap,2 SAFETY ANALYSIS SET    All subjects,null,-1
m5351-px-171-011-app1619-sap,84 subjects,null,-1
m5351-px-171-011-app1619-sap,44 using BSC subjects,null,-1
m5351-px-171-011-app1619-sap,2 SAFETY POPULATION  All subjects,null,-1
m5351-px-171-011-app1619-sap,3 subjects,null,-1
m5351-px-171-011-app1619-sap,302 patients,null,-1
m5351-px-171-011-app1619-sap,2 SAFETY ANALYSIS SET    All patients,null,-1
m5351-px-171-011-app1619-sap,76 patients,null,-1
m5351-px-171-011-app1619-sap,98 patients,null,-1
m5351-px-171-011-app1619-sap,2 patients,null,-1
m5351-px-171-011-app1619-sap,7 patients,null,-1
m5351-px-171-011-app1619-sap,4 patients,null,-1
m5351-px-171-011-app1619-sap,total of 253,null,-1
m5351-px-171-011-app1619-sap,total of 302,null,-1
m5351-px-171-011-app1619-sap,302 subjects enrolled,null,-1
m5351-px-171-011-app1619-sap,302 patients enrolled,null,-1
m5351-px-171-011-p-csr-body,81 sites screening subjects,null,-1
m5351-px-171-011-p-csr-body,302 subjects,null,-1
m5351-px-171-011-p-csr-body,403 subjects,null,-1
m5351-px-171-011-p-csr-body,310 subjects,null,-1
m5351-px-171-011-p-csr-body,315 subjects,null,-1
m5351-px-171-011-p-csr-body,52 subjects,null,-1
m5351-px-171-011-p-csr-body,38 subjects,null,-1
m5351-px-171-011-p-csr-body,28 subjects,null,-1
m5351-px-171-011-p-csr-body,29 subjects,null,-1
m5351-px-171-011-p-csr-body,48 subjects,null,-1
m5351-px-171-011-p-csr-body,2 subjects,null,-1
m5351-px-171-011-p-csr-body,3 subjects,null,-1
m5351-px-171-011-p-csr-body,4 multiple myeloma subjects,null,-1
m5351-px-171-011-p-csr-body,8 subjects,null,-1
m5351-px-171-011-p-csr-body,6 subjects,null,-1
m5351-px-171-011-p-csr-body,184 total subjects,null,-1
m5351-px-171-011-p-csr-body,119 subjects,null,-1
m5351-px-171-011-p-csr-body,5 subjects,null,-1
m5351-px-171-011-p-csr-body,55 subjects,null,-1
m5351-px-171-011-p-csr-body,46 subjects,null,-1
m5351-px-171-011-p-csr-body,266 subjects,null,-1
m5351-px-171-011-p-csr-body,792 subjects,null,-1
m5351-px-171-011-p-csr-body,396 subjects,null,-1
m5351-px-171-011-p-csr-body,42 subjects,null,-1
m5351-px-171-011-p-csr-body,315 randomized subjects,null,-1
m5351-px-171-011-p-csr-body,12 subjects,null,-1
m5351-px-171-011-p-csr-body,4 subjects,null,-1
m5351-px-171-011-p-csr-body,34 subjects,null,-1
m5351-px-171-011-p-csr-body,21 carfilzomib   subjects,null,-1
m5351-px-171-011-p-csr-body,13 control subjects,null,-1
m5351-px-171-011-p-csr-body,11 subjects,null,-1
m5351-px-171-011-p-csr-body,14 subjects,null,-1
m5351-px-171-011-p-csr-body,15 subjects,null,-1
m5351-px-171-011-p-csr-body,23 subjects,null,-1
m5351-px-171-011-p-csr-body,9 carfilzomib subjects,null,-1
m5351-px-171-011-p-csr-body,13 control   subjects,null,-1
m5351-px-171-011-p-csr-body,13 control arm subjects,null,-1
m5351-px-171-011-p-csr-body,21 subjects,null,-1
m5351-px-171-011-p-csr-body,1 of these subjects,null,-1
m5351-px-171-011-p-csr-body,2 carfilzomib   subjects,null,-1
m5351-px-171-011-p-csr-body,4 control subjects,null,-1
m5351-px-171-011-p-csr-body,13 subjects,null,-1
m5351-px-171-011-p-csr-body,1 of these   subjects,null,-1
m5351-px-171-011-p-csr-body,4   The majority of subjects,null,-1
m5351-px-171-011-p-csr-body,7 subjects,null,-1
m5351-px-171-011-p-csr-body,153 subjects,null,-1
m5351-px-171-011-p-csr-body,129 subjects,null,-1
m5351-px-171-011-p-csr-body,123 subjects,null,-1
m5351-px-171-011-p-csr-body,16 subjects,null,-1
m5351-px-171-011-p-csr-body,20 subjects,null,-1
m5351-px-171-011-p-csr-body,3 carfilzomib subjects,null,-1
m5351-px-171-011-p-csr-body,2 carfilzomib subjects,null,-1
m5351-px-171-011-p-csr-body,8 control subjects,null,-1
m5351-px-171-011-p-csr-body,80 subjects,null,-1
m5351-px-171-011-p-csr-body,64 subjects,null,-1
m5351-px-171-011-p-csr-body,2 additional subjects,null,-1
m5351-px-171-011-p-csr-body,21 carfilzomib subjects,null,-1
m5351-px-171-011-p-csr-body,19 control subjects,null,-1
m5351-px-171-011-p-csr-body,19 subjects,null,-1
m5351-px-171-011-p-csr-body,10 subjects,null,-1
m5351-px-171-011-p-csr-body,9 subjects,null,-1
m5351-px-171-011-p-csr-body,5 carfilzomib   subjects,null,-1
m5351-px-171-011-p-csr-body,2 of these subjects,null,-1
m5351-px-171-011-p-csr-body,3 of these subjects,null,-1
m5351-px-171-011-p-csr-body,5 carfilzomib subjects,null,-1
m5351-px-171-011-p-csr-body,2 control subjects,null,-1
m5351-px-171-011-p-csr-body,0   Regimen C subjects,null,-1
m5351-px-171-011-p-csr-body,286 patients,null,-1
m5351-px-171-011-p-csr-body,7 patients,null,-1
m5351-px-171-011-p-csr-body,N = 221,null,-1
m5351-px-171-011-p-csr-body,N = 455,null,-1
m5351-px-171-011-p-csr-body,N = 157,null,-1
m5351-px-171-011-p-csr-body,N = 158,null,-1
m5351-px-171-011-p-csr-body,N = 315,null,-1
m5351-px-171-011-p-csr-body,N = 153,null,-1
m5351-px-171-011-p-csr-body,N = 15,null,-1
m5351-px-171-011-p-csr-body,N = 31,null,-1
m5351-px-171-011-p-csr-body,N = 17,null,-1
m5351-px-171-011-p-csr-body,N = 14,null,-1
m5351-px-171-011-p-csr-body,N = 64,null,-1
m5351-px-171-011-p-csr-body,N = 28,null,-1
m5351-px-171-011-p-csr-body,N = 36,null,-1
m5351-px-171-011-p-csr-body,N = 216,null,-1
m5351-px-171-011-p-csr-body,N = 110,null,-1
m5351-px-171-011-p-csr-body,N = 106,null,-1
m5351-px-171-011-p-csr-body,N = 4,null,-1
m5351-px-171-011-p-csr-body,N = 2,null,-1
m5351-px-171-011-p-csr-body,N = 52,null,-1
m5351-px-171-011-p-csr-body,N = 38,null,-1
m5351-px-171-011-p-csr-body,n = 310,null,-1
m5351-px-171-011-p-csr-body,N=157,null,-1
m5351-px-171-011-p-csr-body,N=158,null,-1
m5351-px-171-011-p-csr-body,N=315,null,-1
m5351-px-171-011-p-csr-body,N=3,null,-1
m5351-px-171-011-p-csr-body,N=153,null,-1
m5351-px-171-011-p-csr-body,n = 60,null,-1
m5351-px-171-011-p-csr-body,n = 3,null,-1
m5351-px-171-011-p-csr-body,n = 5,null,-1
m5351-px-171-011-p-csr-body,N=15,null,-1
m5351-px-171-011-p-csr-body,N=1,null,-1
m5351-px-171-011-p-csr-body,total of 302,null,-1
m5351-px-171-011-p-csr-body,total of 403,null,-1
m5351-px-171-011-p-csr-body,total of 315,null,-1
m5351-px-171-011-p-csr-body,total of 18,null,-1
m5351-px-171-011-p-csr-body,"total of 22,350",null,-1
m5351-px-171-011-p-csr-body,total of 792,null,-1
m5351-px-171-011-p-csr-body,total of 253,null,-1
m5351-px-171-011-p-csr-body,total of 94,null,-1
m5351-px-171-011-p-csr-body,total of 29,null,-1
m5351-px-171-011-p-csr-body,total of 68,null,-1
m5351-px-171-011-p-csr-body,total of 66,null,-1
m5351-px-171-011-p-csr-body,total of 99,null,-1
m5351-px-171-011-p-csr-body,total of 98,null,-1
m5351-px-171-011-p-csr-body,total of 87,null,-1
m5351-px-171-011-p-csr-body,total of 197,null,-1
m5351-px-171-011-p-csr-body,total of   6,null,-1
m5351-px-171-011-p-csr-body,total of 61,null,-1
m5351-px-171-011-p-csr-body,total of 20,null,-1
m5351-px-171-011-p-csr-body,total of 12,null,-1
m5351-px-171-011-p-csr-body,total of 14,null,-1
m5351-px-171-011-p-csr-body,total of 3,null,-1
m5351-px-171-011-p-csr-body,total of   129,null,-1
m5351-px-171-011-p-csr-body,total of 58,null,-1
m5351-px-171-011-p-csr-body,total of 15,null,-1
m5351-px-171-011-p-csr-body,total of 17,null,-1
m5351-px-171-011-p-csr-body,77 sites enrolled,null,-1
m5351-px-171-011-p-csr-body,001   enrolled,null,-1
m5351-px-171-011-p-csr-body,002 enrolled,null,-1
m5351-px-171-011-p-csr-body,266 subjects enrolled,null,-1
m5351-px-171-011-p-csr-body,792 subjects were enrolled,null,-1
m5351-px-171-011-p-csr-body,302 subjects enrolled,null,-1
m5351-px-171-011-p-csr-body,10   The study enrolled,null,-1
m5351-px-171-011-p-csr-body,3 trial which enrolled,null,-1
m5352-px-171-001-app1611-protocol,12 subjects,null,-1
m5352-px-171-001-app1611-protocol,50 subjects,null,-1
m5352-px-171-001-app1611-protocol,62 subjects,null,-1
m5352-px-171-001-app1611-protocol,62   subjects,null,-1
m5352-px-171-001-app1611-protocol,11 Female subjects,null,-1
m5352-px-171-001-app1611-protocol,1 Female subjects,null,-1
m5352-px-171-001-app1611-protocol,3 subjects,null,-1
m5352-px-171-001-app1611-protocol,3 more subjects,null,-1
m5352-px-171-001-app1611-protocol,6 subjects,null,-1
m5352-px-171-001-app1611-protocol,50 subjects will be enrolled,null,-1
m5352-px-171-001-app1611-protocol,62 subjects will be enrolled,null,-1
m5352-px-171-001-app1611-protocol,62   subjects will be enrolled,null,-1
m5352-px-171-001-app1619-sap,62 subjects,null,-1
m5352-px-171-001-app1619-sap,3 subjects,null,-1
m5352-px-171-001-app1619-sap,3 more subjects,null,-1
m5352-px-171-001-app1619-sap,6 subjects,null,-1
m5352-px-171-001-app1619-sap,12 subjects,null,-1
m5352-px-171-001-app1619-sap,62 subjects will be enrolled,null,-1
m5352-px-171-001-s-csr-body,29 treated subjects, t-test ,68802
m5352-px-171-001-s-csr-body,29 subjects, t-test ,68545
m5352-px-171-001-s-csr-body,3 subjects, t-test ,68231
m5352-px-171-001-s-csr-body,6 subjects, t-test ,67843
m5352-px-171-001-s-csr-body,2 subjects, t-test ,67642
m5352-px-171-001-s-csr-body,12 subjects, t-test ,66938
m5352-px-171-001-s-csr-body,4 subjects, t-test ,66177
m5352-px-171-001-s-csr-body,62 subjects, t-test ,37567
m5352-px-171-001-s-csr-body,3 additional subjects, t-test ,36603
m5352-px-171-001-s-csr-body,3 more subjects, t-test ,35315
m5352-px-171-001-s-csr-body,12 total subjects, t-test ,31784
m5352-px-171-001-s-csr-body,12 additional subjects, t-test ,19205
m5352-px-171-001-s-csr-body,2 Efficacy Analyses   All subjects, t-test ,4317
m5352-px-171-001-s-csr-body,5 subjects, t-test ,6453
m5352-px-171-001-s-csr-body,20 subjects, t-test ,6565
m5352-px-171-001-s-csr-body,3 MEDICAL HISTORY   All subjects, t-test ,9831
m5352-px-171-001-s-csr-body,28 subjects, t-test ,13564
m5352-px-171-001-s-csr-body,2   Treated subjects, t-test ,14664
m5352-px-171-001-s-csr-body,3   Evaluable subjects, t-test ,14699
m5352-px-171-001-s-csr-body,9 subjects, t-test ,68544
m5352-px-171-001-s-csr-body,6   Evaluable subjects, t-test ,19310
m5352-px-171-001-s-csr-body,28 evaluable subjects, t-test ,20163
m5352-px-171-001-s-csr-body,4 responding subjects, t-test ,23524
m5352-px-171-001-s-csr-body,2 of these   subjects, t-test ,23664
m5352-px-171-001-s-csr-body,2 responding subjects, t-test ,23697
m5352-px-171-001-s-csr-body,24 subjects, t-test ,32617
m5352-px-171-001-s-csr-body,23 subjects, t-test ,32659
m5352-px-171-001-s-csr-body,19 subjects, t-test ,32727
m5352-px-171-001-s-csr-body,15 subjects, t-test ,32782
m5352-px-171-001-s-csr-body,14 subjects, t-test ,32821
m5352-px-171-001-s-csr-body,10 subjects, t-test ,33110
m5352-px-171-001-s-csr-body,8 subjects, t-test ,13565
m5352-px-171-001-s-csr-body,7 subjects, t-test ,33234
m5352-px-171-001-s-csr-body,10 of these subjects, t-test ,57742
m5352-px-171-001-s-csr-body,13 subjects, t-test ,61841
m5352-px-171-001-s-csr-body,22 subjects, t-test ,62814
m5352-px-171-001-s-csr-body,1 of these subjects, t-test ,70953
m5352-px-171-001-s-csr-body,18 subjects, t-test ,77559
m5352-px-171-001-s-csr-body,2 of these subjects, t-test ,83013
m5352-px-171-001-s-csr-body,n = 29, t-test ,9347
m5352-px-171-001-s-csr-body,n = 3, t-test ,30191
m5352-px-171-001-s-csr-body,n = 11, t-test ,38913
m5352-px-171-001-s-csr-body,n = 18, t-test ,38950
m5352-px-171-001-s-csr-body,n = 28, t-test ,60750
m5352-px-171-001-s-csr-body,N = 27, t-test ,78999
m5352-px-171-001-s-csr-body,N = 15, t-test ,79040
m5352-px-171-001-s-csr-body,total of 16, t-test ,26587
m5352-px-171-001-s-csr-body,total of   8, t-test ,26699
m5352-px-171-001-s-csr-body,total of 14, t-test ,26812
m5352-px-171-001-s-csr-body,total of 397, t-test ,27558
m5352-px-171-001-s-csr-body,12 subjects could be enrolled, t-test ,19949
m5352-px-171-002-p1-app1611-protocol,86 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,12 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,3 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,3 more subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,6 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,6   subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,12 additional subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,27 Expansion   Cohort if subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,50 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,62 subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,62   subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,11 Female subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,1 Female subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,50   subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,0   • Female subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,1 and subjects,null,-1
m5352-px-171-002-p1-app1611-protocol,86 subjects will be enrolled,null,-1
m5352-px-171-002-p1-app1611-protocol,171 treatment who enrolled,null,-1
m5352-px-171-002-p1-app1611-protocol,50 subjects will be enrolled,null,-1
m5352-px-171-002-p1-app1611-protocol,62 subjects will be enrolled,null,-1
m5352-px-171-002-p1-app1611-protocol,62   subjects will be enrolled,null,-1
m5352-px-171-002-p1-app1611-protocol,50   subjects will be enrolled,null,-1
m5352-px-171-002-p1-app1619-sap,62 subjects,null,-1
m5352-px-171-002-p1-app1619-sap,3 subjects,null,-1
m5352-px-171-002-p1-app1619-sap,3 more subjects,null,-1
m5352-px-171-002-p1-app1619-sap,6 subjects,null,-1
m5352-px-171-002-p1-app1619-sap,2• A  minimum of three subjects,null,-1
m5352-px-171-002-p1-app1619-sap,12  subjects,null,-1
m5352-px-171-002-p1-app1619-sap,62 subjects will be enrolled,null,-1
m5352-px-171-002-p1-s-csr-body,86 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,27 evaluable subjects,null,-1
m5352-px-171-002-p1-s-csr-body,37 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,4 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,3 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,3 more subjects,null,-1
m5352-px-171-002-p1-s-csr-body,6 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,18 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,8 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,24 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,2 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,21 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,19 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,15 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,3 MEDICAL HISTORY    All subjects,null,-1
m5352-px-171-002-p1-s-csr-body,3 additional subjects,null,-1
m5352-px-171-002-p1-s-csr-body,10 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,5 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,27 m  Number of treated subjects,null,-1
m5352-px-171-002-p1-s-csr-body,6  Number of evaluable subjects,null,-1
m5352-px-171-002-p1-s-csr-body,5 responding subjects,null,-1
m5352-px-171-002-p1-s-csr-body,9 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,10 excluded subjects,null,-1
m5352-px-171-002-p1-s-csr-body,27 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,10 evaluable subjects,null,-1
m5352-px-171-002-p1-s-csr-body,37 treated subjects,null,-1
m5352-px-171-002-p1-s-csr-body,11 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,15 mg  Treated subjects,null,-1
m5352-px-171-002-p1-s-csr-body,32 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,11      Ten subjects,null,-1
m5352-px-171-002-p1-s-csr-body,3   subjects,null,-1
m5352-px-171-002-p1-s-csr-body,1 DEATHS   Two subjects,null,-1
m5352-px-171-002-p1-s-csr-body,7 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,10 of these subjects,null,-1
m5352-px-171-002-p1-s-csr-body,5 remaining subjects,null,-1
m5352-px-171-002-p1-s-csr-body,5 additional subjects,null,-1
m5352-px-171-002-p1-s-csr-body,2 without   additional subjects,null,-1
m5352-px-171-002-p1-s-csr-body,7 affected subjects,null,-1
m5352-px-171-002-p1-s-csr-body,13 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,6 of the subjects,null,-1
m5352-px-171-002-p1-s-csr-body,14 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,4 additional subjects,null,-1
m5352-px-171-002-p1-s-csr-body,26 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,17 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,23 subjects,null,-1
m5352-px-171-002-p1-s-csr-body,1 of these subjects,null,-1
m5352-px-171-002-p1-s-csr-body,N=37,null,-1
m5352-px-171-002-p1-s-csr-body,N=21,null,-1
m5352-px-171-002-p1-s-csr-body,N=16,null,-1
m5352-px-171-002-p1-s-csr-body,N=0,null,-1
m5352-px-171-002-p1-s-csr-body,N=3,null,-1
m5352-px-171-002-p1-s-csr-body,N=4,null,-1
m5352-px-171-002-p1-s-csr-body,N=8,null,-1
m5352-px-171-002-p1-s-csr-body,N=6,null,-1
m5352-px-171-002-p1-s-csr-body,total of 37,null,-1
m5352-px-171-002-p1-s-csr-body,total of   15,null,-1
m5352-px-171-002-p1-s-csr-body,total   of 6,null,-1
m5352-px-171-002-p1-s-csr-body,total of 8,null,-1
m5352-px-171-002-p1-s-csr-body,total of 344,null,-1
m5352-px-171-002-p1-s-csr-body,total of 23,null,-1
m5352-px-171-002-p1-s-csr-body,total of 4,null,-1
m5352-px-171-002-p1-s-csr-body,total of 19,null,-1
m5352-px-171-002-p1-s-csr-body,total of 93,null,-1
m5352-px-171-002-p1-s-csr-body,37 subjects were enrolled,null,-1
m5352-px-171-002-p2-app1611-protocol,86 subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,86 adult subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,3 subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,3 more subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,6 subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,6   subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,12   additional subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,1 Oral hydration   All subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,9   Defined the inclusion of subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,12 subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,12 additional subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,27 Expansion   Cohort if subjects,null,-1
m5352-px-171-002-p2-app1611-protocol,total of 10,null,-1
m5352-px-171-002-p2-app1611-protocol,total of 12,null,-1
m5352-px-171-002-p2-app1611-protocol,total of 30,null,-1
m5352-px-171-002-p2-app1611-protocol,86 subjects will be enrolled,null,-1
m5352-px-171-002-p2-app1611-protocol,171 treatment who enrolled,null,-1
m5352-px-171-002-p2-app1619-sap,2 dose expansion subjects,null,-1
m5352-px-171-002-p2-app1619-sap,62 subjects,null,-1
m5352-px-171-002-p2-app1619-sap,3 subjects,null,-1
m5352-px-171-002-p2-app1619-sap,3 more subjects,null,-1
m5352-px-171-002-p2-app1619-sap,6 subjects,null,-1
m5352-px-171-002-p2-app1619-sap,12   subjects,null,-1
m5352-px-171-002-p2-app1619-sap,2008      percentage of subjects,null,-1
m5352-px-171-002-p2-app1619-sap,62 subjects will be enrolled,null,-1
m5352-px-171-002-p2-s-csr-body,4 patients,null,-1
m5352-px-171-003-p1a0-app1611-protocol,40 subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,80 evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,20 evaluable   subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,20 subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,20 evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,78   evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,14 Female subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,17 Female subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,20 total subjects,null,-1
m5352-px-171-003-p1a0-app1611-protocol,3 subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap,40 evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap,40   evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap,20 evaluable subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap,20 subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap,30   The number of subjects,null,-1
m5352-px-171-003-p1a0-app1619-sap, data cutoff.   3,null,-1
m5352-px-171-003-p1a0-s-csr-addendum,46 subjects,null,-1
m5352-px-171-003-p1a0-s-csr-addendum,31 aforementioned subjects,null,-1
m5352-px-171-003-p1a0-s-csr-addendum,31 subjects,null,-1
m5352-px-171-003-p1a0-s-csr-addendum,46 subjects who enrolled,null,-1
m5352-px-171-003-p1a0-s-csr-body,11 institutions enrolling patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,12 institutions who screened  patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,40 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,46 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,3 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,42 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,6 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,5 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,2 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,7 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,4 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,250 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,40 evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,2 cohorts of patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,20 evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,55 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,46 of these patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,46 treated patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,4 excluded patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,38 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,4 excluded   patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,7 responding patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,12 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,20 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,24 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,22 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,24 evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,42 response-evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,42 evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,11 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,17 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,3 and as   many patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,2  Fifteen patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,13 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,16 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,4 of these patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,4 Tumor Lysis Syndrome  Two patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,5 Cardiac Failure  Three patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,3 of these patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,15 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,3 additional patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,2 of these latter patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,27 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,8 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,14 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,10 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,8 additional patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,34 patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,42 response-  evaluable patients,null,-1
m5352-px-171-003-p1a0-s-csr-body,N=38,null,-1
m5352-px-171-003-p1a0-s-csr-body,N=10,null,-1
m5352-px-171-003-p1a0-s-csr-body,N=46,null,-1
m5352-px-171-003-p1a0-s-csr-body,N=42,null,-1
m5352-px-171-003-p1a0-s-csr-body,total of 10,null,-1
m5352-px-171-003-p1a0-s-csr-body,total of 5,null,-1
m5352-px-171-003-p1a0-s-csr-body,total of 9,null,-1
m5352-px-171-003-p1a0-s-csr-body,total of 7,null,-1
m5352-px-171-003-p1a0-s-csr-body,total of 4,null,-1
m5352-px-171-003-p1a0-s-csr-body,11 institutions enrolled,null,-1
m5352-px-171-003-p1a0-s-csr-body,2 was never enrolled,null,-1
m5352-px-171-003-p1a0-s-csr-body, data from PX-171,null,-1
m5352-px-171-003-p1a0-s-csr-body, data from   2,null,-1
m5352-px-171-003-p2a1-app1611-protocol,250 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,12 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,36 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,342 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,46 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,46 evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,16 Female subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24 Female subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,7 In subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,6 In subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1 Screening   All subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,7 Safety Analysis   All subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,191 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,3 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,15 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24 evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,25 Female subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,23 Female subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,12   subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40   subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,250 additional subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1 Change Ratio  subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,80 evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,20   evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1 Change Ratio  evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,20   subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,20 evaluable subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24   subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1 Change Ratio  All subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1 Change Ratio  of total subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,20 subjects,null,-1
m5352-px-171-003-p2a1-app1611-protocol,77 patients,null,-1
m5352-px-171-003-p2a1-app1611-protocol,1     In patients,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of 250,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of   250,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of 4,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of 10,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of 12,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total of 30,null,-1
m5352-px-171-003-p2a1-app1611-protocol,total   of 250,null,-1
m5352-px-171-003-p2a1-app1611-protocol,12 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,36 evaluable subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,342 subjects have been enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,46 evaluable subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40 subjects   enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,191 subjects have been enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,3 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24 evaluable subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40 subjects who are   enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,77 patients have been enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,40 subjects who are enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,12   subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,12 subjects   enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol,24 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1611-protocol, data from the 15,null,-1
m5352-px-171-003-p2a1-app1619-sap,46   subjects,null,-1
m5352-px-171-003-p2a1-app1619-sap,250 subjects,null,-1
m5352-px-171-003-p2a1-app1619-sap,12 subjects,null,-1
m5352-px-171-003-p2a1-app1619-sap,40 subjects,null,-1
m5352-px-171-003-p2a1-app1619-sap,2 Clinical Benefit For those patients,null,-1
m5352-px-171-003-p2a1-app1619-sap,243 patients,null,-1
m5352-px-171-003-p2a1-app1619-sap,46   subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1619-sap,12 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1619-sap,40 subjects enrolled,null,-1
m5352-px-171-003-p2a1-app1619-sap, data from the 46,null,-1
m5352-px-171-003-p2a1-s-csr-addendum,132 subjects,null,-1
m5352-px-171-003-p2a1-s-csr-addendum,31 subjects,null,-1
m5352-px-171-003-p2a1-s-csr-addendum,N=266,null,-1
m5352-px-171-003-p2a1-s-csr-addendum,total of 31,null,-1
m5352-px-171-003-p2a1-s-csr-addendum,31 subjects who enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,31 study sites screening patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,250 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 enrolled patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,13 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,47 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,34 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,185 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,157 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,5 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,4 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,9 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,7 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,14 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,286 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,188 evaluable patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,36 evaluable patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,4  patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,6 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,46 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,30 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,24 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,12 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,1 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,250 additional patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2010 after all patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,40 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,33 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,21 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,266  Enrolled patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,42 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,7 summarizes the number of patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,97 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,61 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,17 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,19 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,36 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,1 although per protocol these patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,51 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 and patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 of these patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,4 stated patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 of these patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 enrolled   patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,206 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,56 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,16 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,249 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,234 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,259 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,178 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,39 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,20 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,132 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,113 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,265 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,199 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,95 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,186 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,11 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,25 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,27 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,23 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,44 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,10 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,84 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,72 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,85 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,150 response-evaluable patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,107 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 of these   patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,110 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,003 study patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,257 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,150 efficacy evaluable patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,107 efficacy evaluable patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,286 relapsed and refractory MM patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,215 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,197 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,137 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,100 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,8 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,22 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,26 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,15 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,5 additional patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,6  a Four additional patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,8  Seventy-two patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,168 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,8  Fifty-seven patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,32 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,1 of the patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 treated patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,125 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,141 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,28 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,119 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,193 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,50 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 Hemoglobin  Most patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,4 Lymphocytes  Most patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,5 White Blood Cells  Most patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,8 of these patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,7 of these   patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,50 summarizes the number of patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,1 of these patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,173 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,37 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,128 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,152 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,169 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,254 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 and the majority of patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,2 Includes patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,94 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,1027 patients,null,-1
m5352-px-171-003-p2a1-s-csr-body,N = 266,null,-1
m5352-px-171-003-p2a1-s-csr-body,N =   266,null,-1
m5352-px-171-003-p2a1-s-csr-body,N = 257,null,-1
m5352-px-171-003-p2a1-s-csr-body,N = 61,null,-1
m5352-px-171-003-p2a1-s-csr-body,N = 95,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 6,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 57,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 100,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 92,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 72,null,-1
m5352-px-171-003-p2a1-s-csr-body,n = 185,null,-1
m5352-px-171-003-p2a1-s-csr-body,N=266,null,-1
m5352-px-171-003-p2a1-s-csr-body,N=257,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 9,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of  250,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 250,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 266,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 51,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 186,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 132,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 24,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 28,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 168,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 10,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 44,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 32,null,-1
m5352-px-171-003-p2a1-s-csr-body,total of 55,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,36 evaluable patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,5 enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,46 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,30 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,12 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 patients were enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,4 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,40 patients who are enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 patients were enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,10  Patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,266 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,5 patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,003 study patients enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body,3 ISS stages of MM   enrolled,null,-1
m5352-px-171-003-p2a1-s-csr-body, data from the 46,null,-1
m5352-px-171-003-p2a1-s-csr-body,   data obtained from PX-171,null,-1
m5352-px-171-003-p2a1-s-csr-table-5-1-6,N=266,null,-1
m5352-px-171-004-p1-app1611-protocol,155 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115   evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,50   evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,40 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,35 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,69  Confidential  o Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115 includes subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,65   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,50 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,65 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,50 evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,1  Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,40 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,26 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,27 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,69  Confidential  subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,36 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,191 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,15 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,31 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,16 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115 evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,14 Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,26 Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,7 In subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,6 In subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115  subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,50 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115 evaluable bortezomib-naïve subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,27 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,37  subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,35  subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,155 evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,37 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,1    Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,115 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,1   Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,004 was of subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,120 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,85 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,85 evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,35  All subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,85 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,85 evaluable bortezomib naïve subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,100 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,200   Both serum  will be used  subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,100 subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,100   evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25 evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,1 Screening   All subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25 evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,26 such subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25   evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,27 such subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,27evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,5   Only bortezomib-naïve subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,85 bortezomib naïve subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,27 such evaluable   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,22 Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,25 total subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,33  Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,40   evaluable subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,40   subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,15 Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,17 Female subjects,null,-1
m5352-px-171-004-p1-app1611-protocol,322 patients,null,-1
m5352-px-171-004-p1-app1611-protocol,115 evaluable patients,null,-1
m5352-px-171-004-p1-app1611-protocol,85 evaluable patients,null,-1
m5352-px-171-004-p1-app1611-protocol,77 patients,null,-1
m5352-px-171-004-p1-app1611-protocol,n=32,null,-1
m5352-px-171-004-p1-app1611-protocol,n=5,null,-1
m5352-px-171-004-p1-app1611-protocol,total of 35,null,-1
m5352-px-171-004-p1-app1611-protocol,total of 12,null,-1
m5352-px-171-004-p1-app1611-protocol,total of 37,null,-1
m5352-px-171-004-p1-app1611-protocol,total of 10,null,-1
m5352-px-171-004-p1-app1611-protocol,total of 30,null,-1
m5352-px-171-004-p1-app1611-protocol,35 subjects   were enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,65   subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,50 subjects   enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,36 evaluable subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,191 subjects have been enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,31 subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,50 subjects will be enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,35 subjects were enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,50 evaluable subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,37 subjects were   enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,37 subjects were enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,115 includes subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,65 subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,50 subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,85 evaluable subjects enrolled,null,-1
m5352-px-171-004-p1-app1611-protocol,77 patients have been enrolled,null,-1
m5352-px-171-004-p1-app1619-sap,52   escalation rule as the subjects,null,-1
m5352-px-171-004-p1-app1619-sap,155 evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,115 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,115   includes subjects,null,-1
m5352-px-171-004-p1-app1619-sap,115 evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,50   evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,50 evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,1   Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p1-app1619-sap,40 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,26 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,27 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,35 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,115 evaluable bortezomib-naïve subjects,null,-1
m5352-px-171-004-p1-app1619-sap,27 evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,31 subjects,null,-1
m5352-px-171-004-p1-app1619-sap,16   evaluable subjects,null,-1
m5352-px-171-004-p1-app1619-sap,2 Study Design Certain subjects,null,-1
m5352-px-171-004-p1-app1619-sap,322 patients,null,-1
m5352-px-171-004-p1-app1619-sap,total of 35,null,-1
m5352-px-171-004-p1-app1619-sap,31 subjects enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,8 enrolled subjects,null,-1
m5352-px-171-004-p1-s-csr-body,35 patients,null,-1
m5352-px-171-004-p1-s-csr-body,31   patients,null,-1
m5352-px-171-004-p1-s-csr-body,4 additional patients,null,-1
m5352-px-171-004-p1-s-csr-body,31 patients,null,-1
m5352-px-171-004-p1-s-csr-body,3 patients,null,-1
m5352-px-171-004-p1-s-csr-body,2 patients,null,-1
m5352-px-171-004-p1-s-csr-body,6 patients,null,-1
m5352-px-171-004-p1-s-csr-body,9 patients,null,-1
m5352-px-171-004-p1-s-csr-body,3 of the patients,null,-1
m5352-px-171-004-p1-s-csr-body,1 of the patients,null,-1
m5352-px-171-004-p1-s-csr-body,5 patients,null,-1
m5352-px-171-004-p1-s-csr-body,4 patients,null,-1
m5352-px-171-004-p1-s-csr-body,35 bortezomib-treated patients,null,-1
m5352-px-171-004-p1-s-csr-body,35 bortezomib-treated   patients,null,-1
m5352-px-171-004-p1-s-csr-body,31 enrolled patients,null,-1
m5352-px-171-004-p1-s-csr-body,16 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,10 patients,null,-1
m5352-px-171-004-p1-s-csr-body,115 patients,null,-1
m5352-px-171-004-p1-s-csr-body,28 patients,null,-1
m5352-px-171-004-p1-s-csr-body,7 patients,null,-1
m5352-px-171-004-p1-s-csr-body,15 after patients,null,-1
m5352-px-171-004-p1-s-csr-body,155 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,40 patients,null,-1
m5352-px-171-004-p1-s-csr-body,100 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,40   evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,3 groups of patients,null,-1
m5352-px-171-004-p1-s-csr-body,37 patients,null,-1
m5352-px-171-004-p1-s-csr-body,120 patients,null,-1
m5352-px-171-004-p1-s-csr-body,85 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,322 patients,null,-1
m5352-px-171-004-p1-s-csr-body,115   evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,65 patients,null,-1
m5352-px-171-004-p1-s-csr-body,50 evaluable   patients,null,-1
m5352-px-171-004-p1-s-csr-body,115 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,50 patients,null,-1
m5352-px-171-004-p1-s-csr-body,50 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,115 evaluable   bortezomib-naïve patients,null,-1
m5352-px-171-004-p1-s-csr-body,16 patients,null,-1
m5352-px-171-004-p1-s-csr-body,4 excluded patients,null,-1
m5352-px-171-004-p1-s-csr-body,21 patients,null,-1
m5352-px-171-004-p1-s-csr-body,14 patients,null,-1
m5352-px-171-004-p1-s-csr-body,17 patients,null,-1
m5352-px-171-004-p1-s-csr-body,27 patients,null,-1
m5352-px-171-004-p1-s-csr-body,19 patients,null,-1
m5352-px-171-004-p1-s-csr-body,11 patients,null,-1
m5352-px-171-004-p1-s-csr-body,27 evaluable patients,null,-1
m5352-px-171-004-p1-s-csr-body,20 patients,null,-1
m5352-px-171-004-p1-s-csr-body,2 long-term SD patients,null,-1
m5352-px-171-004-p1-s-csr-body,3 of these patients,null,-1
m5352-px-171-004-p1-s-csr-body,22 patients,null,-1
m5352-px-171-004-p1-s-csr-body,15 patients,null,-1
m5352-px-171-004-p1-s-csr-body,13 patients,null,-1
m5352-px-171-004-p1-s-csr-body,12 patients,null,-1
m5352-px-171-004-p1-s-csr-body,8 patients,null,-1
m5352-px-171-004-p1-s-csr-body,1   a Two patients,null,-1
m5352-px-171-004-p1-s-csr-body,18 patients,null,-1
m5352-px-171-004-p1-s-csr-body,1 of these patients,null,-1
m5352-px-171-004-p1-s-csr-body,5 of the patients,null,-1
m5352-px-171-004-p1-s-csr-body,29 patients,null,-1
m5352-px-171-004-p1-s-csr-body,2 elevation   No patients,null,-1
m5352-px-171-004-p1-s-csr-body,34 is a summary of patients,null,-1
m5352-px-171-004-p1-s-csr-body,7   Na = number of patients,null,-1
m5352-px-171-004-p1-s-csr-body,35 is a summary of patients,null,-1
m5352-px-171-004-p1-s-csr-body,5   Na = number of patients,null,-1
m5352-px-171-004-p1-s-csr-body,2 Includes patients,null,-1
m5352-px-171-004-p1-s-csr-body,n = 35,null,-1
m5352-px-171-004-p1-s-csr-body,N = 35,null,-1
m5352-px-171-004-p1-s-csr-body,n = 31,null,-1
m5352-px-171-004-p1-s-csr-body,N = 31,null,-1
m5352-px-171-004-p1-s-csr-body,n = 6,null,-1
m5352-px-171-004-p1-s-csr-body,n = 11,null,-1
m5352-px-171-004-p1-s-csr-body,N=35,null,-1
m5352-px-171-004-p1-s-csr-body,n = 4,null,-1
m5352-px-171-004-p1-s-csr-body,n = 3,null,-1
m5352-px-171-004-p1-s-csr-body,n = 419,null,-1
m5352-px-171-004-p1-s-csr-body,n = 5,null,-1
m5352-px-171-004-p1-s-csr-body,n = 1,null,-1
m5352-px-171-004-p1-s-csr-body,n = 10,null,-1
m5352-px-171-004-p1-s-csr-body,n = 2,null,-1
m5352-px-171-004-p1-s-csr-body,n = 30,null,-1
m5352-px-171-004-p1-s-csr-body,N=31,null,-1
m5352-px-171-004-p1-s-csr-body,total of 7,null,-1
m5352-px-171-004-p1-s-csr-body,total of 35,null,-1
m5352-px-171-004-p1-s-csr-body,total of 6,null,-1
m5352-px-171-004-p1-s-csr-body,35 patients were enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,31 enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,85 evaluable patients enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,8 enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,31 patients were enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,35 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,13 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,12 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,11 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,29 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,5 patients who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body,1 patient who enrolled,null,-1
m5352-px-171-004-p1-s-csr-body, data cutoff of 30,null,-1
m5352-px-171-004-p1-s-csr-body, data cutoff of 19,null,-1
m5352-px-171-004-p1-s-csr-body, data cut-off 3,null,-1
m5352-px-171-004-p2-app1611-protocol,155 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115   evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,50   evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,40 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,35 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,69  Confidential  o Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115 includes subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,65   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,50 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,65 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,50 evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,1  Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,40 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,26 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,27 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,69  Confidential  subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,36 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,191 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,15 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,31 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,16 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115 evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,14 Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,26 Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,7 In subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,6 In subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115  subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,50 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115 evaluable bortezomib-naïve subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,27 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,37  subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,35  subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,155 evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,37 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,1    Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,115 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,1   Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,004 was of subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,120 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,85 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,35  All subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable bortezomib naïve subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,100 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,200   Both serum  will be used  subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,100 subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,100   evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25 evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,1 Screening   All subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25 evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,26 such subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25   evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,27 such subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,27evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,5   Only bortezomib-naïve subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,85 bortezomib naïve subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,27 such evaluable   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,22 Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,25 total subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,33  Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,40   evaluable subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,40   subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,15 Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,17 Female subjects,null,-1
m5352-px-171-004-p2-app1611-protocol,100 evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,40 evaluable   patients,null,-1
m5352-px-171-004-p2-app1611-protocol,3 groups of patients,null,-1
m5352-px-171-004-p2-app1611-protocol,37 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,120 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,85   evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,322 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,155 evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,115 evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,65 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,50 evaluable patients,null,-1
m5352-px-171-004-p2-app1611-protocol,50   patients,null,-1
m5352-px-171-004-p2-app1611-protocol,115 evaluable bortezomib-  naïve patients,null,-1
m5352-px-171-004-p2-app1611-protocol,35 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,77 patients,null,-1
m5352-px-171-004-p2-app1611-protocol,n=32,null,-1
m5352-px-171-004-p2-app1611-protocol,n=5,null,-1
m5352-px-171-004-p2-app1611-protocol,total of 35,null,-1
m5352-px-171-004-p2-app1611-protocol,total of 12,null,-1
m5352-px-171-004-p2-app1611-protocol,total of 37,null,-1
m5352-px-171-004-p2-app1611-protocol,total of 10,null,-1
m5352-px-171-004-p2-app1611-protocol,total of 30,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable patients enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,35 subjects   were enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,65   subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,50 subjects   enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,36 evaluable subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,191 subjects have been enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,31 subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,50 subjects will be enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,35 subjects were enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,50 evaluable subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,37 subjects were   enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,37 subjects were enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,115 includes subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,65 subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,50 subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,85 evaluable subjects enrolled,null,-1
m5352-px-171-004-p2-app1611-protocol,77 patients have been enrolled,null,-1
m5352-px-171-004-p2-app1619-sap,52   escalation rule as the subjects,null,-1
m5352-px-171-004-p2-app1619-sap,155 evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,115 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,115   includes subjects,null,-1
m5352-px-171-004-p2-app1619-sap,115 evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,50   evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,50 evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,1   Bortezomib prior-treated subjects,null,-1
m5352-px-171-004-p2-app1619-sap,40 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,26 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,27 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,35 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,115 evaluable bortezomib-naïve subjects,null,-1
m5352-px-171-004-p2-app1619-sap,27 evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,31 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,16   evaluable subjects,null,-1
m5352-px-171-004-p2-app1619-sap,2 Study Design Certain subjects,null,-1
m5352-px-171-004-p2-app1619-sap,46 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,250 subjects,null,-1
m5352-px-171-004-p2-app1619-sap,322 patients,null,-1
m5352-px-171-004-p2-app1619-sap,12 patients,null,-1
m5352-px-171-004-p2-app1619-sap,40 patients,null,-1
m5352-px-171-004-p2-app1619-sap,total of 35,null,-1
m5352-px-171-004-p2-app1619-sap,total of 250,null,-1
m5352-px-171-004-p2-app1619-sap,total of   250,null,-1
m5352-px-171-004-p2-app1619-sap,31 subjects enrolled,null,-1
m5352-px-171-004-p2-app1619-sap,1 enrolled,null,-1
m5352-px-171-004-p2-app1619-sap,12 patients enrolled,null,-1
m5352-px-171-004-p2-app1619-sap,40 patients enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,129 patients,null,-1
m5352-px-171-004-p2-s-csr-body,155 evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,119 patients,null,-1
m5352-px-171-004-p2-s-csr-body,38 bortezomib-naïve patients,null,-1
m5352-px-171-004-p2-s-csr-body,59 patients,null,-1
m5352-px-171-004-p2-s-csr-body,70 patients,null,-1
m5352-px-171-004-p2-s-csr-body,322 patients,null,-1
m5352-px-171-004-p2-s-csr-body,46 patients,null,-1
m5352-px-171-004-p2-s-csr-body,38 patients,null,-1
m5352-px-171-004-p2-s-csr-body,5 patients,null,-1
m5352-px-171-004-p2-s-csr-body,22 patients,null,-1
m5352-px-171-004-p2-s-csr-body,8 patients,null,-1
m5352-px-171-004-p2-s-csr-body,3 patients,null,-1
m5352-px-171-004-p2-s-csr-body,2 patients,null,-1
m5352-px-171-004-p2-s-csr-body,14 patients,null,-1
m5352-px-171-004-p2-s-csr-body,4 patients,null,-1
m5352-px-171-004-p2-s-csr-body,27 patients,null,-1
m5352-px-171-004-p2-s-csr-body,12 patients,null,-1
m5352-px-171-004-p2-s-csr-body,13 patients,null,-1
m5352-px-171-004-p2-s-csr-body,7 patients,null,-1
m5352-px-171-004-p2-s-csr-body,1 patients,null,-1
m5352-px-171-004-p2-s-csr-body,6 patients,null,-1
m5352-px-171-004-p2-s-csr-body,129 bortezomib-naïve patients,null,-1
m5352-px-171-004-p2-s-csr-body,31 enrolled patients,null,-1
m5352-px-171-004-p2-s-csr-body,14 bortezomib-naïve patients,null,-1
m5352-px-171-004-p2-s-csr-body,85 patients,null,-1
m5352-px-171-004-p2-s-csr-body,115 patients,null,-1
m5352-px-171-004-p2-s-csr-body,15 after patients,null,-1
m5352-px-171-004-p2-s-csr-body,126 patients,null,-1
m5352-px-171-004-p2-s-csr-body,50 evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,50 evaluable   patients,null,-1
m5352-px-171-004-p2-s-csr-body,5 additional patients,null,-1
m5352-px-171-004-p2-s-csr-body,56 patients,null,-1
m5352-px-171-004-p2-s-csr-body,2 of the patients,null,-1
m5352-px-171-004-p2-s-csr-body,10 patients,null,-1
m5352-px-171-004-p2-s-csr-body,53 patients,null,-1
m5352-px-171-004-p2-s-csr-body,6   A majority of patients,null,-1
m5352-px-171-004-p2-s-csr-body,60 response evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,35 evaluable   patients,null,-1
m5352-px-171-004-p2-s-csr-body,78 evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,43 evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,55 patients,null,-1
m5352-px-171-004-p2-s-csr-body,58 patients,null,-1
m5352-px-171-004-p2-s-csr-body,2   The total number of patients,null,-1
m5352-px-171-004-p2-s-csr-body,322 bortezomib-treated patients,null,-1
m5352-px-171-004-p2-s-csr-body,54 patients,null,-1
m5352-px-171-004-p2-s-csr-body,27 evaluable patients,null,-1
m5352-px-171-004-p2-s-csr-body,60 patients,null,-1
m5352-px-171-004-p2-s-csr-body,25 patients,null,-1
m5352-px-171-004-p2-s-csr-body,322 bortezomib-  treated patients,null,-1
m5352-px-171-004-p2-s-csr-body,64 patients,null,-1
m5352-px-171-004-p2-s-csr-body,65 patients,null,-1
m5352-px-171-004-p2-s-csr-body,82 patients,null,-1
m5352-px-171-004-p2-s-csr-body,16 patients,null,-1
m5352-px-171-004-p2-s-csr-body,19 patients,null,-1
m5352-px-171-004-p2-s-csr-body,9 patients,null,-1
m5352-px-171-004-p2-s-csr-body,43 patients,null,-1
m5352-px-171-004-p2-s-csr-body,21 patients,null,-1
m5352-px-171-004-p2-s-csr-body,23 patients,null,-1
m5352-px-171-004-p2-s-csr-body,33 patients,null,-1
m5352-px-171-004-p2-s-csr-body,20 patients,null,-1
m5352-px-171-004-p2-s-csr-body,18 patients,null,-1
m5352-px-171-004-p2-s-csr-body,37 is a summary of patients,null,-1
m5352-px-171-004-p2-s-csr-body,3 of these patients,null,-1
m5352-px-171-004-p2-s-csr-body,38 is a summary of patients,null,-1
m5352-px-171-004-p2-s-csr-body,5   a N = number of patients,null,-1
m5352-px-171-004-p2-s-csr-body,116 patients,null,-1
m5352-px-171-004-p2-s-csr-body,109 patients,null,-1
m5352-px-171-004-p2-s-csr-body,6 SAFETY CONCLUSIONS   All patients,null,-1
m5352-px-171-004-p2-s-csr-body,3 fatigue among patients,null,-1
m5352-px-171-004-p2-s-csr-body,45 patients,null,-1
m5352-px-171-004-p2-s-csr-body,15 patients,null,-1
m5352-px-171-004-p2-s-csr-body,2 Includes patients,null,-1
m5352-px-171-004-p2-s-csr-body,n = 35,null,-1
m5352-px-171-004-p2-s-csr-body,N=129,null,-1
m5352-px-171-004-p2-s-csr-body,n = 119,null,-1
m5352-px-171-004-p2-s-csr-body,N = 129,null,-1
m5352-px-171-004-p2-s-csr-body,n = 59,null,-1
m5352-px-171-004-p2-s-csr-body,n = 70,null,-1
m5352-px-171-004-p2-s-csr-body,N = 119,null,-1
m5352-px-171-004-p2-s-csr-body,n = 53,null,-1
m5352-px-171-004-p2-s-csr-body,n = 66,null,-1
m5352-px-171-004-p2-s-csr-body,n = 126,null,-1
m5352-px-171-004-p2-s-csr-body,n = 129,null,-1
m5352-px-171-004-p2-s-csr-body,N = 126,null,-1
m5352-px-171-004-p2-s-csr-body,n = 67,null,-1
m5352-px-171-004-p2-s-csr-body,n = 60,null,-1
m5352-px-171-004-p2-s-csr-body,n = 78,null,-1
m5352-px-171-004-p2-s-csr-body,n = 322,null,-1
m5352-px-171-004-p2-s-csr-body,n = 333,null,-1
m5352-px-171-004-p2-s-csr-body,n = 335,null,-1
m5352-px-171-004-p2-s-csr-body,n = 177,null,-1
m5352-px-171-004-p2-s-csr-body,n = 176,null,-1
m5352-px-171-004-p2-s-csr-body,n = 175,null,-1
m5352-px-171-004-p2-s-csr-body,n = 353,null,-1
m5352-px-171-004-p2-s-csr-body,n = 351,null,-1
m5352-px-171-004-p2-s-csr-body,N = 59,null,-1
m5352-px-171-004-p2-s-csr-body,N = 70,null,-1
m5352-px-171-004-p2-s-csr-body,n = 7,null,-1
m5352-px-171-004-p2-s-csr-body,n = 2,null,-1
m5352-px-171-004-p2-s-csr-body,n = 4,null,-1
m5352-px-171-004-p2-s-csr-body,N = 331,null,-1
m5352-px-171-004-p2-s-csr-body,N = 177,null,-1
m5352-px-171-004-p2-s-csr-body,N = 176,null,-1
m5352-px-171-004-p2-s-csr-body,N=59,null,-1
m5352-px-171-004-p2-s-csr-body,N=70,null,-1
m5352-px-171-004-p2-s-csr-body,N=67,null,-1
m5352-px-171-004-p2-s-csr-body,N=126,null,-1
m5352-px-171-004-p2-s-csr-body,N=53,null,-1
m5352-px-171-004-p2-s-csr-body,N=66,null,-1
m5352-px-171-004-p2-s-csr-body,N=119,null,-1
m5352-px-171-004-p2-s-csr-body,total of 119,null,-1
m5352-px-171-004-p2-s-csr-body,total of 38,null,-1
m5352-px-171-004-p2-s-csr-body,total of   59,null,-1
m5352-px-171-004-p2-s-csr-body,total of 22,null,-1
m5352-px-171-004-p2-s-csr-body,total of 44,null,-1
m5352-px-171-004-p2-s-csr-body,total of 12,null,-1
m5352-px-171-004-p2-s-csr-body,total of 126,null,-1
m5352-px-171-004-p2-s-csr-body,total of 78,null,-1
m5352-px-171-004-p2-s-csr-body,total of 55,null,-1
m5352-px-171-004-p2-s-csr-body,total of 58,null,-1
m5352-px-171-004-p2-s-csr-body,total of 54,null,-1
m5352-px-171-004-p2-s-csr-body,total of 13,null,-1
m5352-px-171-004-p2-s-csr-body,total of 26,null,-1
m5352-px-171-004-p2-s-csr-body,total of   18,null,-1
m5352-px-171-004-p2-s-csr-body,total of 7,null,-1
m5352-px-171-004-p2-s-csr-body,total of 89,null,-1
m5352-px-171-004-p2-s-csr-body,total of 23,null,-1
m5352-px-171-004-p2-s-csr-body,total of 33,null,-1
m5352-px-171-004-p2-s-csr-body,total of 20,null,-1
m5352-px-171-004-p2-s-csr-body,total of 15,null,-1
m5352-px-171-004-p2-s-csr-body,total of   8,null,-1
m5352-px-171-004-p2-s-csr-body,total of 46,null,-1
m5352-px-171-004-p2-s-csr-body,129 patients were enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,59 patients were enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,70 patients enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,31 enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,129 patients enrolled,null,-1
m5352-px-171-004-p2-s-csr-body,38 patients enrolled,null,-1
m5352-px-171-004-p2-s-csr-body, data cutoff 4,null,-1
m5352-px-171-004-p2-s-csr-body, data derived from 322,null,-1
m5352-px-171-004-p2-s-csr-body, data from the 20,null,-1
m5352-px-171-005-app1611-protocol,36 subjects,null,-1
m5352-px-171-005-app1611-protocol,6 subjects,null,-1
m5352-px-171-005-app1611-protocol,3 subjects,null,-1
m5352-px-171-005-app1611-protocol,29 subjects,null,-1
m5352-px-171-005-app1611-protocol,5 subjects,null,-1
m5352-px-171-005-app1611-protocol,2 subjects,null,-1
m5352-px-171-005-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-005-app1611-protocol,190 subjects,null,-1
m5352-px-171-005-app1611-protocol,21 subjects,null,-1
m5352-px-171-005-app1611-protocol,"2,380 newly diagnosed MM subjects",null,-1
m5352-px-171-005-app1611-protocol,6 evaluable subjects,null,-1
m5352-px-171-005-app1611-protocol,12 evaluable subjects,null,-1
m5352-px-171-005-app1611-protocol,4 Clinical Monitoring   Inform subjects,null,-1
m5352-px-171-005-app1611-protocol,1 Screening   All subjects,null,-1
m5352-px-171-005-app1611-protocol,12 subjects,null,-1
m5352-px-171-005-app1611-protocol,2 Safety Analysis   All subjects,null,-1
m5352-px-171-005-app1611-protocol,2 if subjects,null,-1
m5352-px-171-005-app1611-protocol,3   Multiple myeloma subjects,null,-1
m5352-px-171-005-app1611-protocol,30 subjects,null,-1
m5352-px-171-005-app1611-protocol,77 subjects,null,-1
m5352-px-171-005-app1611-protocol,30 evaluable subjects,null,-1
m5352-px-171-005-app1611-protocol,145 patients,null,-1
m5352-px-171-005-app1611-protocol,1353 patients,null,-1
m5352-px-171-005-app1611-protocol,1027 patients,null,-1
m5352-px-171-005-app1611-protocol,N=12,null,-1
m5352-px-171-005-app1611-protocol,N=6,null,-1
m5352-px-171-005-app1611-protocol,N = 6,null,-1
m5352-px-171-005-app1611-protocol,n = 12,null,-1
m5352-px-171-005-app1611-protocol,N = 12,null,-1
m5352-px-171-005-app1611-protocol,total   of 12,null,-1
m5352-px-171-005-app1611-protocol,total of 29,null,-1
m5352-px-171-005-app1611-protocol,total of   12,null,-1
m5352-px-171-005-app1611-protocol,total of 12,null,-1
m5352-px-171-005-app1611-protocol,total of 30,null,-1
m5352-px-171-005-app1611-protocol,29 subjects were enrolled,null,-1
m5352-px-171-005-app1611-protocol,36 evaluable subjects enrolled,null,-1
m5352-px-171-005-app1611-protocol,190 subjects have been enrolled,null,-1
m5352-px-171-005-app1611-protocol,21 subjects enrolled,null,-1
m5352-px-171-005-app1611-protocol,6 subjects will be enrolled,null,-1
m5352-px-171-005-app1611-protocol,77 subjects have been enrolled,null,-1
m5352-px-171-005-app1619-sap,5 will   consist of subjects,null,-1
m5352-px-171-005-app1619-sap,6 subjects,null,-1
m5352-px-171-005-app1619-sap,5 subjects,null,-1
m5352-px-171-005-app1619-sap,N=12,null,-1
m5352-px-171-005-app1619-sap,N=6,null,-1
m5352-px-171-005-app1619-sap,total of 12,null,-1
m5352-px-171-005-s-csr-body,50 subjects,null,-1
m5352-px-171-005-s-csr-body,35 subjects,null,-1
m5352-px-171-005-s-csr-body,35 PK-evaluable subjects,null,-1
m5352-px-171-005-s-csr-body,47 subjects,null,-1
m5352-px-171-005-s-csr-body,7 subjects,null,-1
m5352-px-171-005-s-csr-body,6 of these subjects,null,-1
m5352-px-171-005-s-csr-body,2 subjects,null,-1
m5352-px-171-005-s-csr-body,3 of these subjects,null,-1
m5352-px-171-005-s-csr-body,3 Method of Assigning subjects,null,-1
m5352-px-171-005-s-csr-body,526 subjects,null,-1
m5352-px-171-005-s-csr-body,526 total subjects,null,-1
m5352-px-171-005-s-csr-body,5 subjects,null,-1
m5352-px-171-005-s-csr-body,4 subjects,null,-1
m5352-px-171-005-s-csr-body,36 evaluable subjects,null,-1
m5352-px-171-005-s-csr-body,21 subjects,null,-1
m5352-px-171-005-s-csr-body,1 Contraceptives  Female subjects,null,-1
m5352-px-171-005-s-csr-body,20 For subjects,null,-1
m5352-px-171-005-s-csr-body,5  subjects,null,-1
m5352-px-171-005-s-csr-body,6 subjects,null,-1
m5352-px-171-005-s-csr-body,6 additional   subjects,null,-1
m5352-px-171-005-s-csr-body,2 was allowed if subjects,null,-1
m5352-px-171-005-s-csr-body,16  NA Two subjects,null,-1
m5352-px-171-005-s-csr-body,1  Fifty subjects,null,-1
m5352-px-171-005-s-csr-body,2 additional subjects,null,-1
m5352-px-171-005-s-csr-body,14 subjects,null,-1
m5352-px-171-005-s-csr-body,15 subjects,null,-1
m5352-px-171-005-s-csr-body,19 subjects,null,-1
m5352-px-171-005-s-csr-body,3 subjects,null,-1
m5352-px-171-005-s-csr-body,1 subjects,null,-1
m5352-px-171-005-s-csr-body,19 evaluable subjects,null,-1
m5352-px-171-005-s-csr-body,28 subjects,null,-1
m5352-px-171-005-s-csr-body,3 additional subjects,null,-1
m5352-px-171-005-s-csr-body,1  a Of the subjects,null,-1
m5352-px-171-005-s-csr-body,8 subjects,null,-1
m5352-px-171-005-s-csr-body,12 subjects,null,-1
m5352-px-171-005-s-csr-body,49 is a summary of subjects,null,-1
m5352-px-171-005-s-csr-body,6 SAFETY CONCLUSIONS  All subjects,null,-1
m5352-px-171-005-s-csr-body,266 subjects,null,-1
m5352-px-171-005-s-csr-body,266 patients,null,-1
m5352-px-171-005-s-csr-body,1027 multiple myeloma patients,null,-1
m5352-px-171-005-s-csr-body,300 multiple myeloma patients,null,-1
m5352-px-171-005-s-csr-body,266 carfilzomib-treated patients,null,-1
m5352-px-171-005-s-csr-body,1027 patients,null,-1
m5352-px-171-005-s-csr-body,1353 patients,null,-1
m5352-px-171-005-s-csr-body,N = 12,null,-1
m5352-px-171-005-s-csr-body,N = 6,null,-1
m5352-px-171-005-s-csr-body,N = 10,null,-1
m5352-px-171-005-s-csr-body,N = 8,null,-1
m5352-px-171-005-s-csr-body,N = 50,null,-1
m5352-px-171-005-s-csr-body,N=12,null,-1
m5352-px-171-005-s-csr-body,N=10,null,-1
m5352-px-171-005-s-csr-body,N=8,null,-1
m5352-px-171-005-s-csr-body,N=50,null,-1
m5352-px-171-005-s-csr-body,N =12,null,-1
m5352-px-171-005-s-csr-body,N = 9,null,-1
m5352-px-171-005-s-csr-body,N = 5,null,-1
m5352-px-171-005-s-csr-body,N=6,null,-1
m5352-px-171-005-s-csr-body,N=3,null,-1
m5352-px-171-005-s-csr-body,N=4,null,-1
m5352-px-171-005-s-csr-body,N=5,null,-1
m5352-px-171-005-s-csr-body,N = 7,null,-1
m5352-px-171-005-s-csr-body,N = 4,null,-1
m5352-px-171-005-s-csr-body,N = 3,null,-1
m5352-px-171-005-s-csr-body,N = 1,null,-1
m5352-px-171-005-s-csr-body,N = 0,null,-1
m5352-px-171-005-s-csr-body,N = 2,null,-1
m5352-px-171-005-s-csr-body,n = 47,null,-1
m5352-px-171-005-s-csr-body,N = 11,null,-1
m5352-px-171-005-s-csr-body,N = 47,null,-1
m5352-px-171-005-s-csr-body,N = 28,null,-1
m5352-px-171-005-s-csr-body,N = 46,null,-1
m5352-px-171-005-s-csr-body,N=11,null,-1
m5352-px-171-005-s-csr-body,N=9,null,-1
m5352-px-171-005-s-csr-body,N=42,null,-1
m5352-px-171-005-s-csr-body,total of 12,null,-1
m5352-px-171-005-s-csr-body,total of 50,null,-1
m5352-px-171-005-s-csr-body,total of 35,null,-1
m5352-px-171-005-s-csr-body,total of 526,null,-1
m5352-px-171-005-s-csr-body,total   of 34,null,-1
m5352-px-171-005-s-csr-body,total of 19,null,-1
m5352-px-171-005-s-csr-body,total of 42,null,-1
m5352-px-171-005-s-csr-body,total of 4,null,-1
m5352-px-171-005-s-csr-body,total of 28,null,-1
m5352-px-171-005-s-csr-body,total of 22,null,-1
m5352-px-171-005-s-csr-body,50 subjects   were enrolled,null,-1
m5352-px-171-005-s-csr-body,50 subjects enrolled,null,-1
m5352-px-171-005-s-csr-body,21 subjects enrolled,null,-1
m5352-px-171-005-s-csr-body,   data cut-off  0,null,-1
m5352-px-171-005-s-csr-body, data   cut-off  0,null,-1
m5352-px-171-005-s-csr-body, data from 19,null,-1
m5352-px-171-005-s-csr-body, data from 36,null,-1
m5352-px-171-006-app1611-protocol,3 Number of subjects,null,-1
m5352-px-171-006-app1611-protocol,6 subjects,null,-1
m5352-px-171-006-app1611-protocol,3 subjects,null,-1
m5352-px-171-006-app1611-protocol,2 subjects,null,-1
m5352-px-171-006-app1611-protocol,3 more subjects,null,-1
m5352-px-171-006-app1611-protocol,15 subjects,null,-1
m5352-px-171-006-app1611-protocol,30 subjects,null,-1
m5352-px-171-006-app1611-protocol,25 subjects,null,-1
m5352-px-171-006-app1611-protocol,15 additional subjects,null,-1
m5352-px-171-006-app1611-protocol,70 evaluable subjects,null,-1
m5352-px-171-006-app1611-protocol,5  Twenty-eight MM subjects,null,-1
m5352-px-171-006-app1611-protocol,10 additional subjects,null,-1
m5352-px-171-006-app1611-protocol,36 evaluable subjects,null,-1
m5352-px-171-006-app1611-protocol,36 subjects,null,-1
m5352-px-171-006-app1611-protocol,480 subjects,null,-1
m5352-px-171-006-app1611-protocol,165   subjects,null,-1
m5352-px-171-006-app1611-protocol,141 subjects,null,-1
m5352-px-171-006-app1611-protocol,800 subjects,null,-1
m5352-px-171-006-app1611-protocol,84 subjects,null,-1
m5352-px-171-006-app1611-protocol,40 subjects,null,-1
m5352-px-171-006-app1611-protocol,44 subjects,null,-1
m5352-px-171-006-app1611-protocol,84   subjects,null,-1
m5352-px-171-006-app1611-protocol,5 subjects,null,-1
m5352-px-171-006-app1611-protocol,4 Clinical Monitoring  Inform subjects,null,-1
m5352-px-171-006-app1611-protocol,1 SCREENING  All subjects,null,-1
m5352-px-171-006-app1611-protocol,1  number of subjects,null,-1
m5352-px-171-006-app1611-protocol,70 subjects,null,-1
m5352-px-171-006-app1611-protocol,191   subjects,null,-1
m5352-px-171-006-app1611-protocol,191 480 subjects,null,-1
m5352-px-171-006-app1611-protocol,40   subjects,null,-1
m5352-px-171-006-app1611-protocol,165 subjects,null,-1
m5352-px-171-006-app1611-protocol,40141 subjects,null,-1
m5352-px-171-006-app1611-protocol,6   subjects,null,-1
m5352-px-171-006-app1611-protocol,3   subjects,null,-1
m5352-px-171-006-app1611-protocol,55 evaluable subjects,null,-1
m5352-px-171-006-app1611-protocol,30 evaluable subjects,null,-1
m5352-px-171-006-app1611-protocol,2   subjects,null,-1
m5352-px-171-006-app1611-protocol,15   subjects,null,-1
m5352-px-171-006-app1611-protocol,12 subjects,null,-1
m5352-px-171-006-app1611-protocol,36   subjects,null,-1
m5352-px-171-006-app1611-protocol,2007    three subjects,null,-1
m5352-px-171-006-app1611-protocol,18 subjects,null,-1
m5352-px-171-006-app1611-protocol,6 patients,null,-1
m5352-px-171-006-app1611-protocol,"19,900 US patients",null,-1
m5352-px-171-006-app1611-protocol,35  Total patients,null,-1
m5352-px-171-006-app1611-protocol,010 since these patients,null,-1
m5352-px-171-006-app1611-protocol,51 patients,null,-1
m5352-px-171-006-app1611-protocol,40 patients,null,-1
m5352-px-171-006-app1611-protocol,28 patients,null,-1
m5352-px-171-006-app1611-protocol,215   patients,null,-1
m5352-px-171-006-app1611-protocol,215 patients,null,-1
m5352-px-171-006-app1611-protocol,32 patients,null,-1
m5352-px-171-006-app1611-protocol,26 patients,null,-1
m5352-px-171-006-app1611-protocol,145 patients,null,-1
m5352-px-171-006-app1611-protocol,3   The number of patients,null,-1
m5352-px-171-006-app1611-protocol,77 patients,null,-1
m5352-px-171-006-app1611-protocol,"19,900   US patients",null,-1
m5352-px-171-006-app1611-protocol,total of 36,null,-1
m5352-px-171-006-app1611-protocol,total of   4,null,-1
m5352-px-171-006-app1611-protocol,total of 18,null,-1
m5352-px-171-006-app1611-protocol,total of 16,null,-1
m5352-px-171-006-app1611-protocol,total of 4,null,-1
m5352-px-171-006-app1611-protocol,total of   16,null,-1
m5352-px-171-006-app1611-protocol,25 subjects will be enrolled,null,-1
m5352-px-171-006-app1611-protocol,35  Total patients enrolled,null,-1
m5352-px-171-006-app1611-protocol,36 subjects were enrolled,null,-1
m5352-px-171-006-app1611-protocol,84 subjects enrolled,null,-1
m5352-px-171-006-app1611-protocol,40 subjects have been enrolled,null,-1
m5352-px-171-006-app1611-protocol,44 subjects have been enrolled,null,-1
m5352-px-171-006-app1611-protocol,84   subjects enrolled,null,-1
m5352-px-171-006-app1611-protocol,70 subjects will be enrolled,null,-1
m5352-px-171-006-app1611-protocol,165 subjects have been enrolled,null,-1
m5352-px-171-006-app1611-protocol,84 subjects   enrolled,null,-1
m5352-px-171-006-app1611-protocol,25 subjects will be   enrolled,null,-1
m5352-px-171-006-app1611-protocol,12 subjects will be enrolled,null,-1
m5352-px-171-006-app1611-protocol,36   subjects were enrolled,null,-1
m5352-px-171-006-app1611-protocol,18 subjects will be enrolled,null,-1
m5352-px-171-006-app1611-protocol,30 subjects will be enrolled,null,-1
m5352-px-171-006-app1611-protocol, data.   As of 24,null,-1
m5352-px-171-006-app1619-sap,2 subjects,null,-1
m5352-px-171-006-app1619-sap,3 more subjects,null,-1
m5352-px-171-006-app1619-sap,15 subjects,null,-1
m5352-px-171-006-app1619-sap,30 subjects,null,-1
m5352-px-171-006-app1619-sap,70 subjects,null,-1
m5352-px-171-006-app1619-sap,40 subjects,null,-1
m5352-px-171-006-app1619-sap,84 subjects,null,-1
m5352-px-171-006-app1619-sap,44 subjects,null,-1
m5352-px-171-006-app1619-sap,2 rounds of QC on subjects,null,-1
m5352-px-171-006-app1619-sap,6 subjects,null,-1
m5352-px-171-006-app1619-sap,6 patients,null,-1
m5352-px-171-006-app1619-sap,2 patients,null,-1
m5352-px-171-006-app1619-sap,1 For patients,null,-1
m5352-px-171-006-app1619-sap,2 For patients,null,-1
m5352-px-171-006-app1619-sap,70 subjects will be enrolled,null,-1
m5352-px-171-006-app1619-sap,84 subjects enrolled,null,-1
m5352-px-171-006-app1619-sap,1 For patients enrolled,null,-1
m5352-px-171-006-app1619-sap,2 For patients enrolled,null,-1
m5352-px-171-006-s-csr-body,"9,510 in women",null,-1
m5352-px-171-006-s-csr-body,3 subjects,null,-1
m5352-px-171-006-s-csr-body,6 subjects,null,-1
m5352-px-171-006-s-csr-body,70 subjects,null,-1
m5352-px-171-006-s-csr-body,84 subjects,null,-1
m5352-px-171-006-s-csr-body,40 subjects,null,-1
m5352-px-171-006-s-csr-body,44 subjects,null,-1
m5352-px-171-006-s-csr-body,43 subjects,null,-1
m5352-px-171-006-s-csr-body,33 subjects,null,-1
m5352-px-171-006-s-csr-body,16 subjects,null,-1
m5352-px-171-006-s-csr-body,9 subjects,null,-1
m5352-px-171-006-s-csr-body,30 subjects,null,-1
m5352-px-171-006-s-csr-body,21 subjects,null,-1
m5352-px-171-006-s-csr-body,5 subjects,null,-1
m5352-px-171-006-s-csr-body,14 subjects,null,-1
m5352-px-171-006-s-csr-body,10 subjects,null,-1
m5352-px-171-006-s-csr-body,4 subjects,null,-1
m5352-px-171-006-s-csr-body,18 subjects,null,-1
m5352-px-171-006-s-csr-body,2 subjects,null,-1
m5352-px-171-006-s-csr-body,7 subjects,null,-1
m5352-px-171-006-s-csr-body,58 subjects,null,-1
m5352-px-171-006-s-csr-body,34 subjects,null,-1
m5352-px-171-006-s-csr-body,61 subjects,null,-1
m5352-px-171-006-s-csr-body,526 subjects,null,-1
m5352-px-171-006-s-csr-body,2   studies of subjects,null,-1
m5352-px-171-006-s-csr-body,526 total subjects,null,-1
m5352-px-171-006-s-csr-body,66 treatment-naïve subjects,null,-1
m5352-px-171-006-s-csr-body,36 subjects,null,-1
m5352-px-171-006-s-csr-body,70 adult male and female subjects,null,-1
m5352-px-171-006-s-csr-body,006 subjects,null,-1
m5352-px-171-006-s-csr-body,30 additional subjects,null,-1
m5352-px-171-006-s-csr-body,55 evaluable subjects,null,-1
m5352-px-171-006-s-csr-body,100 subjects,null,-1
m5352-px-171-006-s-csr-body,52 subjects,null,-1
m5352-px-171-006-s-csr-body,81 subjects,null,-1
m5352-px-171-006-s-csr-body,3   subjects,null,-1
m5352-px-171-006-s-csr-body,15 subjects,null,-1
m5352-px-171-006-s-csr-body,8 subjects,null,-1
m5352-px-171-006-s-csr-body,19 subjects,null,-1
m5352-px-171-006-s-csr-body,56 subjects,null,-1
m5352-px-171-006-s-csr-body,27 subjects,null,-1
m5352-px-171-006-s-csr-body,57 subjects,null,-1
m5352-px-171-006-s-csr-body,82 subjects,null,-1
m5352-px-171-006-s-csr-body,65 subjects,null,-1
m5352-px-171-006-s-csr-body,59 subjects,null,-1
m5352-px-171-006-s-csr-body,16 of these subjects,null,-1
m5352-px-171-006-s-csr-body,84 enrolled subjects,null,-1
m5352-px-171-006-s-csr-body,47 subjects,null,-1
m5352-px-171-006-s-csr-body,45 subjects,null,-1
m5352-px-171-006-s-csr-body,1 study of   subjects,null,-1
m5352-px-171-006-s-csr-body,64 subjects,null,-1
m5352-px-171-006-s-csr-body,54 subjects,null,-1
m5352-px-171-006-s-csr-body,28 subjects,null,-1
m5352-px-171-006-s-csr-body,20 subjects,null,-1
m5352-px-171-006-s-csr-body,39 subjects,null,-1
m5352-px-171-006-s-csr-body,25 subjects,null,-1
m5352-px-171-006-s-csr-body,22 subjects,null,-1
m5352-px-171-006-s-csr-body,51 subjects,null,-1
m5352-px-171-006-s-csr-body,78 subjects,null,-1
m5352-px-171-006-s-csr-body,76 subjects,null,-1
m5352-px-171-006-s-csr-body,32 subjects,null,-1
m5352-px-171-006-s-csr-body,2 total subjects,null,-1
m5352-px-171-006-s-csr-body,11 subjects,null,-1
m5352-px-171-006-s-csr-body,84 treated subjects,null,-1
m5352-px-171-006-s-csr-body,12 subjects,null,-1
m5352-px-171-006-s-csr-body,3 of these subjects,null,-1
m5352-px-171-006-s-csr-body,4 of   these subjects,null,-1
m5352-px-171-006-s-csr-body,2   subjects,null,-1
m5352-px-171-006-s-csr-body,10   Eleven subjects,null,-1
m5352-px-171-006-s-csr-body,5   Twenty-four subjects,null,-1
m5352-px-171-006-s-csr-body,5   Three subjects,null,-1
m5352-px-171-006-s-csr-body,10   Seventy-two subjects,null,-1
m5352-px-171-006-s-csr-body,1 Three patients,null,-1
m5352-px-171-006-s-csr-body,526 patients,null,-1
m5352-px-171-006-s-csr-body,N = 84,null,-1
m5352-px-171-006-s-csr-body,n = 52,null,-1
m5352-px-171-006-s-csr-body,n = 2,null,-1
m5352-px-171-006-s-csr-body,n = 1,null,-1
m5352-px-171-006-s-csr-body,n = 83,null,-1
m5352-px-171-006-s-csr-body,n = 40,null,-1
m5352-px-171-006-s-csr-body,n = 58,null,-1
m5352-px-171-006-s-csr-body,n = 23,null,-1
m5352-px-171-006-s-csr-body,n = 13,null,-1
m5352-px-171-006-s-csr-body,n = 14,null,-1
m5352-px-171-006-s-csr-body,n = 84,null,-1
m5352-px-171-006-s-csr-body,N = 52,null,-1
m5352-px-171-006-s-csr-body,n = 6,null,-1
m5352-px-171-006-s-csr-body,n = 8,null,-1
m5352-px-171-006-s-csr-body,n = 43,null,-1
m5352-px-171-006-s-csr-body,N = 51,null,-1
m5352-px-171-006-s-csr-body,N = 83,null,-1
m5352-px-171-006-s-csr-body,n =13,null,-1
m5352-px-171-006-s-csr-body,N = 58,null,-1
m5352-px-171-006-s-csr-body,n = 44,null,-1
m5352-px-171-006-s-csr-body,n= 52,null,-1
m5352-px-171-006-s-csr-body,n=2,null,-1
m5352-px-171-006-s-csr-body,n=1,null,-1
m5352-px-171-006-s-csr-body,n=792,null,-1
m5352-px-171-006-s-csr-body,N=6,null,-1
m5352-px-171-006-s-csr-body,N=8,null,-1
m5352-px-171-006-s-csr-body,N=44,null,-1
m5352-px-171-006-s-csr-body,N=52,null,-1
m5352-px-171-006-s-csr-body,N=84,null,-1
m5352-px-171-006-s-csr-body,N=43,null,-1
m5352-px-171-006-s-csr-body,N=51,null,-1
m5352-px-171-006-s-csr-body,N=83,null,-1
m5352-px-171-006-s-csr-body,total of 84,null,-1
m5352-px-171-006-s-csr-body,total of 33,null,-1
m5352-px-171-006-s-csr-body,total of 14,null,-1
m5352-px-171-006-s-csr-body,total of 3,null,-1
m5352-px-171-006-s-csr-body,total of 6,null,-1
m5352-px-171-006-s-csr-body,total of 58,null,-1
m5352-px-171-006-s-csr-body,total of 526,null,-1
m5352-px-171-006-s-csr-body,total of 100,null,-1
m5352-px-171-006-s-csr-body,total of   52,null,-1
m5352-px-171-006-s-csr-body,total of 36,null,-1
m5352-px-171-006-s-csr-body,total of 57,null,-1
m5352-px-171-006-s-csr-body,total of 47,null,-1
m5352-px-171-006-s-csr-body,total of 45,null,-1
m5352-px-171-006-s-csr-body,total of 39,null,-1
m5352-px-171-006-s-csr-body,total of 54,null,-1
m5352-px-171-006-s-csr-body,total of 28,null,-1
m5352-px-171-006-s-csr-body,total of 25,null,-1
m5352-px-171-006-s-csr-body,total of   27,null,-1
m5352-px-171-006-s-csr-body,total of 59,null,-1
m5352-px-171-006-s-csr-body,total of 51,null,-1
m5352-px-171-006-s-csr-body,total of 78,null,-1
m5352-px-171-006-s-csr-body,total of 32,null,-1
m5352-px-171-006-s-csr-body,total of 22,null,-1
m5352-px-171-006-s-csr-body,total of 11,null,-1
m5352-px-171-006-s-csr-body,40 enrolled,null,-1
m5352-px-171-006-s-csr-body,44 enrolled,null,-1
m5352-px-171-006-s-csr-body,84 subjects were enrolled,null,-1
m5352-px-171-006-s-csr-body,9 subjects were enrolled,null,-1
m5352-px-171-006-s-csr-body,84 enrolled,null,-1
m5352-px-171-006-s-csr-body,526 patients enrolled,null,-1
m5352-px-171-007-app1611-protocol,3   subjects,null,-1
m5352-px-171-007-app1611-protocol,3 subjects,null,-1
m5352-px-171-007-app1611-protocol,6 subjects,null,-1
m5352-px-171-007-app1611-protocol,12 additional subjects,null,-1
m5352-px-171-007-app1611-protocol,16 subjects,null,-1
m5352-px-171-007-app1611-protocol,200 subjects,null,-1
m5352-px-171-007-app1611-protocol,12 subjects,null,-1
m5352-px-171-007-app1611-protocol,134 evaluable subjects,null,-1
m5352-px-171-007-app1611-protocol,1 subjects,null,-1
m5352-px-171-007-app1611-protocol,14   subjects,null,-1
m5352-px-171-007-app1611-protocol,30 subjects,null,-1
m5352-px-171-007-app1611-protocol,36 evaluable   subjects,null,-1
m5352-px-171-007-app1611-protocol,12   additional subjects,null,-1
m5352-px-171-007-app1611-protocol,2 subjects,null,-1
m5352-px-171-007-app1611-protocol,190 evaluable subjects,null,-1
m5352-px-171-007-app1611-protocol,3 more subjects,null,-1
m5352-px-171-007-app1611-protocol,1b subjects,null,-1
m5352-px-171-007-app1611-protocol,14 subjects,null,-1
m5352-px-171-007-app1611-protocol,14 evaluable subjects,null,-1
m5352-px-171-007-app1611-protocol,16 additional subjects,null,-1
m5352-px-171-007-app1611-protocol,6 Safety Analysis   All subjects,null,-1
m5352-px-171-007-app1611-protocol,150  subjects,null,-1
m5352-px-171-007-app1611-protocol,30   subjects,null,-1
m5352-px-171-007-app1611-protocol,29 subjects,null,-1
m5352-px-171-007-app1611-protocol,36 subjects,null,-1
m5352-px-171-007-app1611-protocol,134  evaluable subjects,null,-1
m5352-px-171-007-app1611-protocol,4 Clinical Monitoring   Inform subjects,null,-1
m5352-px-171-007-app1611-protocol,1b and five subjects,null,-1
m5352-px-171-007-app1611-protocol,235 subjects,null,-1
m5352-px-171-007-app1611-protocol,65 subjects,null,-1
m5352-px-171-007-app1611-protocol,120 subjects,null,-1
m5352-px-171-007-app1611-protocol,4 peripheral neuropathy and no subjects,null,-1
m5352-px-171-007-app1611-protocol,20 MM   subjects,null,-1
m5352-px-171-007-app1611-protocol,5 subjects,null,-1
m5352-px-171-007-app1611-protocol,3 additional   subjects,null,-1
m5352-px-171-007-app1611-protocol,190 subjects,null,-1
m5352-px-171-007-app1611-protocol,6   subjects,null,-1
m5352-px-171-007-app1611-protocol,12 additional   subjects,null,-1
m5352-px-171-007-app1611-protocol,3 additional subjects,null,-1
m5352-px-171-007-app1611-protocol,1 Screening   All subjects,null,-1
m5352-px-171-007-app1611-protocol,8 subjects,null,-1
m5352-px-171-007-app1611-protocol,15 additional subjects,null,-1
m5352-px-171-007-app1611-protocol,180 subjects,null,-1
m5352-px-171-007-app1611-protocol,75  subjects,null,-1
m5352-px-171-007-app1611-protocol,3   All subjects,null,-1
m5352-px-171-007-app1611-protocol,467 subjects,null,-1
m5352-px-171-007-app1611-protocol,75 subjects,null,-1
m5352-px-171-007-app1611-protocol,4   Infections  For subjects,null,-1
m5352-px-171-007-app1611-protocol,4 Clinical Monitoring  Inform subjects,null,-1
m5352-px-171-007-app1611-protocol,3    For Lymphoma subjects,null,-1
m5352-px-171-007-app1611-protocol,1 Screening  All subjects,null,-1
m5352-px-171-007-app1611-protocol,6 Safety Analysis  All subjects,null,-1
m5352-px-171-007-app1611-protocol,1215 additional subjects,null,-1
m5352-px-171-007-app1611-protocol,15 additional   subjects,null,-1
m5352-px-171-007-app1611-protocol,120   subjects,null,-1
m5352-px-171-007-app1611-protocol,190   subjects,null,-1
m5352-px-171-007-app1611-protocol,467 190 subjects,null,-1
m5352-px-171-007-app1611-protocol,16   subjects,null,-1
m5352-px-171-007-app1611-protocol,14 evaluable   subjects,null,-1
m5352-px-171-007-app1611-protocol,16   additional subjects,null,-1
m5352-px-171-007-app1611-protocol,20 additional MM subjects,null,-1
m5352-px-171-007-app1611-protocol,70 subjects,null,-1
m5352-px-171-007-app1611-protocol,20 subjects,null,-1
m5352-px-171-007-app1611-protocol,20 MM subjects,null,-1
m5352-px-171-007-app1611-protocol,476 subjects,null,-1
m5352-px-171-007-app1611-protocol,460 subjects,null,-1
m5352-px-171-007-app1611-protocol,20   subjects,null,-1
m5352-px-171-007-app1611-protocol,6  subjects,null,-1
m5352-px-171-007-app1611-protocol,4  For MM subjects,null,-1
m5352-px-171-007-app1611-protocol,77 patients,null,-1
m5352-px-171-007-app1611-protocol,14 patients,null,-1
m5352-px-171-007-app1611-protocol,145 patients,null,-1
m5352-px-171-007-app1611-protocol,6 patients,null,-1
m5352-px-171-007-app1611-protocol,35 patients,null,-1
m5352-px-171-007-app1611-protocol,20 patients,null,-1
m5352-px-171-007-app1611-protocol,400 patients,null,-1
m5352-px-171-007-app1611-protocol,9  For multiple myeloma patients,null,-1
m5352-px-171-007-app1611-protocol,6 NHL patients,null,-1
m5352-px-171-007-app1611-protocol,1 data on patients,null,-1
m5352-px-171-007-app1611-protocol,9    For solid tumor patients,null,-1
m5352-px-171-007-app1611-protocol,9 For   multiple myeloma patients,null,-1
m5352-px-171-007-app1611-protocol,8 patients,null,-1
m5352-px-171-007-app1611-protocol,11 patients,null,-1
m5352-px-171-007-app1611-protocol,33 patients,null,-1
m5352-px-171-007-app1611-protocol,5 patients,null,-1
m5352-px-171-007-app1611-protocol,n = 14,null,-1
m5352-px-171-007-app1611-protocol,n =30,null,-1
m5352-px-171-007-app1611-protocol,n = 30,null,-1
m5352-px-171-007-app1611-protocol,n = 16,null,-1
m5352-px-171-007-app1611-protocol,N= 120,null,-1
m5352-px-171-007-app1611-protocol,n = 70,null,-1
m5352-px-171-007-app1611-protocol,N= 134,null,-1
m5352-px-171-007-app1611-protocol,total of 29,null,-1
m5352-px-171-007-app1611-protocol,total of 10,null,-1
m5352-px-171-007-app1611-protocol,total of 12,null,-1
m5352-px-171-007-app1611-protocol,total of 30,null,-1
m5352-px-171-007-app1611-protocol,total of 33,null,-1
m5352-px-171-007-app1611-protocol,3 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,12 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,2007    be enrolled,null,-1
m5352-px-171-007-app1611-protocol,16 subjects will be   enrolled,null,-1
m5352-px-171-007-app1611-protocol,77 patients have been enrolled,null,-1
m5352-px-171-007-app1611-protocol,14 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,235 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,14 patients were enrolled,null,-1
m5352-px-171-007-app1611-protocol,36 subjects may be   enrolled,null,-1
m5352-px-171-007-app1611-protocol,65 subjects were enrolled,null,-1
m5352-px-171-007-app1611-protocol,120 subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,20 MM   subjects enrolled,null,-1
m5352-px-171-007-app1611-protocol,36 subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,8 subjects will be   enrolled,null,-1
m5352-px-171-007-app1611-protocol,16 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,180 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,75  subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,75 subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,75 subjects may   be enrolled,null,-1
m5352-px-171-007-app1611-protocol,75 subjects may be   enrolled,null,-1
m5352-px-171-007-app1611-protocol,120 subjects   may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,120   subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,2 Bolus portion enrolled,null,-1
m5352-px-171-007-app1611-protocol,200 subjects will be enrolled,null,-1
m5352-px-171-007-app1611-protocol,33 patients had been enrolled,null,-1
m5352-px-171-007-app1611-protocol,20 subjects will   be enrolled,null,-1
m5352-px-171-007-app1611-protocol,70 subjects may be enrolled,null,-1
m5352-px-171-007-app1611-protocol,4  For MM subjects enrolled,null,-1
m5352-px-171-007-app1612-crf,1 subjects,null,-1
m5352-px-171-007-app1612-crf,4  For subjects,null,-1
m5352-px-171-007-app1612-crf,200              Summarize subjects,null,-1
m5352-px-171-007-app1619-sap,2   added a second cohort of subjects,null,-1
m5352-px-171-007-app1619-sap,6 subjects,null,-1
m5352-px-171-007-app1619-sap,3 subjects,null,-1
m5352-px-171-007-app1619-sap,15 additional subjects,null,-1
m5352-px-171-007-app1619-sap,14 subjects,null,-1
m5352-px-171-007-app1619-sap,2 subjects,null,-1
m5352-px-171-007-app1619-sap,16 subjects,null,-1
m5352-px-171-007-app1619-sap,14   response evaluable subjects,null,-1
m5352-px-171-007-app1619-sap,007   • Lymphoma subjects,null,-1
m5352-px-171-007-app1619-sap,14 subjects will be enrolled,null,-1
m5352-px-171-007-s-bolus,2 subjects,null,-1
m5352-px-171-007-s-bolus,N=3,null,-1
m5352-px-171-007-s-bolus,N=4,null,-1
m5352-px-171-007-s-bolus,N=7,null,-1
m5352-px-171-007-s-bolus,N=14,null,-1
m5352-px-171-007-s-bolus,N=15,null,-1
m5352-px-171-007-s-bolus,N=9,null,-1
m5352-px-171-007-s-bolus,N=10,null,-1
m5352-px-171-007-s-bolus,N=16,null,-1
m5352-px-171-007-s-bolus,N=65,null,-1
m5352-px-171-007-s-bolus,N=79,null,-1
m5352-px-171-007-s-bolus,N=  3,null,-1
m5352-px-171-007-s-bolus,N=  4,null,-1
m5352-px-171-007-s-bolus,N=  7,null,-1
m5352-px-171-007-s-bolus,N= 15,null,-1
m5352-px-171-007-s-bolus,N=  9,null,-1
m5352-px-171-007-s-bolus,N= 10,null,-1
m5352-px-171-007-s-bolus,N= 16,null,-1
m5352-px-171-007-s-csr-body,526 subjects, t-test ,208620
m5352-px-171-007-s-csr-body,3 subjects, t-test ,196877
m5352-px-171-007-s-csr-body,6 subjects, t-test ,208618
m5352-px-171-007-s-csr-body,15 additional subjects, t-test ,196348
m5352-px-171-007-s-csr-body,20 additional multiple myeloma subjects, t-test ,195801
m5352-px-171-007-s-csr-body,14 subjects, t-test ,195134
m5352-px-171-007-s-csr-body,2 subjects, t-test ,194975
m5352-px-171-007-s-csr-body,16 subjects, t-test ,194758
m5352-px-171-007-s-csr-body,3 additional subjects, t-test ,179249
m5352-px-171-007-s-csr-body,2  All subjects, t-test ,178770
m5352-px-171-007-s-csr-body,33 subjects, t-test ,175074
m5352-px-171-007-s-csr-body,5 subjects, t-test ,174803
m5352-px-171-007-s-csr-body,20 subjects, t-test ,173104
m5352-px-171-007-s-csr-body,3 Solid tumor subjects, t-test ,162522
m5352-px-171-007-s-csr-body,14 All subjects, t-test ,158840
m5352-px-171-007-s-csr-body,18 For subjects, t-test ,157732
m5352-px-171-007-s-csr-body,21 MM subjects, t-test ,157040
m5352-px-171-007-s-csr-body,22 MM subjects, t-test ,156690
m5352-px-171-007-s-csr-body,23 All MM subjects, t-test ,156396
m5352-px-171-007-s-csr-body,24 MM subjects, t-test ,156176
m5352-px-171-007-s-csr-body,1b Bolus Solid tumor subjects, t-test ,148833
m5352-px-171-007-s-csr-body,30 subjects, t-test ,126014
m5352-px-171-007-s-csr-body,2 multiple myeloma   subjects, t-test ,121992
m5352-px-171-007-s-csr-body,79 subjects, t-test ,121376
m5352-px-171-007-s-csr-body,65 subjects, t-test ,120973
m5352-px-171-007-s-csr-body,4 subjects, t-test ,195133
m5352-px-171-007-s-csr-body,40 subjects, t-test ,117193
m5352-px-171-007-s-csr-body,7 subjects, t-test ,113336
m5352-px-171-007-s-csr-body,22 subjects, t-test ,112335
m5352-px-171-007-s-csr-body,40 solid tumor subjects, t-test ,106616
m5352-px-171-007-s-csr-body,33 multiple myeloma subjects, t-test ,103249
m5352-px-171-007-s-csr-body,10 lymphoma subjects, t-test ,99021
m5352-px-171-007-s-csr-body,22 multiple myeloma subjects, t-test ,96617
m5352-px-171-007-s-csr-body,31 subjects, t-test ,95476
m5352-px-171-007-s-csr-body,10 subjects, t-test ,91126
m5352-px-171-007-s-csr-body,1b subjects, t-test ,91017
m5352-px-171-007-s-csr-body,27 subjects, t-test ,90812
m5352-px-171-007-s-csr-body,16 additional subjects, t-test ,88192
m5352-px-171-007-s-csr-body,29 subjects, t-test ,81388
m5352-px-171-007-s-csr-body,24 subjects, t-test ,78207
m5352-px-171-007-s-csr-body,21 subjects, t-test ,71141
m5352-px-171-007-s-csr-body,1b   subjects, t-test ,60471
m5352-px-171-007-s-csr-body,2 solid tumor bolus subjects, t-test ,56616
m5352-px-171-007-s-csr-body,16 multiple myeloma subjects, t-test ,45921
m5352-px-171-007-s-csr-body,12 multiple myeloma subjects, t-test ,43955
m5352-px-171-007-s-csr-body,72 total combined solid   tumor subjects, t-test ,41812
m5352-px-171-007-s-csr-body,19 subjects, t-test ,41715
m5352-px-171-007-s-csr-body,40 total solid tumor   subjects, t-test ,40126
m5352-px-171-007-s-csr-body,8 subjects, t-test ,37688
m5352-px-171-007-s-csr-body,22 multiple myeloma total subjects, t-test ,35556
m5352-px-171-007-s-csr-body,2 solid tumor subjects, t-test ,33701
m5352-px-171-007-s-csr-body,40 total solid tumor subjects, t-test ,32087
m5352-px-171-007-s-csr-body,5    subjects, t-test ,8252
m5352-px-171-007-s-csr-body,12 subjects, t-test ,11590
m5352-px-171-007-s-csr-body,23   Number of subjects, t-test ,23844
m5352-px-171-007-s-csr-body,15 subjects, t-test ,30418
m5352-px-171-007-s-csr-body,38   Number of subjects, t-test ,31697
m5352-px-171-007-s-csr-body,26   Number of subjects, t-test ,37144
m5352-px-171-007-s-csr-body,34   Number of subjects, t-test ,43580
m5352-px-171-007-s-csr-body,79 solid tumor subjects, t-test ,50137
m5352-px-171-007-s-csr-body,23 subjects, t-test ,53111
m5352-px-171-007-s-csr-body,6 evaluable   subjects, t-test ,66049
m5352-px-171-007-s-csr-body,6 evaluable subjects, t-test ,66187
m5352-px-171-007-s-csr-body,3 evaluable subjects, t-test ,75558
m5352-px-171-007-s-csr-body,2 dose and both   subjects, t-test ,75651
m5352-px-171-007-s-csr-body,17 subjects, t-test ,82869
m5352-px-171-007-s-csr-body,13 subjects, t-test ,102949
m5352-px-171-007-s-csr-body,5 of these subjects, t-test ,103786
m5352-px-171-007-s-csr-body,1b solid tumor bolus subjects, t-test ,155931
m5352-px-171-007-s-csr-body,2 was performed using all subjects, t-test ,216294
m5352-px-171-007-s-csr-body,105 subjects, t-test ,218770
m5352-px-171-007-s-csr-body,37 bolus subjects, t-test ,218790
m5352-px-171-007-s-csr-body,68 infusion subjects, t-test ,218812
m5352-px-171-007-s-csr-body,3 multiple myeloma   subjects, t-test ,224386
m5352-px-171-007-s-csr-body,2 was performed   using all subjects, t-test ,228446
m5352-px-171-007-s-csr-body,5  subjects, t-test ,236743
m5352-px-171-007-s-csr-body,33 MM subjects, t-test ,236839
m5352-px-171-007-s-csr-body,6 patients, t-test ,195353
m5352-px-171-007-s-csr-body,526 patients, t-test ,6408349
m5352-px-171-007-s-csr-body,N = 445, t-test ,173630
m5352-px-171-007-s-csr-body,N = 14, t-test ,119310
m5352-px-171-007-s-csr-body,N = 3, t-test ,119288
m5352-px-171-007-s-csr-body,N = 4, t-test ,173630
m5352-px-171-007-s-csr-body,N = 7, t-test ,119240
m5352-px-171-007-s-csr-body,N = 65, t-test ,118046
m5352-px-171-007-s-csr-body,N = 15, t-test ,118027
m5352-px-171-007-s-csr-body,N = 9, t-test ,118009
m5352-px-171-007-s-csr-body,N = 10, t-test ,117970
m5352-px-171-007-s-csr-body,N = 16, t-test ,117951
m5352-px-171-007-s-csr-body,N = 6, t-test ,118046
m5352-px-171-007-s-csr-body,N = 11, t-test ,117000
m5352-px-171-007-s-csr-body,N = 40, t-test ,115970
m5352-px-171-007-s-csr-body,N = 24, t-test ,114573
m5352-px-171-007-s-csr-body,N = 2, t-test ,114573
m5352-px-171-007-s-csr-body,N = 33, t-test ,114530
m5352-px-171-007-s-csr-body,N = 8, t-test ,111268
m5352-px-171-007-s-csr-body,N = 22, t-test ,111250
m5352-px-171-007-s-csr-body,N = 79, t-test ,107724
m5352-px-171-007-s-csr-body,n = 4, t-test ,84795
m5352-px-171-007-s-csr-body,n = 3, t-test ,84712
m5352-px-171-007-s-csr-body,N = 72, t-test ,55422
m5352-px-171-007-s-csr-body,n = 5, t-test ,49282
m5352-px-171-007-s-csr-body,N = 1, t-test ,119310
m5352-px-171-007-s-csr-body,N = 5, t-test ,24257
m5352-px-171-007-s-csr-body,N = 30, t-test ,20162
m5352-px-171-007-s-csr-body,N = 13, t-test ,20053
m5352-px-171-007-s-csr-body,n = 23, t-test ,18529
m5352-px-171-007-s-csr-body,n = 10, t-test ,18487
m5352-px-171-007-s-csr-body,N = 21, t-test ,15640
m5352-px-171-007-s-csr-body,n = 18, t-test ,14233
m5352-px-171-007-s-csr-body,n = 2, t-test ,18529
m5352-px-171-007-s-csr-body,N = 51, t-test ,10994
m5352-px-171-007-s-csr-body,n = 28, t-test ,9767
m5352-px-171-007-s-csr-body,n = 27, t-test ,9755
m5352-px-171-007-s-csr-body,n = 46, t-test ,9743
m5352-px-171-007-s-csr-body,n = 45, t-test ,9731
m5352-px-171-007-s-csr-body,N = 12, t-test ,9089
m5352-px-171-007-s-csr-body,n = 1, t-test ,18487
m5352-px-171-007-s-csr-body,n = 32, t-test ,212576
m5352-px-171-007-s-csr-body,n = 17, t-test ,213031
m5352-px-171-007-s-csr-body,n = 13, t-test ,213490
m5352-px-171-007-s-csr-body,n = 12, t-test ,213788
m5352-px-171-007-s-csr-body,n = 24, t-test ,213999
m5352-px-171-007-s-csr-body,n = 14, t-test ,214221
m5352-px-171-007-s-csr-body,n = 8, t-test ,215637
m5352-px-171-007-s-csr-body,n=14, t-test ,226857
m5352-px-171-007-s-csr-body,n=8, t-test ,226882
m5352-px-171-007-s-csr-body,N=6, t-test ,244690
m5352-px-171-007-s-csr-body,N=7, t-test ,244707
m5352-px-171-007-s-csr-body,N=10, t-test ,244747
m5352-px-171-007-s-csr-body,N=11, t-test ,245988
m5352-px-171-007-s-csr-body,N=4, t-test ,280686
m5352-px-171-007-s-csr-body,N=3, t-test ,280706
m5352-px-171-007-s-csr-body,N=24, t-test ,280726
m5352-px-171-007-s-csr-body,N=2, t-test ,280726
m5352-px-171-007-s-csr-body,N=14, t-test ,335439
m5352-px-171-007-s-csr-body,N=8, t-test ,335463
m5352-px-171-007-s-csr-body,N=15, t-test ,378778
m5352-px-171-007-s-csr-body,N=9, t-test ,378818
m5352-px-171-007-s-csr-body,N=13, t-test ,381433
m5352-px-171-007-s-csr-body,N=65, t-test ,390894
m5352-px-171-007-s-csr-body,N=51, t-test ,392171
m5352-px-171-007-s-csr-body,N=23, t-test ,395267
m5352-px-171-007-s-csr-body,N=1, t-test ,244747
m5352-px-171-007-s-csr-body,N=40, t-test ,677558
m5352-px-171-007-s-csr-body,N=33, t-test ,1980161
m5352-px-171-007-s-csr-body,N=22, t-test ,5028592
m5352-px-171-007-s-csr-body,total of 526, t-test ,208629
m5352-px-171-007-s-csr-body,total of 14, t-test ,121274
m5352-px-171-007-s-csr-body,total of   33, t-test ,110079
m5352-px-171-007-s-csr-body,total of 10, t-test ,81615
m5352-px-171-007-s-csr-body,total of 5, t-test ,208629
m5352-px-171-007-s-csr-body,total of 26, t-test ,56277
m5352-px-171-007-s-csr-body,total of 8, t-test ,37697
m5352-px-171-007-s-csr-body,total of 79, t-test ,7111
m5352-px-171-007-s-csr-body,total of 84, t-test ,9148
m5352-px-171-007-s-csr-body,total of   16, t-test ,9439
m5352-px-171-007-s-csr-body,total of 72, t-test ,11313
m5352-px-171-007-s-csr-body,total of 12, t-test ,11581
m5352-px-171-007-s-csr-body,total of 4, t-test ,22539
m5352-px-171-007-s-csr-body,total of 31, t-test ,72851
m5352-px-171-007-s-csr-body,total of 7, t-test ,7111
m5352-px-171-007-s-csr-body,total of 40, t-test ,213222
m5352-px-171-007-s-csr-body,total of 33, t-test ,213881
m5352-px-171-007-s-csr-body,total of 22, t-test ,215347
m5352-px-171-007-s-csr-body,total of   79, t-test ,222089
m5352-px-171-007-s-csr-body,total of 2, t-test ,56277
m5352-px-171-007-s-csr-body,14 subjects were enrolled, t-test ,195134
m5352-px-171-007-s-csr-body,33 subjects had been enrolled, t-test ,175074
m5352-px-171-007-s-csr-body,22 subjects enrolled, t-test ,94713
m5352-px-171-007-s-csr-body,10 subjects were enrolled, t-test ,8162
m5352-px-171-007-s-csr-body,33 subjects were enrolled, t-test ,29618
m5352-px-171-007-s-csr-body,3 subjects were enrolled, t-test ,29619
m5352-px-171-007-s-csr-body,4 subjects were enrolled, t-test ,195133
m5352-px-171-007-s-csr-body,7 subjects were enrolled, t-test ,60328
m5352-px-171-007-s-csr-body,7 subjects enrolled, t-test ,63047
m5352-px-171-007-s-csr-body,2 dose levels enrolled, t-test ,66004
m5352-px-171-007-s-csr-body,2 subjects enrolled, t-test ,94712
m5352-px-171-007-s-csr-body,40 subjects enrolled, t-test ,223117
m5352-px-171-007-s-csr-body,3 subjects enrolled, t-test ,225787
m5352-px-171-007-s-csr-body,5 subjects    were enrolled, t-test ,235725
m5352-px-171-007-s-csr-body,526 patients enrolled, t-test ,6408349
m5352-px-171-007-s-csr-synopsis,3 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,6 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,15 additional subjects,null,-1
m5352-px-171-007-s-csr-synopsis,200 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,14 ST subjects,null,-1
m5352-px-171-007-s-csr-synopsis,65 ST subjects,null,-1
m5352-px-171-007-s-csr-synopsis,70 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,20 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,20 MM subjects,null,-1
m5352-px-171-007-s-csr-synopsis,79 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,65 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,40 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,33 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,7 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,22 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,2 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,5 lymphoma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,16 multiple myeloma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,5  subjects,null,-1
m5352-px-171-007-s-csr-synopsis,12 multiple myeloma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,72 total combined solid tumor subjects,null,-1
m5352-px-171-007-s-csr-synopsis,19 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,40 solid tumor subjects,null,-1
m5352-px-171-007-s-csr-synopsis,24 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,33 multiple myeloma   subjects,null,-1
m5352-px-171-007-s-csr-synopsis,4 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,22 multiple myeloma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,2 solid tumor subjects,null,-1
m5352-px-171-007-s-csr-synopsis,33 multiple myeloma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,5 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,8 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,1b   solid tumor bolus subjects,null,-1
m5352-px-171-007-s-csr-synopsis,15 subjects,null,-1
m5352-px-171-007-s-csr-synopsis,11   subjects,null,-1
m5352-px-171-007-s-csr-synopsis,79 solid tumor subjects,null,-1
m5352-px-171-007-s-csr-synopsis,3 multiple myeloma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,10 lymphoma subjects,null,-1
m5352-px-171-007-s-csr-synopsis,2  subjects,null,-1
m5352-px-171-007-s-csr-synopsis,N = 40,null,-1
m5352-px-171-007-s-csr-synopsis,N = 33,null,-1
m5352-px-171-007-s-csr-synopsis,N = 10,null,-1
m5352-px-171-007-s-csr-synopsis,N = 22,null,-1
m5352-px-171-007-s-csr-synopsis,total of 4,null,-1
m5352-px-171-007-s-csr-synopsis,total of   2,null,-1
m5352-px-171-007-s-csr-synopsis,14 were enrolled,null,-1
m5354-2011-002-app1611-protocol,500 patients,null,-1
m5354-2011-002-app1611-protocol,"20,000 patients",null,-1
m5354-2011-002-app1611-protocol,"11,000 patients",null,-1
m5354-2011-002-app1611-protocol,"1,515 patients",null,-1
m5354-2011-002-app1611-protocol,36 patients,null,-1
m5354-2011-002-app1611-protocol,3 patients,null,-1
m5354-2011-002-app1611-protocol,8 patients,null,-1
m5354-2011-002-app1611-protocol,6 patients,null,-1
m5354-2011-002-app1611-protocol,5 patients,null,-1
m5354-2011-002-app1611-protocol,2 patients,null,-1
m5354-2011-002-app1611-protocol,36 evaluable patients,null,-1
m5354-2011-002-app1611-protocol,44 patients,null,-1
m5354-2011-002-app1611-protocol,40 patients,null,-1
m5354-2011-002-app1611-protocol,81 evaluable   patients,null,-1
m5354-2011-002-app1611-protocol,50 patients,null,-1
m5354-2011-002-app1611-protocol,42 evaluable patients,null,-1
m5354-2011-002-app1611-protocol,331 patients,null,-1
m5354-2011-002-app1611-protocol,14 patients,null,-1
m5354-2011-002-app1611-protocol,10 patients,null,-1
m5354-2011-002-app1611-protocol,266 patients,null,-1
m5354-2011-002-app1611-protocol,65 patients,null,-1
m5354-2011-002-app1611-protocol,1 cohort of   patients,null,-1
m5354-2011-002-app1611-protocol,1 cohort of patients,null,-1
m5354-2011-002-app1611-protocol,24 patients,null,-1
m5354-2011-002-app1611-protocol,250 patients,null,-1
m5354-2011-002-app1611-protocol,250 additional patients,null,-1
m5354-2011-002-app1611-protocol,2 Confidential  All patients,null,-1
m5354-2011-002-app1611-protocol,1 Contraception  Female patients,null,-1
m5354-2011-002-app1611-protocol,3 Anti-herpes Prophylaxis  All patients,null,-1
m5354-2011-002-app1611-protocol,3 RESPONSE ASSESSMENT  All patients,null,-1
m5354-2011-002-app1611-protocol,1027 patients,null,-1
m5354-2011-002-app1611-protocol,1 on female patients,null,-1
m5354-2011-002-app1611-protocol,2   separate cohorts of patients,null,-1
m5354-2011-002-app1611-protocol,7 patients,null,-1
m5354-2011-002-app1611-protocol,500   patients,null,-1
m5354-2011-002-app1611-protocol,42   evaluable patients,null,-1
m5354-2011-002-app1611-protocol,970 patients,null,-1
m5354-2011-002-app1611-protocol,800 of   these patients,null,-1
m5354-2011-002-app1611-protocol,2011  In patients,null,-1
m5354-2011-002-app1611-protocol,42 evaluable   patients,null,-1
m5354-2011-002-app1611-protocol,81 evaluable patients,null,-1
m5354-2011-002-app1611-protocol,2 separate cohorts of   patients,null,-1
m5354-2011-002-app1611-protocol,2011  patients,null,-1
m5354-2011-002-app1611-protocol,3 Clinical Monitoring  Inform patients,null,-1
m5354-2011-002-app1611-protocol,10 RESPONSE ASSESSMENT  All patients,null,-1
m5354-2011-002-app1611-protocol,"60,000 people",null,-1
m5354-2011-002-app1611-protocol,"180,000 people",null,-1
m5354-2011-002-app1611-protocol,N = 6,null,-1
m5354-2011-002-app1611-protocol,N = 4,null,-1
m5354-2011-002-app1611-protocol,N = 46,null,-1
m5354-2011-002-app1611-protocol,N = 266,null,-1
m5354-2011-002-app1611-protocol,N = 257,null,-1
m5354-2011-002-app1611-protocol,N = 36,null,-1
m5354-2011-002-app1611-protocol,N = 127,null,-1
m5354-2011-002-app1611-protocol,N = 59,null,-1
m5354-2011-002-app1611-protocol,N = 68,null,-1
m5354-2011-002-app1611-protocol,N=46,null,-1
m5354-2011-002-app1611-protocol,N=266,null,-1
m5354-2011-002-app1611-protocol,N=127,null,-1
m5354-2011-002-app1611-protocol,N=36,null,-1
m5354-2011-002-app1611-protocol,n=6,null,-1
m5354-2011-002-app1611-protocol,n=4,null,-1
m5354-2011-002-app1611-protocol,n=31,null,-1
m5354-2011-002-app1611-protocol,n=50,null,-1
m5354-2011-002-app1611-protocol,N=29,null,-1
m5354-2011-002-app1611-protocol,total of 4,null,-1
m5354-2011-002-app1611-protocol,total of   4,null,-1
m5354-2011-002-app1611-protocol,36 evaluable patients enrolled,null,-1
m5354-2011-002-app1611-protocol,44 patients were enrolled,null,-1
m5354-2011-002-app1611-protocol,500 patients have been enrolled,null,-1
m5354-2011-002-app1619-sap,500 patients,null,-1
m5354-2011-002-app1619-sap,2    number of patients,null,-1
m5354-2011-002-s-csr-body,500 subjects,null,-1
m5354-2011-002-s-csr-body,223 subjects,null,-1
m5354-2011-002-s-csr-body,68 subjects,null,-1
m5354-2011-002-s-csr-body,34 subjects,null,-1
m5354-2011-002-s-csr-body,51 subjects,null,-1
m5354-2011-002-s-csr-body,338 subjects,null,-1
m5354-2011-002-s-csr-body,1   Three subjects,null,-1
m5354-2011-002-s-csr-body,277 subjects,null,-1
m5354-2011-002-s-csr-body,328 subjects,null,-1
m5354-2011-002-s-csr-body,199 subjects,null,-1
m5354-2011-002-s-csr-body,7 subjects,null,-1
m5354-2011-002-s-csr-body,44 subjects,null,-1
m5354-2011-002-s-csr-body,40 subjects,null,-1
m5354-2011-002-s-csr-body,54 subjects,null,-1
m5354-2011-002-s-csr-body,266 refractory multiple myeloma subjects,null,-1
m5354-2011-002-s-csr-body,56 subjects,null,-1
m5354-2011-002-s-csr-body,231 subjects,null,-1
m5354-2011-002-s-csr-body,150 subjects,null,-1
m5354-2011-002-s-csr-body,3   Serum Creatinine   Twelve subjects,null,-1
m5354-2011-002-s-csr-body,4 subjects,null,-1
m5354-2011-002-s-csr-body,9 subjects,null,-1
m5354-2011-002-s-csr-body,25 subjects,null,-1
m5354-2011-002-s-csr-body,75 subjects,null,-1
m5354-2011-002-s-csr-body,72 subjects,null,-1
m5354-2011-002-s-csr-body,53 subjects,null,-1
m5354-2011-002-s-csr-body,32 subjects,null,-1
m5354-2011-002-s-csr-body,6 and most   subjects,null,-1
m5354-2011-002-s-csr-body,266 subjects,null,-1
m5354-2011-002-s-csr-body,6 subjects,null,-1
m5354-2011-002-s-csr-body,22 subjects,null,-1
m5354-2011-002-s-csr-body,N = 277,null,-1
m5354-2011-002-s-csr-body,N = 328,null,-1
m5354-2011-002-s-csr-body,N=328,null,-1
m5354-2011-002-s-csr-body,N=277,null,-1
m5354-2011-002-s-csr-body,N= 328,null,-1
m5354-2011-002-s-csr-body,total of 85,null,-1
m5354-2011-002-s-csr-body,total of 223,null,-1
m5354-2011-002-s-csr-body,total of 318,null,-1
m5354-2011-002-s-csr-body,total of 68,null,-1
m5354-2011-002-s-csr-body,total of 34,null,-1
m5354-2011-002-s-csr-body,total of 51,null,-1
m5354-2011-002-s-csr-body,total of 338,null,-1
m5354-2011-002-s-csr-body,total of 145,null,-1
m5354-2011-002-s-csr-body,total of 108,null,-1
m5354-2011-002-s-csr-body,total of 277,null,-1
m5354-2011-002-s-csr-body,total of 328,null,-1
m5354-2011-002-s-csr-body,total of 243,null,-1
m5354-2011-002-s-csr-body,total of 171,null,-1
m5354-2011-002-s-csr-body,total of 25,null,-1
m5354-2011-002-s-csr-body,total of 244,null,-1
m5354-2011-002-s-csr-body,total of 231,null,-1
m5354-2011-002-s-csr-body,total of 150,null,-1
m5354-2011-002-s-csr-body,total of 75,null,-1
m5354-2011-002-s-csr-body,total of 72,null,-1
m5354-2011-002-s-csr-body,total of 32,null,-1
m5354-2011-002-s-csr-body,338 were enrolled,null,-1
m5354-d120-tfls,2 subjects,null,-1
m5354-d120-tfls,N=32,null,-1
m5354-d120-tfls,N=392,null,-1
m5354-d120-tfls,N=444,null,-1
m5354-d120-tfls,N=12,null,-1
m5354-d120-tfls,N=3,null,-1
m5354-d120-tfls,N=48,null,-1
m5354-d120-tfls,N=31,null,-1
m5354-d120-tfls,N=1,null,-1
m5354-d120-tfls,N=80,null,-1
m5354-d120-tfls,N=19,null,-1
m5354-d120-tfls,N=22,null,-1
m5354-d120-tfls,N=315,null,-1
m5354-d120-tfls,N=389,null,-1
m5354-d120-tfls,N=157,null,-1
m5354-d120-tfls,N=153,null,-1
m5354-d120-tfls,N=40,null,-1
m5354-d120-tfls,N=24,null,-1
m5354-d120-tfls,N=121,null,-1
m5354-d120-tfls,N=143,null,-1
m5354-d120-tfls,N=38,null,-1
m5354-d120-tfls,N=20,null,-1
m5354-d120-tfls,N=10,null,-1
m5354-d120-tfls,N=8,null,-1
m5354-d120-tfls,N=0,null,-1
m5354-d120-tfls,N=28,null,-1
m5354-d120-tfls,N=115,null,-1
m5354-d120-tfls,N=25,null,-1
m5354-d120-tfls,N=35,null,-1
m5354-d120-tfls,N=15,null,-1
m5354-d120-tfls,N=16,null,-1
m5354-d120-tfls,N=11,null,-1
m5354-d120-tfls,N=13,null,-1
m5354-d120-tfls,N=6,null,-1
m5354-d120-tfls,N=5,null,-1
m5354-d120-tfls,N=27,null,-1
m5354-d120-tfls,N=123,null,-1
m5354-d120-tfls,N=146,null,-1
m5354-d120-tfls,N=14,null,-1
m5354-d120-tfls,N=9,null,-1
m5354-d120-tfls,N=396,null,-1
m5354-d120-tfls,N=161,null,-1
m5354-d120-tfls,N=231,null,-1
m5354-d120-tfls,N=192,null,-1
m5354-d120-tfls,N=252,null,-1
m5354-d120-tfls,N=2,null,-1
m5354-d120-tfls,N=30,null,-1
m5354-d120-tfls,N=84,null,-1
m5354-d120-tfls,N=308,null,-1
m5354-d120-tfls,N=94,null,-1
m5354-d120-tfls,N=350,null,-1
m5354-d120-tfls,N=51,null,-1
m5354-d120-tfls,N=338,null,-1
m5354-d120-tfls,N=66,null,-1
m5354-d120-tfls,N=103,null,-1
m5354-d120-tfls,N = 389,null,-1
m5354-d120-tfls,N = 392,null,-1
m5354-d120-tfls,N = 456,null,-1
m5354-d120-tfls,N = 463,null,-1
m5354-d120-tfls,N=190,null,-1
m5354-d120-tfls,N=7,null,-1
m5354-d120-tfls,N=598,null,-1
m5354-d120-tfls,N=37,null,-1
m5354-d120-tfls,N=21,null,-1
m5354-d120-tfls,N=456,null,-1
m5354-d120-tfls,N=78,null,-1
m5354-d120-tfls,N=39,null,-1
m5354-d120-tfls,N=465,null,-1
m5354-d120-tfls,N=59,null,-1
m5354-d120-tfls,N=42,null,-1
m5354-d120-tfls,N=33,null,-1
m5354-d120-tfls,N=29,null,-1
m5354-d120-tfls,N=26,null,-1
m5354-d120-tfls,N=139,null,-1
m5354-tr-0480-171-s-csr-with-app,700 patients,null,-1
m5354-tr-0480-171-s-csr-with-app,625 patients,null,-1
m5354-tr-0480-171-s-csr-with-app,21 patients,null,-1
m5354-tr-0480-171-s-csr-with-app,N=12,null,-1
m5354-tr-0480-171-s-csr-with-app,N=10,null,-1
m5354-tr-0480-171-s-csr-with-app,N=8,null,-1
m5354-tr-0480-171-s-csr-with-app,N=41,null,-1
m5354-tr-0480-171-s-csr-with-app,N=28,null,-1
m5354-tr-0480-171-s-csr-with-app,21 patients enrolled,null,-1
m5354-tr-0480-171-s-csr-with-app, data from C2,null,-1
m5354-tr-0481-171-s-csr-with-app,22 MM subjects,null,-1
m5354-tr-0481-171-s-csr-with-app,1b patients,null,-1
m5354-tr-0481-171-s-csr-with-app,2 so patients,null,-1
m5354-tr-0481-171-s-csr-with-app,105   patients,null,-1
m5354-tr-0481-171-s-csr-with-app,68 infusion patients,null,-1
m5354-tr-0481-171-s-csr-with-app,79 patients,null,-1
m5354-tr-0481-171-s-csr-with-app,68 patients,null,-1
m5354-tr-0481-171-s-csr-with-app,22 MM subjects were enrolled,null,-1
module-5353-d120-safetyupdate-us,3884 subjects,null,-1
module-5353-d120-safetyupdate-us,1834 subjects,null,-1
module-5353-d120-safetyupdate-us,1949 subjects,null,-1
module-5353-d120-safetyupdate-us,1858 subjects,null,-1
module-5353-d120-safetyupdate-us,57 subjects,null,-1
module-5353-d120-safetyupdate-us,34 subjects,null,-1
module-5353-d120-safetyupdate-us,789 treated subjects,null,-1
module-5353-d120-safetyupdate-us,3 subjects,null,-1
module-5353-d120-safetyupdate-us,14 subjects,null,-1
module-5353-d120-safetyupdate-us,2424 subjects,null,-1
module-5353-d120-safetyupdate-us,2967 subjects,null,-1
module-5353-d120-safetyupdate-us,2868 subjects,null,-1
module-5353-d120-safetyupdate-us,65 subjects,null,-1
module-5353-d120-safetyupdate-us,456 subjects,null,-1
module-5353-d120-safetyupdate-us,392 subjects,null,-1
module-5353-d120-safetyupdate-us,389 subjects,null,-1
module-5353-d120-safetyupdate-us,204 subjects,null,-1
module-5353-d120-safetyupdate-us,118 subjects,null,-1
module-5353-d120-safetyupdate-us,86 subjects,null,-1
module-5353-d120-safetyupdate-us,170 subjects,null,-1
module-5353-d120-safetyupdate-us,97 subjects,null,-1
module-5353-d120-safetyupdate-us,73 subjects,null,-1
module-5353-d120-safetyupdate-us,781 subjects,null,-1
module-5353-d120-safetyupdate-us,84 subjects,null,-1
module-5353-d120-safetyupdate-us,52 subjects,null,-1
module-5353-d120-safetyupdate-us,157 subjects,null,-1
module-5353-d120-safetyupdate-us,153 subjects,null,-1
module-5353-d120-safetyupdate-us,12 subjects,null,-1
module-5353-d120-safetyupdate-us,2 subjects,null,-1
module-5353-d120-safetyupdate-us,010 does not include new unique subjects,null,-1
module-5353-d120-safetyupdate-us,5 active   subjects,null,-1
module-5353-d120-safetyupdate-us,4 subjects,null,-1
module-5353-d120-safetyupdate-us,2013 after which subjects,null,-1
module-5353-d120-safetyupdate-us,52   Number of subjects,null,-1
module-5353-d120-safetyupdate-us,4 MEDICAL HISTORY   As no new subjects,null,-1
module-5353-d120-safetyupdate-us,3 ongoing subjects,null,-1
module-5353-d120-safetyupdate-us,6 subjects,null,-1
module-5353-d120-safetyupdate-us,162 subjects,null,-1
module-5353-d120-safetyupdate-us,32 subjects,null,-1
module-5353-d120-safetyupdate-us,3 new subjects,null,-1
module-5353-d120-safetyupdate-us,5 new subjects,null,-1
module-5353-d120-safetyupdate-us,100 subjects,null,-1
module-5353-d120-safetyupdate-us,46 are still enrolling subjects,null,-1
module-5353-d120-safetyupdate-us,1595 subjects,null,-1
module-5353-d120-safetyupdate-us,2 new subjects,null,-1
module-5353-d120-safetyupdate-us,3 Renal   The proportion of subjects,null,-1
module-5353-d120-safetyupdate-us,4 Hepatic   The proportion of subjects,null,-1
module-5353-d120-safetyupdate-us,20 subjects,null,-1
module-5353-d120-safetyupdate-us,111 subjects,null,-1
module-5353-d120-safetyupdate-us,50 subjects,null,-1
module-5353-d120-safetyupdate-us,28 subjects,null,-1
module-5353-d120-safetyupdate-us,8 subjects,null,-1
module-5353-d120-safetyupdate-us,26 subjects,null,-1
module-5353-d120-safetyupdate-us,5 subjects,null,-1
module-5353-d120-safetyupdate-us,7 subjects,null,-1
module-5353-d120-safetyupdate-us,27 subjects,null,-1
module-5353-d120-safetyupdate-us,9 subjects,null,-1
module-5353-d120-safetyupdate-us,15 of the subjects,null,-1
module-5353-d120-safetyupdate-us,11 subjects,null,-1
module-5353-d120-safetyupdate-us,45 multiple myeloma subjects,null,-1
module-5353-d120-safetyupdate-us,17 subjects,null,-1
module-5353-d120-safetyupdate-us,12      CONFIDENTIAL   subjects,null,-1
module-5353-d120-safetyupdate-us,31 subjects,null,-1
module-5353-d120-safetyupdate-us,"12,602 patients",null,-1
module-5353-d120-safetyupdate-us,"16,500 patients",null,-1
module-5353-d120-safetyupdate-us,351 patients,null,-1
module-5353-d120-safetyupdate-us,111 patients,null,-1
module-5353-d120-safetyupdate-us,10 patients,null,-1
module-5353-d120-safetyupdate-us,4 patients,null,-1
module-5353-d120-safetyupdate-us,2 patients,null,-1
module-5353-d120-safetyupdate-us,6      CONFIDENTIAL   patients,null,-1
module-5353-d120-safetyupdate-us,6 patients,null,-1
module-5353-d120-safetyupdate-us,3 patients,null,-1
module-5353-d120-safetyupdate-us,526 patients,null,-1
module-5353-d120-safetyupdate-us,5 patients,null,-1
module-5353-d120-safetyupdate-us,n = 392,null,-1
module-5353-d120-safetyupdate-us,n = 389,null,-1
module-5353-d120-safetyupdate-us,n = 3,null,-1
module-5353-d120-safetyupdate-us,n = 14,null,-1
module-5353-d120-safetyupdate-us,N = 392,null,-1
module-5353-d120-safetyupdate-us,N = 389,null,-1
module-5353-d120-safetyupdate-us,n = 1,null,-1
module-5353-d120-safetyupdate-us,N =392,null,-1
module-5353-d120-safetyupdate-us,n = 162,null,-1
module-5353-d120-safetyupdate-us,n = 117,null,-1
module-5353-d120-safetyupdate-us,n = 351,null,-1
module-5353-d120-safetyupdate-us,N = 38,null,-1
module-5353-d120-safetyupdate-us,n = 25,null,-1
module-5353-d120-safetyupdate-us,n = 19,null,-1
module-5353-d120-safetyupdate-us,n = 12,null,-1
module-5353-d120-safetyupdate-us,N=392,null,-1
module-5353-d120-safetyupdate-us,N=389,null,-1
module-5353-d120-safetyupdate-us,n = 22,null,-1
module-5353-d120-safetyupdate-us,n = 4,null,-1
module-5353-d120-safetyupdate-us,n=2,null,-1
module-5353-d120-safetyupdate-us,n=1,null,-1
module-5353-d120-safetyupdate-us,N=153,null,-1
module-5353-d120-safetyupdate-us,N=157,null,-1
module-5353-d120-safetyupdate-us,N=788,null,-1
module-5353-d120-safetyupdate-us,N=444,null,-1
module-5353-d120-safetyupdate-us,N=46,null,-1
module-5353-d120-safetyupdate-us,n=13,null,-1
module-5353-d120-safetyupdate-us,n=7,null,-1
module-5353-d120-safetyupdate-us,n=3,null,-1
module-5353-d120-safetyupdate-us,n=4,null,-1
module-5353-d120-safetyupdate-us,n=6,null,-1
module-5353-d120-safetyupdate-us,n=20,null,-1
module-5353-d120-safetyupdate-us,n=23,null,-1
module-5353-d120-safetyupdate-us,n=14,null,-1
module-5353-d120-safetyupdate-us,n=9,null,-1
module-5353-d120-safetyupdate-us,n=60,null,-1
module-5353-d120-safetyupdate-us,n=44,null,-1
module-5353-d120-safetyupdate-us,n=15,null,-1
module-5353-d120-safetyupdate-us,n = 50,null,-1
module-5353-d120-safetyupdate-us,n = 2,null,-1
module-5353-d120-safetyupdate-us,n = 7,null,-1
module-5353-d120-safetyupdate-us,n = 8,null,-1
module-5353-d120-safetyupdate-us,n = 5,null,-1
module-5353-d120-safetyupdate-us,n = 11,null,-1
module-5353-d120-safetyupdate-us,n = 24,null,-1
module-5353-d120-safetyupdate-us,n = 20,null,-1
module-5353-d120-safetyupdate-us,n = 21,null,-1
module-5353-d120-safetyupdate-us,total of 84,null,-1
module-5353-d120-safetyupdate-us,total of 24,null,-1
module-5353-d120-safetyupdate-us,total of 162,null,-1
module-5353-d120-safetyupdate-us,total of 32,null,-1
module-5353-d120-safetyupdate-us,total of 71,null,-1
module-5353-d120-safetyupdate-us,total of 1696,null,-1
module-5353-d120-safetyupdate-us,total of 86,null,-1
module-5353-d120-safetyupdate-us,total of 58,null,-1
module-5353-d120-safetyupdate-us,total of 1812,null,-1
module-5353-d120-safetyupdate-us,9 ongoing studies   enrolled,null,-1
module-5353-d120-safetyupdate-us,34 subjects enrolled,null,-1
module-5353-d120-safetyupdate-us,9 ongoing studies enrolled,null,-1
module-5353-d120-safetyupdate-us,84 subjects   were enrolled,null,-1
module-5353-d120-safetyupdate-us,4 centers enrolled,null,-1
module-5353-d120-safetyupdate-us,3 centers enrolled,null,-1
module-5353-d120-safetyupdate-us,2424 subjects have been enrolled,null,-1
module-5353-d120-safetyupdate-us,100 subjects   enrolled,null,-1
module-5353-d120-safetyupdate-us,2868 subjects were enrolled,null,-1
module-5353-d120-safetyupdate-us,2868 subjects enrolled,null,-1
module-5353-d120-safetyupdate-us,65 subjects were enrolled,null,-1
module-5353-d120-safetyupdate-us,57 subjects   enrolled,null,-1
module-5353-d120-safetyupdate-us,351 patients enrolled,null,-1
module-5353-d120-safetyupdate-us,28 subjects enrolled,null,-1
module-5353-d120-safetyupdate-us,26 subjects were enrolled,null,-1
module-5353-d120-safetyupdate-us,18 enrolled,null,-1
module-5353-d120-safetyupdate-us, data as of 12,null,-1
module-5353-d120-safetyupdate-us, data cutoff of   12,null,-1
module-5353-d120-safetyupdate-us, data   As of 12,null,-1
module-5353-d120-safetyupdate-us, data from PX-171,null,-1
module-5353-d120-safetyupdate-us, data from 2,null,-1
module-5353-d120-safetyupdate-us, data from 2011,null,-1
module-5353-d120-safetyupdate-us,   data from 2011,null,-1
module-5353-gi-perforation,N=153,null,-1
module-5353-gi-perforation,N=157,null,-1
module-5353-gi-perforation,N=389,null,-1
module-5353-gi-perforation,N=392,null,-1
module-5353-gi-perforation,N=456,null,-1
module-5353-gi-perforation,N=463,null,-1
module-5353-gi-perforation,N=20,null,-1
module-5353-gi-perforation,N=11,null,-1
module-5353-gi-perforation, database as of Q2,null,-1
module-5353-tr-1118-171-s-csr,764 patients,null,-1
module-5353-tr-1118-171-s-csr,N=310,null,-1
module-5353-tr-1118-171-s-csr,N=781,null,-1
module-5353-tr-1118-171-s-csr,N=157,null,-1
module-5353-tr-1118-171-s-csr,N=153,null,-1
module-5353-tr-1118-171-s-csr,N=392,null,-1
module-5353-tr-1118-171-s-csr,N=389,null,-1
module-5353-tr-1118-171-s-csr,N=764,null,-1
module-5353-tr-1118-171-s-csr,n=217,null,-1
module-5353-tr-1118-171-s-csr,n=547,null,-1
module-5353-tr-1118-171-s-csr,009 enrolled,null,-1
module-5353-tr-1118-171-s-csr,011 enrolled,null,-1
module-5353-tr-1119-171-s-csr,1 Examine  eDISH plot of all subjects,null,-1
module-5353-tr-1119-171-s-csr,3 Examine eDISH plot of all subjects,null,-1
module-5353-tr-1119-171-s-csr,1232 total subjects,null,-1
module-5353-tr-1119-171-s-csr,542 subjects,null,-1
module-5353-tr-1119-171-s-csr,788 subjects,null,-1
module-5353-tr-1119-171-s-csr,444 subjects,null,-1
module-5353-tr-1119-171-s-csr,317 patients,null,-1
module-5353-tr-1119-171-s-csr,011 patients,null,-1
module-5353-tr-1119-171-s-csr,788 patients,null,-1
module-5353-tr-1119-171-s-csr,153 patients,null,-1
module-5353-tr-1119-171-s-csr,12 patients,null,-1
module-5353-tr-1119-171-s-csr,444 patients,null,-1
module-5353-tr-1119-171-s-csr,"12,000 patients",null,-1
module-5353-tr-1119-171-s-csr,2012 as third line  treatment of patients,null,-1
module-5353-tr-1119-171-s-csr,N=190,null,-1
module-5353-tr-1119-171-s-csr,N=788,null,-1
module-5353-tr-1119-171-s-csr,N=598,null,-1
module-5353-tr-1119-171-s-csr,N=157,null,-1
module-5353-tr-1119-171-s-csr,N=32,null,-1
module-5353-tr-1119-171-s-csr,N=392,null,-1
module-5353-tr-1119-171-s-csr,N=444,null,-1
module-5353-tr-1119-171-s-csr,N=389,null,-1
module-5353-tr-1119-171-s-csr,n= 46,null,-1
module-5353-tr-1119-171-s-csr,n= 29,null,-1
module-5353-tr-1119-171-s-csr,n = 6,null,-1
module-5353-tr-1119-171-s-csr,n = 3,null,-1
module-5353-tr-1119-171-s-csr, data from 317,null,-1
module-5353-tr-171-007-s-csr,22 MM  subjects,null,-1
module-5353-tr-171-007-s-csr,2 subjects,null,-1
module-5353-tr-171-007-s-csr,1b patients,null,-1
module-5353-tr-171-007-s-csr,2 so patients,null,-1
module-5353-tr-171-007-s-csr,154 patients,null,-1
module-5353-tr-171-007-s-csr,49 patients,null,-1
module-5353-tr-171-007-s-csr,105 patients,null,-1
module-5353-tr-171-007-s-csr,68   infusion patients,null,-1
module-5353-tr-171-007-s-csr,N=12,null,-1
module-5353-tr-171-007-s-csr,N=10,null,-1
module-5353-tr-171-007-s-csr,N=8,null,-1
module-5353-tr-171-007-s-csr,n=37,null,-1
module-5353-tr-171-007-s-csr,n=49,null,-1
module-5353-tr-171-007-s-csr,n=32,null,-1
module-5353-tr-171-007-s-csr,22 MM  subjects were enrolled,null,-1
module-5354-adrs,N=153,null,-1
module-5354-adrs,N=157,null,-1
module-5354-adrs,N=389,null,-1
module-5354-adrs,N=392,null,-1
module-5354-adrs,N=456,null,-1
module-5354-adrs,N=463,null,-1
module-5354-adrs,n = 2,null,-1
module-5354-adrs,n = 5,null,-1
module-5354-adrs,n = 4,null,-1
module-5354-adrs, database as of Q2,null,-1
